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Abstract.
Ligation of the T cell costimulatory molecule CD28 has previously been demonstrated to 
induce tyrosine phosphorylation of its cytoplasmic domain and activation of the putative 
signalling molecule phosphatidylinositol 3-kinase (PI 3-kinase). Here, ligation-induced 
tyrosine phosphorylation of CD28 is shown to represent only a minor component of 
phosphorylated residues, whilst heavier phosphorylation resides within serine and 
threonine residues. The ligation-dependent phosphorylation of CD28 has been 
characterised here as resistant to known inhibitors of a range of known serine/threonine 
kinases.
Recruitment of PI 3-kinase to CD28 is dependent upon the phosphorylation of 173y 
within the cytoplasmic domain of CD28, but independent of lck, subsequent activation of 
PI 3-kinase however, is severely impaired in the absence of lck. The CD28-mediated PI 
3-kinase signal is also inhibited by the PMA-mediated activation of PKC which disrupts 
CD28/PI 3-kinase association, and potentially by an SH2 containing inositol 
polyphosphate 5-phosphatase (SHIP), since CD28 ligation is followed by tyrosine 
phosphorylation, and stimulation of catalytic activity, of SHIP. In vitro protein kinase 
assays, of SHIP immunoprecipitates, reveal CD28-mediated phosphorylation of SHIP to 
be accompanied by phosphorylation of unidentified substrates of approximately 40 and 
100 kDa, and these may facilitate CD28 regulation of SHIP.
CD28-mediated activation of PI 3-kinase has been demonstrated to stimulate the activity 
of the downstream effectors p70 S6  kinase and protein kinase B (PKB). Effects of CD28 
ligation on other biochemical events such as activation of the MAP kinases JNK and p38 
have also been investigated. Finally, ligation of CD95 has been shown to stimulate the 
activity PI 3-kinase and the downstream effector PKB.
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T lymphocytes play a central role in both the induction and coordination of an acquired 
immune response, performing diverse functions in recognition of foreign material, 
cytotoxicity, the facilitation of B cell antibody production and recruitment of accessory 
cells. Resting T cells circulating in the peripheral blood become activated on encountering 
processed antigenic peptide in complex with major histocompatibility protein (Ag-MHC) 
on the surface of an antigen presenting cell (APC). This recognition event is mediated by 
the T cell antigen receptor and intiates a series of biochemical events enabling the T cell to 
produce a range of cytokines including IL-2, and express the IL-2 receptor. It is now 
generally accepted however, that the biochemical signals elicited by the T cell antigen 
receptor alone, are insufficient to allow for optimal IL-2 production, and that the presence 
of a second, or costimulatory, signal is required [Bretscher and Cohn (1970)]. This 
second signal is provided by molecules present on “professional” antigen presenting 
cells, such as dendritic cells, monocytes and activated B cells.
The interaction of CD28 with its natural ligand B7, has emerged as the major source of 
costimulation in T cells. In combination, the signals transduced by the T cell antigen 
receptor and CD28 stimulate optimal IL-2 production, allowing for paracrine and 
autocrine driven progression through the cell division cycle (proliferation). Lymphocytes 
that are activated by ligation of the T cell receptor alone may enter a state of antigen 
unresponsiveness, termed anergy, or undergo death by apoptosis. Apoptosis, or 
programmed cell death, is a form of cell suicide which is believed to play an important 
role in development, tissue homeostasis and clearance of damaged cells from multicellular 
organisms [Steller (1995)]. The presence of the CD28-mediated costimulatory signal, 
effectively drives the cell away from apoptosis, highlighting a role for CD28 in cell 
survival, towards a proliferative response [Mueller et a l (1989)]. CD28 can thus be 
regarded as a pivotal signal in T cell activation. The signals elicited by CD28 must be at 
least partially distinct from those transduced by the T cell antigen receptor, since the 
former signal is classically described as resistant to cyclosporin A and FK506 [June et al 
(1987)]. Given these functional and biochemical distinctions it is important to understand 
the differences between the signals transduced the TCR and CD28.
1
1.2.1 Structure of the T cell antigen receptor
In any study of costimulatory signalling, it is important to consider the cellular 
environment within which these signals are elicited. Effectual T cell activation is believed 
to begin with the recognition of MHC complexed antigenic peptide expressed on the 
surface of an antigen presenting cell (APC). Recognition of the Ag-MHC complex is 
mediated by the T cell antigen receptor (TCR). The TCR is a complex oligomer composed 
of the products of six genes, all of which are required for efficient plasma membrane 
expression. A ligand binding site, formed by an a  and (3 chain (or less frequently a y and 
8 chain) is responsible for the recognition of Ag-MHC. The transmembrane and 
membrane proximal moieties are responsible for interchain associations and assembly of 
the oligomeric structure, whilst CD3 and TCR £ chains are responsible for signal 
transduction.
hTCR^l QL Y NE L NLGRREE- Y D V L
hTC R p GL Y 'JE L QKDKMAEA Y S E I
hTCR£3 GL Y Q L STATKDT- Y D A L
hCD3y QI A QF L KDREDDQ- Y SH L
hCD35 Q> A QF L RDRDDAQ- Y SH L
mCD3e PI A EP I IKGQRDL- Y SG L
m lga NL Y EG L NLDDCSM- Y ED I
hlgE FcRy G \ YTG L STRNQET- Y ET L
BLV gp30 SE Y QA L LPSAPEI- Y SH L
EBV-LMP2A I Y SH I SPVKPD— Y IN L
Figure 1.1 S tructure of the im m unoreceptor tyrosine-based activation  
m otif (ITA M ). ITAMs are expressed in T and B cell antigen receptors, the mast cell 
receptor for IgE, and in the viral glycoproteins of bovine leukaemia virus (BLV) and 
Epstein-Barr virus (EBV) latent membrane protein 2A.
The principal structural unit which regulates TCR coupling to downstream signal 
transduction is the immunoreceptor tyrosine-based activation motif (ITAM) or 
alternatively the antigen recognition and activation motif (ARAM), first described by Reth 
(1989). These are present as single copies in each of the CD3 chains and triplicated in the
2
£ chain. Each ITAM consists of two YXXL/I repeats separated by 6 -8  residues, this 
arrangement is represented in Figure 1.1 from sequences in proteins expressing IT AMs. 
The tyrosine residues of the ITAM undergo ligation dependent phosphorylation. The 
multiplicity of the ITAMs within the TCR is striking, since each TCR can contain a total 
of 10 ITAMs. One function of this multimerisation of the motif is thought to be signal 
amplification. This is an attractive hypothesis since relatively few Ag-MHC molecular 
complexes are available on APCs. Thus, a single recognition event could involve the 
participation of multiple ITAMs that each interact with intracellular signalling molecules.
1.2.2 Biochemical events elicited by the T cell antigen receptor.
Signal transduction events following ligation of the TCR (termed signal 1) are mediated 
by the cytoplasmic domains of the CD3 complex, by the co-receptor CD4 or CD8 and by 
accessory molecules such as CD45. An early event associated with signal 1 is the 
phosphorylation of several protein substrates. Three distinct protein tyrosine kinases 
(PTKs) have been implicated in TCR function: p 5 6 ^ ,  p59fyn and ZAP-70. Lck is a T 
cell restricted member of the src family PTKs and is associated at a high stochiometry 
with the co-receptors CD4 and CD 8 . The co-receptors may function to increase the 
overall avidity of the interaction of the TCR with Ag-MHC. Alternatively it is postulated 
that simultaneous binding of the TCR and CD4 or CD8 co-receptor results in the 
juxtaposition of p 5 6 ^  and CD3 cytoplasmic domains, facilitating their phosphorylation. 
Expression of a constitutively activated (505Tyr to 505phe mutant) form of lck in a CD4 
negative mouse T cell hybridoma increases TCR stimulated tyrosine phosphorylation of 
proteins and its sensitivity to antigenic stimulation [Abraham et a l (1991)]. A critical 
function for lck in TCR signal transduction is also suggested by genetic studies. A mutant 
leukaemic cell line selected for its inability to increase cytoplasmic free calcium (a 
consequence of phospholipase C y l activation) in response to anti-CD3 mAb, is unable 
to activate the TCR PTK pathway. The defect in this mutant was shown to represent its 
failure to express functional lck [Straus and Weiss (1992)].
Another member of the src family PTKs, namely p 5 9 ^ n, was implicated in TCR 
signalling when fyn kinase activity was detected in TCR immunoprecipitates using in 
vitro kinase assays [Samelson et a l (1990)]. The authours did acknowledge however, 
that this may have been an indirect association. Additionally TCR stimulation is followed 
by rapid but transient 2-4 fold increase in fyn  kinase activity [Tsygankov et a l (1992)]. 
The N-terminal 10 amino acids offyn  have been shown to associate with distinct regions
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of the £ chains [Gauen et a l (1992)], however the stoichiometry of fyn  association 
appears to be quite low.
The ability of CD8/TCR £ chimaeras, containing the £ cytoplasmic domain, to induce 
cellular tyrosine phosphorylation, suggested that £ might interact directly with a PTK 
[Chan etal. (1991)]. Immunoprecipitates of £ from stimulated cells have been shown to 
contain a tightly associated 70 kDa protein named ZAP-70 [Chan et a l (1991)]. Further 
characterisation of ZAP-70 has revealed its expression to be restricted to T cells and NK 
cells. It has two N-terminal SH2 domains and a C-terminal kinase domain. ZAP-70 is 
most homologous to Syk, a 72 kDa PTK abundant in B cells and myeloid cells, which 
may associate with the B cell antigen receptor. The association of ZAP-70 with 
phosphorylated CD3 £ is rapid and specific.
Several cellular substrates have been identified for TCR-activated PTKs, including 
components of at least two signalling pathways believed to be important links in the 
control of cell activation. The first of these is phospholipase C yl (PLCyl) [Park et a l 
(1991)], which regulates the hydrolysis of membrane phospholipids, namely 
PtdIns(4,5)P2> yielding two important products, Ins(l,4,5)P3 and diacylglycerol (DAG). 
Ins(l,4,5)P3 regulates intracellular calcium release [Berridge (1993)], whilst DAG 
activates the serine/threonine kinase protein kinase C (PKC) [Nishizuka (1998)]. 
Secondly, TCR activation of the guanine nucleotide binding protein p21ras is PTK- 
dependent and is essential for the coupling of the TCR/CD3 complex to mitogenic- 
activated protein kinase (MAP kinase), also termed extracellular-signal-regulated kinase 
1/2 (ERK1/2) [Izquierdo et a l (1995)]. The calcium signalling system cooperates, via the 
calcium phosphatase calcineurin, with p2 1 ras for induction of the transcription factor 
nuclear factor of activated T cells (NFAT) which, along with nuclear transcription factor 
kB (NFkB), AP-1 and Oct-1, is involved in IL-2 gene expression [Izquierdo et a l
(1995)]. A third signalling pathway, which is putatively mediated by PI 3-kinase, has 
also been implicated in cell growth and activation. This may also be controlled by TCR- 
activated PTKs, since the p85 subunit of phosphatidylinositol 3-kinase (PI 3-kinase) 
binds to the TCR £ chain, although this has not been consistently observed to correlate 
with PI 3-kinase activation [Ward et a l (1992); Carrera et a l (1994)]. The biochemical 
signals comprising signal 1 are summarised schematically in the Figure 1.2.
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Following the identification of the necessity of a costimulatory signal, several possibilities 
were proposed as to the biochemical nature of this signal: i) it could be a unique signal 
activating distinct signal transduction pathways which complement those activated by the 
TCR, ii) it could correspond to signal 1 but occur at different time points or in different 
cellular compartments, or iii) it could be the same as signal 1 but act in an additive 
fashion, enhancing the amplitude or duration of signal 1, allowing activation thresholds to 
be crossed and activation of downstream targets. Subsequent investigations have revealed 
elements of signal 2  to correspond with each of these hypotheses, for example both 
signals 1 and 2 result in the phosphorylation of the adaptor proteins p95vav [Tuosto et al
(1996); Klasen et al. (1998)] and SLP76, whilst only signal two has been reported to 
induce phosphorylation of p62dok [Klasen et al. (1998)]. Some of these features of 
TCR-mediated and co-stimulatory signalling are summarised below and discussed in 
section 1.5.
Signalling event Signal 1 (TCR/CD3) Signal 2 (CD28)
Activation of PTK’s p561ck, p59fyn [Tsygankov et 
al. (1992)], ZAP-70 [Chan et 
al. (1991)]
p561ck, p59fyn, ITK [August 
and DuPont (1994)]
PTK substrates PLCyl [Straus and Weiss 
(1992)]
PLCyl activation in response 
to anti-CD28 Ab [Nunes et al. 




p95vav [Tuosto etal. (1996)]. 
SLP76
p36 LAT [Zhang et al. (1998)]
p95vav [Klasen et a l (1998)]. 
SLP76
Ceramide Not reported A-SMase [Boucher et al. 
(1995)].
SHIP activation Via TCR£ [Daeron et al. 
(1995)].




Activation of JNK reported as synergistic in response TCR 
and CD28 ligation [Su et al. (1994)]
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Figure 1 .2  Schem atic summary of signalling events com prising signal 1 .
TCR ligation induces the activation of src-family PTKs lck and fyn. Substrates include 
PLCyl. When phosphorylated PLCyl catalyses the breakdown of Ptdlns(4,5)7*2 
forming DAG which activates PKC and Ins(l,4,5)P 3 which regulates intracellular 
calcium levels.
1 .3  Two signal model: The concept of costim ulation.
It is now accepted that signalling events intiated by the TCR alone are insufficient to allow 
for optimal IL-2 production and proliferation. For a T cell to support sufficient IL-2 
production to allow for clonal expansion, there is a further requirement for costimulatory 
signals, additional to those produced on TCR/Ag-MHC ligation. This observation was 
summarised nearly thirty years ago by Bretscher and Cohn (1970), in their two signal 
model of signal transduction. In its simplest form the model, as originally proposed, 
describes that an individual APC can independently express the Ag-MHC complex 
(transducing signal 1), and/ora costimulatory ligand (transducing signal 2). Thus, given 
the binary nature of the model it is possible to predict three potential outcomes of the 
interactions of APCs and T cells: i) When resting cells encounter costimulatory ligand in 
the absence of Ag-MHC, no effects are observed; ii) the interactions of T cells with Ag- 
MHC in the absence of costimulatory ligand is not a neutral event but leads to a state of 
induced Ag unresponsiveness termed anergy, or to cell death by apoptosis; iii) activation 
of the TCR in the presence of costimulatory signals results in T cell clonal expansion and 
induction of effector functions. Thus, in the third case the presence of the costimulatory 
signal is driving the T cell away from apoptosis or anergy, towards effector function.
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1 .4  The CD28/CTLA-4 “family”.
The first evidence that CD28 could intiate costimulatory signals in resting human T cells 
came from the observation that, in conjunction with phorbol-12-myristate- 13-acetate 
(PMA), CD28 induced cyclosporin A-resistant T cell proliferation and IL-2 production 
[Hara et al. (1985); June et al. (1987)]. Further studies led to the identification of an 
additional "family" member namely, CTLA-4. The genes for CD28 and CTLA-4 are 
closely linked on human chromosome 2 (2q33-34) and display a similar genomic 
organisation, implying a common evolutionary origin [Harper et al. (1991)]. Despite this 
genomic relationship, the overall amino acid conservation between the two molecules is 
only 30%. CD28 is a homodimeric glycoprotein expressed on 95% of CD4+ T cells and 
approximately 50% of CD8+ T cells [Damle et al. (1983)]. Although the extracellular 
domains display little sequence identity, mapping of the ligand binding sites of CD28 and 
CTLA-4 has localised the site of interaction with B7.1 and B7.2 to a conserved sequence 
M-Y-P-P-P-Y in the complementary determining region 3-like region, (CDR3)-like 
region, of both CD28 and CTLA-4. The amino acid sequences of the CD28 and CTLA-4 
cytoplasmic tails are given in Figure 1.3. CD28 is composed of two glycosylated 44 kDa 
chains, which are members of the immunoglobulin super-family each containing a single 
disulphide linked extracellular Ig V-like domain. The CD28 polypeptide contains 202 
amino acids giving a molecular mass of 23 kDa which is then glycosylated to the 
molecular mass of the mature protein. The extracellular domain is linked, via a single 
pass transmembrane region, to a 41 amino acid cytoplasmic domain which is responsible 
for initiating costimulatory signals. The cytoplasmic domain of CD28 does not encode 
any recognised motif for kinase activity, and is therefore presumed to signal via the 
recruitment of cellular enzymes. Notably, there is a consensus sequence motif, 
173(p)YMNM, within the cytoplasmic tail of CD28 which binds SH2 domains of the p85 
subunit of phosphatidylinositol 3-kinase [Pages et al. (1994)] and growth-factor-receptor 
binding protein (Grb-2), a ubiquitous adaptor protein [Schneider et al. (1995a)]. 
Additionally, CD28 also contains two proline rich motifs which conform to the P-X-X-P 
SH3 consensus binding sequence [Ren et al. (1992)], and this may allow for CD28 
interaction with further signalling proteins.
CTLA-4 displays a similar structure to CD28 as a disulphide linked homodimer of 
predicted molecular mass of 20 kDa with a single glycosylation site. This protein also 
consists of a single disulphide linked extracellular IgV like domain linked via a short 
amino acid stretch to a transmembrane region and cytoplasmic domain of 36 amino acids. 
There is only limited sequence homology (approximately 30% at the amino acid level) 
between the cytoplasmic domains of CD28 and CTLA-4, possibly suggesting an ability
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£  Proline-rich region 
SH2 domain binding
region
B >Figure 1.3 Schem atic sum m ary  of CD28 and CTLA-4 cy to p lasm ic  
dom ains. [Amended from Ward (1996)]. A) Amino acid sequence of CD28 [Aruffo 
and Seed (1987)] and CTLA-4 [Harper et al. (1991)] is given, with potential interactions 
with signalling domains indicated. B) Schematic summary of functional domains of 
CD28 and CTLA-4 cytoplasmic tails.
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to generate different signals. Although the biochemical signals generated by CTLA-4 are 
poorly defined, CTLA-4 does contain a consensus site for PI 3-kinase binding and anti- 
CTLA-4 mAbs have been reported to induce PI 3-kinase binding to this site [Schneider et 
a l  (1995a)]. CTLA-4 is not constitutively expressed but expression is induced following 
T cell activation by TCR and CD28 ligation [Alegre et al. (1996)]. The functional role of 
CTLA-4 is currently the subject of intense investigation which, to date, has yielded 
conflicting reports. Both amplification [Jenkins (1994)], and suppression [Walunas et al
(1994)] of the T cell immune response has been postulated. Studies of gene-targeted mice 
lacking CTLA-4 however, demonstrate a progressive accumulation of T cell blasts, 
indicating CTLA-4 as a negative regulator [Waterhouse et al. (1995)]. The intra- 
cytoplasmic domains of CD28 and CTLA-4 are represented schematically in Figure 1.3.
1.4.1 Functional outcomes of CD28 ligation.
Ligation of CD28 alone has little effect on resting T cell proliferation, however CD28 
ligation in the presence of limited concentrations of anti-CD3 Ab promotes T cell 
proliferation and IL-2 production by regulating IL-2 mRNA at the level of both 
transcription and mRNA stabilisation. Costimulation via CD28 also mediates strong 
upregulation of the IL-4, EL-5, IL-13, y-interferon, tumour necrosis factor a  and 
granulocyte/macrophage colony-stimulating factor (GM-CSF) [Thompson et a l (1989); 
Minty et a l (1993); Seder et a l (1994)], up regulation of the IL-2 receptor a  and (3 
chains, and upregulation of CD40 ligand expression. Up-regulation of the chemokines 
IL-8  [Wechsler et a l  (1994)], RANTES [Turner et a l (1995)] and M IP-la  [Herold et al 
(1997)] have also been reported following CD28 stimulation. Two transcription factors 
namely, activator protein (AP)-l and nuclear factor-KB (NF-kB), have been suggested to 
be influenced by CD28, enabling such transcriptional effects [Edmead et a l (1996)]. The 
mechanisms by which CD28 regulates AP-1 and NF-kB have not yet been defined 
however, studies with inhibitors suggest that they may involve activation of PI 3-kinase 
and generation of ceramide repectively [Edmead et a l (1996)].
CD28 not only enhances EL-2 production, which can act as an extrinsic survival factor, 
but also augments the expression of the intrinsic cell survival factor Bc1-Xl [Boise et al
(1995)]. Furthermore, protein kinase B appears to be regulated by the lipid products of PI 
3-kinase [Franke et a l (1997); Stokoe et a l (1997)], and thus may be influenced by 
CD28. PKB provides a signal that is protective of cells from apoptosis induced by 
various stresses, which may correlate with its amplification in many human tumours 
[Cheng et a l  (1996)].
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1.4.2 The CD28 response element
The IL-2 gene is the best characterised of those cytokine genes affected by CD28. The 5’ 
upstream region of the IL-2 promoter, between -325 and the transcriptional start site, 
contains a number of binding sites for transcriptional factors, including API, NFkB, 
NFAT and OCT [Fraser et al. (1993)], for transcriptional activation. The binding of these 
proteins to their recognition sites within the IL-2 promoter upregulates IL-2 gene 
transcription. The CD28 response element (CD28RE) is located within the IL-2 promoter 
between -160 and -152 relative to the transcription start site. Mutation of the CD28RE, 
which appears to be related to, but distinct from the NFkB element, results in the loss of 
CD28 induced activity without affecting the TCR induced IL-2 promoter activities [Fraser 
et al. (1992a)]. In common with IL-2, several other lymphokines have conserved 
sequences within their promoters and studies have indicated that the GM-CSF, IL-3 and 
IFN-y promoters are responsive to CD28 signal transduction [Fraser et al. (1992b)].
1.4.3 The B7 family.
Ligands for CD28 and CTLA-4 have been identified as B7.1 [Freeman et al. (1989)] and 
B7.2 [Azuma et al. (1993)]. B70 is an alternate splice variant of B7.2 that is identical to 
B7.2, except for six additional amino acids at the N terminus of the B7.2 sequence 
[Azuma et al. (1993)]. Additionally, there is evidence for a further B7 molecule 
provisionally termed B7.3 [Boussiotis et al. (1993)], although this molecule has never 
been cloned or characterised. B7.1 and B7.2 are members of the immunoglobulin 
superfamily with two Ig like domains (Ig-C and Ig-V), although they share only 25% 
sequence homology. B7.1 is a 60 kDa glycoprotein consisting of the two extracellular 
disulphide-linked Ig-like domains, a transmembrane region and a 19 amino acid 
cytoplasmic domain. B7.2 is a 70 kDa glycoprotein whose major feature is an extended 
cytoplasmic region which contains potential PKC phosphorylation sites.
1.4.4 Evidence that B7.1 and B7.2 differentially regulate the immune 
response.
A number of differences have been reported between B7.1 and B7.2 which suggest these 
molecules differentially regulate the immune system: i) Whilst both B7.1 and B7.2 are
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expressed on activated monocytes, activated B and T cells and activated natural killer 
cells, only B7.2 is expressed constitutively on dendritic cells and resting monocytes 
[Lenschow et al. (1993)]. ii) B7.2 expression on human B cells activated by 
immunoglobulin crosslinking peaks within 24 hours, whilst maximal expression of B7.1 
is observed more than three days later [Boussiotis et al. (1993)]. iii) In contrast to anti- 
B7.1 mAbs, anti-B7.2 mAbs are potent inhibitors of T cell proliferation and cytokine 
production in vitro [Lenschow etal. (1993); Chen e ta l  (1994)]. iv) B7.1 is superior to 
B7.2 costimulation in the induction and maintenance of T cell-mediated anti-leukaemia 
immunity [Matulonis et al. (1996)]. v) The dissociation of the B7.2/CTLA-4 complex 
occurs much faster than the B7.1/CTLA-4 complex [Linsley et al. (1994)]. Thus the fast 
on-off nature of B7.2/CTLA-4 interactions may function to, limit an immune response 
from the high avidity CTLA-4 receptor. In support of the hypothesis that B7.1 and B7.2 
can regulate different functions, in vivo studies have shown that the molecules may play 
distinct roles in the differentiation of CD4+ Th cells. ThO cells can differentiate into either 
Thl cells (which produce IL-2, y-interferon and TN F-a, and mediate cell-mediated 
immune responses) or Th2 cells (which produce IL-4, IL-5 and IL-10 and which regulate 
humoral immune responses). It has been proposed that Th2 immune responses are 
dependent on high doses of initial antigen and CD28 costimulation, whereas Thl immune 
responses are less dependent on CD28 costimulation. Hence reports have shown that 
B7.1 preferentially acts as a costimulator of Thl cells, where as B7.2 costimulates and 
induces Th2 cells [Kuchroo etal. (1995)]. The molecular basis for the distinct regulation 
of differentiation is obscure since there are no significant differences reported in the 
ability of B7.1 and B7.2 to activate second messengers.
1.4.5 Therapeutic implications of CD28
Since effective T cell activation can orchestrate the induction of a coordinated immune 
response, there is great therapeutic potential for intervention at this point. Accordingly a 
number of trials have demonstrated a potent immunosuppressive effect associated with 
blocking T cell costimulation. This approach has been successfully applied to transplant 
biology in the prevention of graft versus host disease (GVHD) [Turka et al. (1992); 
reviewed by Guinan etal. (1994)], arthritis [Webb et al. (1996)], asthma [Tsuyuki et al.
(1997)], and multiple sclerosis [Winhagen et al. (1985)]. Conversely, blockade of 
negative regulatory pathways by antibody blocking of the CTLA-4 receptor, can also be 
used to enhance immune responses for example in tumour therapy [Leach et al. (1996)]. 
Additional to these reports, some dramatic studies have revealed an antiviral effect as a 
result of CD28 costimulation [Levine etal. (1996)]. Furthermore, CD28 costimulation of
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CD4+ T cells may confer some resistance to T cell infection by human immunodeficiency 
virus (HIV) type 1 [Riley etal. (1997)].
Despite the successes in GVHD prevention and anti-tumour therapy, unpredicted 
outcomes have arisen during trials, such as the induction of both disease suppression and 
exacerbation following the administration of anti CD80/CD86 antibodies to non-obese 
diabetic (NOD) mice [Lenschow et a l (1995); Lenschow et al. (1996)]. These findings 
reinforce the need for fundamental research in this area since the current hypotheses do 
not adequately explain all the data. A better understanding of the events which lead to T 
cell activation is therefore essential both for the identification of defects which lead to 
various diseases, and for the successful design of therapies to treat these conditions.
1.5.1 Phosphatidylinositol 3-kinase dependent signalling cascades: 
Background and discovery of phosphatidylinositol 3-kinase.
PI 3-kinase was first isolated from cells, associated with the virally encoded PTK, v-src 
[Sugimoto etal. (1984)]. Since this lipid kinase activity copurified, and was inhibited in 
parallel, with tyrosine kinase activity, the two properties were thought to be intrinsic 
activities of the same polypeptide [Sugimoto et al. (1984)]. The relationship between PI 
3-kinase and PTKs was further clarified by the observation that the PDGF receptor, 
which possesses intrinsic PTK activity, could recruit Ptdlns 3-kinase within less than a 
minute after PDGF stimulation [Whitman et al. (1987)]. Interest in the PI 3-kinase 
preceeded the discovery that it functioned in a new pathway, since association of this 
enzyme with the polyoma virus middle T antigen tightly correlated with cell 
transformation. Mutants of middle T antigen that failed to associate with the PI 3-kinase, 
also failed to transform 3T3 fibroblasts [Courtneidge and Heber (1987)].
The first full characterisation of PI 3-kinase came from the purification and cDNA cloning 
of the enzyme from bovine brain [Otsu et al. (1991); Hiles et al. (1992)]. This revealed 
the enzyme to consist of two subunits: a regulatory protein termed p85a; and a catalytic 
subunit p i 10a. The structure of the heterodimer is summarised in Figure 1.4. The p85a 
subunit contains two SH2 domains that interact with a phosphotyrosine based binding 
motif pYXXM [Pawson et al. (1995)], allowing p85a to interact with activated receptors 
or other tyrosine-phosphorylated molecules which contain this motif. The p85a subunit 
also contains an SH3 domain which may mediate protein-protein interactions through 
specific recognition of proline rich sequences [Ren et al. (1995)]. Two proline rich 
regions have also been defined on p85a which border the breakpoint cluster region
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(BCR). Interestingly, activation of PI 3-kinase via the SH3 domains binding to one 
proline-rich region (residues 84 to 99) of p85 has been reported [Pleiman et al (1994)], 
although it is not clear how this mechanism operates. The BCR has limited homology to 
the GAP (GTPase activating protein) domain of the BCR gene product. Although BCR 
domains have been identified in a number of proteins which display GAP activity towards 
the Rho family GTPases, no equivalent biochemical activity has been found for the BCR 
domain of p85 [Fry et a l (1992)]. The inter SH2 region of p85a is predicted to adopt a 
helical conformation, possibly positioning the two SH2 domains for optimal interaction 
with target proteins. This region also contains the pi 10a binding site. The pi 10a subunit 
has a corresponding interaction site for p85a at the amino terminus (residues 20-108). 
The catalytic domain of pi 10a is situated at the carboxy terminus. Several features of this 
domain are conserved in protein kinases, such as the D-F-G motif which forms part of 
the ATP binding motif. The phosphoinositide kinase (PIK) domain, which lies outside 
the catalytic domain, is conserved amongst all PI 3- and PI 4-kinases [Flanagan et a l

















Figure 1.4 Schem atic representation  of PI 3-kinase.
The lipid kinase activity of the enzyme results in the transfer of a terminal phosphate 
group from ATP to the D-3 position of the inositol ring of phophatidylinositol lipids. 
Thus PI 3-kinase can potentially generate three products: PtdIns(3)P, PtdIns(3,4)P2 or 
PtdIns(3,4,5)P3, collectively termed the D-3 phosphoinositide lipids. Considerable 
importance has been attached to the generation of these compounds, given their putative 
role as regulatory molecules. Kinetic and stoichiometric evidence indicates that
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Figure 1.5 The synthesis of D-3 phosphory lated  lip id s, a) The structure of 
Ptdlns is represented, with the numbering of the inositol ring and point of 
phosphorylation by Ptdlns 3-kinase indicated, b) Pathways leading to formation of D- 3- 
phosphorylated inositides are represented. D-series enantiomers are so called since their 
phosphodiester phosphates are analogous to that in D-InslP. PtdIns(3)P may facilitate 
roles in sorting of vesicular proteins and PtdIns(3,5)P2 may play a role in an 
osmoregulatory pathway [Dove et a l (1997)]. Further enzymes contributing to the 
formation and breakdown of these compounds are also shown.
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PtdIns(3,4,5)P3, formed by a PtdIns(4,5)P2-specific 3-kinase, is the probable major 
mediator of intracellular events [Stephens et al. (1991)]. The molecular structure of 
Ptdlns, and pathway of phosphoinositide synthesis are represented in Figure 1.5. 
Phospholipid products of PI 3-kinase recieved attention when a highly polar phospholipid 
was identified in human neutrophils, levels of which increased rapidly in response to 
fMLP stimulation [Stephens et al. (1991)]. From the chromatographic properties of the 
head group, this molecule was identified as PtdIns(3,4,5)P3 [Traynor-Kaplan et al. 
(1988)]. The identification of a second 3-phosphorylated lipid, namely PtdIns(3,4)P2 m 
the same cells [Traynor-Kaplan et al. (1989)], suggested a connection between PI 3- 
kinase and these lipids, which was further defined by the demonstration that PDGF not 
only stimulated the translocation of PI 3-kinase to its receptor but could also induce rapid 
accumulation of PtdIns(3,4,5)P3 and PtdIns(3,4)P2 which were absent from 
unstimulated cells. Since its discovery, phosphatidylinositol 3-kinase (PI 3-kinase) has 
been widely implicated in signalling cascades and cellular functions, some of which are 
summarised in Table 1.4.
In contrast to Ptdlns(3,4)7*2 and PtdIns(3,4,5)P3, cellular levels of PtdIns(3)P remain 
relatively constant on receptor stimulation [Auger et al. (1989)], indicating that the 
molecule may not play a role in signal transduction. The yeast protein Vps34, which 
displays sequence homology with the kinase domain of p i 10, only phosphorylates 
Ptdlns to PtdIns(3)P [Volinia et al. (1995)], and is known to be involved in vacuolar 
protein sorting. This has led to the belief that PtdIns(3)P is involved in vesicular 
trafficking of proteins.
The p i 10 subunit of PI 3-kinase displays a unique dual specificity as both a lipid and 
protein serine kinase [Dhand et al. (1994)]. There is limited knowledge of the significance 
of the protein serine kinase activity of the enzyme although, substrates are known to 
include 608$er on the p85a subunit [Carpenter et al. (1993)] which inhibits lipid kinase 
activity, and IRS 1 [Lam et al. (1994)], implying a role in insulin signalling.
1.5.2 The PI 3-kinase family.
Since the intial characterisation of PI 3-kinase [Otsu etal. (1991); Hiles etal. (1992)], a 
family of related proteins has emerged. At least three biochemically distinct PI 3-kinases 
have been described in mammalian cells [Reviewed by Ward et al. (1996) and 

























/Ptdlns 3-kinase Ptdlns V psl5p/p l50
Kinase domain PIK domain C2 domain
t / / / i  Proline rich domain Q  ras binding p85 binding.
Table 1.2: The classification of P I 3-kinase family m em bers. [Amended from 
Domin and Waterfield (1997)]. Members of the PI 3-kinase family display heterogeneity 
with respect to subunit compostion and substrate specificity, these are summarised above. 
The assignment of catalytic subunits to a particular class is based on sequence homology 
within the catalytic domain [Zvelebil et al. (1996)]. To date, PI 3-K-C2a is the only 
Class II member which has been shown to phosphorylate PtdIns(4,5)P2- PI3K_68D is a 
Drosophila protein whilst m-cpk and p i70 are murine proteins. The yeast enzyme 
Vps34p and its human homologue Ptdlns 3-kinase can only phosphorylate Ptdlns 
[Volinia et al. (1995)]. Ths C2 domain was originally defined as the second of four
regions within mamalian PKC where it conferred a Ca^+ sensitive phospholipid binding 
[Kaibuchi e ta l.(1980)].
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Ptdlns and PtdIns(4)P and PtdIns(4,5)P2- This class of enzymes can be further 
subdivided into Class IA and Class IB. Class IA PI 3-kinases consist of the p i 10 
catalytic subunits that are regulated by the SH2/SH3-domain containing p85 family of 
adaptor subunits just described. Class IB PI 3-kinases consist of p i 10y, an enzyme that 
associates with a plOl adaptor protein and is stimulated by G protein py subunits. 2)
Class II PI 3-kinases are larger enzymes (>200 kDa) that phosphorylate Ptdlns and 
PtdIns(4)P but not PtdIns(4,5)P2. 3) Class III PI 3-kinases which phosphorylate only
Ptdlns. Unless otherwise stated, the term PI 3-kinase will be used henceforth, to identify 
the p85/pll0  heterodimeric PI 3-kinase. The classes of PI 3-kinases are summarised in 
Table 1.2.
There is considerable heterogeneity within the family of PI 3-kinases with respect to their 
subunit composition, substrate specificity and sensitivity to PI 3-kinase inhibitors (some 
of these features are summarised in the Table 1.2). Additionally, multiple isoforms of the 
p85 (cx/P) regulatory and p i 10 (a , P, 8) catalyic subunits exist. Thus, functional 
diversity of the prototypical Ptdlns 3-kinase-dependent pathway is offered by the 
following: (i) p i 108, unlike p i 10 a  or P, does not phosphorylate the tightly associated 
p85 subunit, but instead harbours an autophosphorylatoiy capacity [Vanhaesebroeck et 
a l (1997)] which raises the possibility of differential patterns of protein phosphorylation 
occurring, (ii) compartmentalisation of the D-3 Ptdlns lipids formed by different receptors 
or classes of Ptdlns 3-kinases, (iii) distinct effector proteins mediated by individual D-3 
Ptdlns lipids formed by different receptors, (iv) multiple protein-protein interactions via 
the SH2/SH3/proline rich regions of p85.
1.5.3 PI 3-kinase couples to CD28 and the TCR.
PI 3-kinase couples to CD28 and CTLA-4 [Schneider et al. (1994)] apparently via a direct 
interaction between src-homology 2 (SH2) domain motifs and a (p)YXXM in the 
cytoplasmic tails of these molecules. The interaction of the YXXM motif with SH2 
domains of the p85 subunit depends on the tyrosine phosphorylation of this motif. CD28 
is tyrosine phosphorylated following ligation [Pages et a l (1994); August and DuPont
(1994)], and mutagenesis [Pages et a l (1994); Prasad et a l (1994); Truitt et a l (1995)] 
and phosphopeptide binding studies [Prasad et a l (1994)] have confirmed that PI 3-
kinase binds directly to CD28 via the (p)^3yM N M  motif.
The coupling of PI 3-kinase to the TCR must occur independently of a (p)YXXM motif
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since this motif is absent from the TCR. ITAMs (see section 1.2.1) however, are 
expressed singly in TCRy, 5 and e chains, whilst the TCR £ chain contains three (£1, £2 
and £3). PI 3-kinase predominantly associates with phosphopeptides that correspond to 
the phosphorylated £1 proximal motif [Exley et al. (1994)] and has been detected in £ 
immunoprecipitates [Carrera ef a l (1994)]. Although both the TCR [Ward et al. (1992)] 
andCD28 [Wardetal. (1993)] activate PI 3-kinase as evidenced by the accumulation of 
D-3 phosphoinositide lipids, there is a considerable difference in the magnitude of 
responses elicited with CD28 inducing a response 5-10 fold greater than the TCR.
1.5.4 R egulation of P I 3-K inase signal by an  S H 2 containing inosito l 5 ’ 
ph o sp h atase  (SH IP).
Afyo-inositol containing phospholipids represent a minor, but metabolically highly active, 
component of the cell membrane playing a central role in signal transduction pathways. 
Enzymes which terminate the signal transduction processes and regulate the levels of 
inositol phosphate and phospholipid messengers are thus essential to proper cell function. 
This is graphically illustrated by the case of Lowe’s oculocerebrorenal syndrome, where 
aberrant cell function is found to represent a mutation in an inositol polyphosphate 5’- 
phosphatase protein [Attree et al. (1992)]. A family of inositol 5’-phosphatases exists and 
these are summarised in Table 1.3. A recentiy identified inositol polyphosphate 5’- 
phosphatase that is expressed in haematopoietic cells is SHIP [Damen et al. (1996)]. 
SHIP is a 145 kDa protein consisting of an inositol polyphosphate 5’-phosphatase 
catalytic domain, an NH2 terminal SH2 domain, a COOH terminal proline rich domain,
which may bind SH3 domains mediating protein-protein interactions, and two NPXY 
motifs which when phosphorylated, act as ligands for phosphotyrosine binding domains 




SH2 5’Phosphatase P P P
Figure 1.6 Schem atic rep resen ta tion  of the s tru c tu re  of S H IP . Amino acid 
sequence of SHIP isolated from murine haematopoietic cell line B6SUtAi is given in 
[Damen et al. (1995)]. SH2: Src-homology domain 2; 5’ Phosphatase: inositol 
polyphosphate-5’-phosphatase domain; NXXY: potential protein tyrosine binding domain 
ligands; P: potential SH3 Ligands.
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SHIP is tyrosine phosphorylated in a variety of activated haematopoietic cell lines, but not 
quiescent cells, in response to growth factors, cytokines and crosslinking of antigen 
receptors, possibly with lek playing a role [Lamkin et a l  (1997)]. This tyrosine 
phosphorylation of SHIP mediates interactions with adaptor molecules such as She and 
Grb2 [Kavanaugh et a l (1996)], which are believed to mediate the subcellular location of 
the phosphatase. SHIP is unique, amongst 5-phosphatases, in that it targets only 
substrates that are phosphorylated on the D-3 position such as Ins(l,3,4,5)P4 and 
PtdIns(3,4,5)/>3.
5 -p h o sp h a tase MW S u b stra te s C om m ents
5-phosphatase I 43 kDa Ins(l,4,5)P3
Ins(l,3,4,5)P4
[Matzaris et a l  (1994)]




[Rosse ta l  (1991)]
OCRL 75 kDa PtdIns(4,5)P2
Ins(l,3,4,5)P4
Ins(l,4,5)P3
Golgi localised [Attree et al 
(1992)].
Synaptojanin 145 kDa Ins(l,4,5)P3
Ins(l,3,4,5)P4
PtdIns(4,5)P2
Nerve terminal protein. Contains 
region homologous to yeastSac 1 
gene which is implicated in 
phosphoinositide metabolism. 
[McPherson et a l  (1996)]
SHIP 145 kDa Ins(l,3,4,5)P4
PtdIns(3,4,5)P3
Unique in substrate specificity 
and SH2 domain [Damen et a l 
(1996)]
SHIP2 142 kDa Ins(l,3,4,5)P4
PtdIns(3,4,5)P3
[Pesesse et a l  (1998)]
INPPL-1 126 kDa Not demonstrated to 
date.
Closely homologous to SHIP. 
Discovered in Fanconi’s anaemia 
cells. [Lioubin e ta l  (1996)]
Table 1.3: Sum m ary of know n 5 -p h o sp h a ta se s . All enzymes mentioned encode 
a signature motif of 5-phosphatases comprising GDXN(F/Y)R and /or 
P(A/S)W(C/T)DRIL, however alignment of family members indicates the catalytic 
domain spreads over 300 amino acids with several highly conserved motifs [Mitchell et 
al (1996)]. Additionally, inositol polyphosphate-like protein 1 (INPPL 1), SHIP and 
Synaptojanin contain carboxy terminal proline rich regions, which bind to SH3 domains.
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SHIP has been implicated as inhibitory to B cell activation [Amigorena etal. (1992)], due 
to its association with FcyRIIB (CD32), a low affinity IgG receptor expressed on 
monocytes and B cells. IgG antibodies inhibit B cell activation by co-aggregating 
FcyRIIB and the B cell antigen receptor. The negative regulatory function of FcyRIIB 
was found to be dependent upon the presence of an I/VxYxxL/V motif, termed the 
immunoreceptor tyrosine-based inhibitory motif (ITIM) [D’ambrosia et a l (1995)], 
reflecting its structural and functional similarity to the ITAM (see section 1.2). FcyRIIB 
has also been found to inhibit cells activated by single chain chimaeric molecules bearing 
the intracytoplasmic domain of Ig-a [Muta et al. (1994)], FcRy or CD3 C, [Daeron et a l 
(1995)]. Thus, rather than being a B cell specific regulatory molecule, FcyRIIB is a 
general negative co-receptor for all ITAM-bearing receptors expressed by haematopoietic 
cells. The mechanisms of SHIP inhibitory signalling in B cell activation are obscure but 
may involve modulating calcium influx [Muta et al. (1994); Ono et al. (1996)], via an 
effect on Bruton’s tyrosine kinase (Btk) [Bolland et al. (1998)]. PtdIns(3,4,5)P3 in turn
recruits Btk to the plasma membrane through an interaction with its PH domain, to 
regulate calcium fluxes. Activation of SHIP inhibits the levels of PtdIns(3,4,5)P3
inhibiting Btk association with the plasma membrane. Whether SHIP truly represents an 
“o ff’ switch, or rather a modification of the cell activating signal is a moot point. Taking 
the case of PI 3-kinase generated PtdIns(3,4,5)P3, clearly SHIP activity will deplete
levels of the putative signalling molecule. However, there may be downstream targets for 
the SHIP-generated inositides, that include Ptdlns (3,4)P2> such as PKB [Carpenter and
Cantley (1996)] or PKC family members [Toker et al.(1994)].
1.5.5.1 Inhibitors of PI 3-kinase: Wortmannin.
Whilst the exact role of the D-3 phosphorylated products of PI 3-kinase is not entirely 
clear, one of the most valuable tools in elucidating a role for PI 3-kinase is wortmannin 
[Arcaro and Wymann (1993)]. Wortmannin is a cell permeant, fungal metabolite which 
has been widely employed as an inhibitor of PI 3-kinase-dependent pathways, since PI 3- 
kinase enzymatic function was shown to be inhibited by wortmannin at low nanomolar 
concentrations (e.g. <10 nM) [Arcaro and Wymann (1993)]. Inhibition of both protein 
serine and lipid kinase activities is achieved by covalent binding to the p i 10 catalytic 
subunit [Thelen et a l (1994)], an interaction which appears dependent upon Lys^02 
within p i 10 [Wymann et al. (1996)]. Some of the cellular functions inhibited by 
wortmannin are summarised in Table 1.4.
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F unctiona l response A gon ist W ortm annin
co n cen tra tio n
(nM )
R eference
i) Respiratory burst from 
neutrophils
fMLP 5 Arcaro and
Wymann
(1993)
ii) T cell chemotaxis RANTES 5 Turner et al. 
(1996)
iii) IL-2 production from T 
cells
CD28 10 Ward et al. 
(1995)
iv) T cell proliferation CD28+CD3 10-100 Kamitz et al. 
(1995)
v) Actin rearrangements in 
fibroblasts
PDGF 5 Wymann and 
Arcaro (1994)
vi) Membrane ruffling in 
endothelial cells
PDGF 10-100 Wennstrom et 
al. (1994)
vii) p i integrin upregulation in 





10-100 Shimizu et al. 
(1995)
viii) Histamine secretion and 
leukotriene release from RBL 
cells
FcsRl 3 Yano et al. 
(1993)
ix) Phagocytosis in U937 cells Fey receptor 
induced
10-100 Ninomiya et 
al.{1994)
x) Inhibition of iNOS 10-100 Wright et al. 
(1997).
Table 1.4 Functional responses of P I 3 -k in ase . Some of the functional 
responses sensitive to nanomolar concentrations of wortmannin are given in the Table.
Limitations exist however on the use of wortmannin as a specific inhibitor of PI 3-kinase, 
since further targets for wortmannin have been identified in phospholipase A2 (with an 
IC5 0  of 2 nM) [Cross et al. (1995)] and mammalian soluble PI 4-kinase (with an IC5 0  of 
3-5 nM) [Nakanishi et al. (1995)], and at elevated concentrations phospholipase D
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[Reinhold et al. (1990)] and phospholipase C [Bonser et al. (1991)]. Additionally 
wortmanin has been reported to inhibit the mammalian target of rapamycin (mTOR) 
which regulates p70 S6 kinase, a potential PI 3-kinase target (see section 1.5.6.2) [Brunn 
et al. (1996)]. Further problems are placed on the interpretation of data generated using 
wortmannin as it inhibits different classes of PI 3-kinases to different extents, for 
example wortmannin inhibits class IA PI 3-kinases and class III PI 3-kinase with an IC5 0  
of <10 nM [Arcaro and Wymann (1993); Volinia et al. (1995)], whilst the IC5 0  for 
inhibition of class IB PI 3-kinase is 40-50 nM. Furthermore, mammalian class II PI 3- 
kinases such as PI 3-kinase C 2a are refractory to wortmannin [Domin et al. (1997)].
1.5.5.2 O th er inh ib ito rs  o f P I 3-kinase.
— o
LY294002 Wortmannin
F igure  1.7 The chem ical s tru c tu res  of LY294002 and w o rtm an n in .
Wortmannin [Arcaro and Wyman (1993)] and LY294002 [Vlahos et al. (1994)] are 
structurally unrelated, but both inhibit PI 3kinase with an IC5 0  of 5nM and 1.4 mM, 
respectively.
A novel PI 3-kinase inhibitor, namely 2-(4-morpholinyl)-8-phenyl-4H-l-benzopyran-4- 
one (LY294002) has been synthesised, and demonstrated to inhibit purified bovine brain 
PI 3-kinase with an IC5 0  of 1.4 pM [Vlahos et al. (1994)]. LY294002 was found to
inhibit PI 3-kinase dependent proliferation of cultured rabbit aortic smooth muscle cells 
and completely abolish fMLP-induced PI 3-kinase activity in human neutrophils. No 
significant effects of LY294002 were observed on the activity of other enzymes 
including PI 4-kinase, src, MAP-kinase, S6 kinase, DAG kinase, PKA and PKC [Vlahos 
et al. (1994)].
Demethoxyviridine is structurally related to, but distinct from, wortmannin and has been 
observed to inhibit purified class-IA PI 3-kinase with an IC5 0  of 3.4 nM [Wolscholki et
al. (1994)]. Demethoxy viridine, in common with wortmannin however, has been 
reported to inhibit targets other than PI 3-kinase [Bonser et al. (1991)].
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1.5.5.3 Alternative strategies to investigate the role of PI 3-kinase.
The potential problems of non-specific inhibitors can be circumvented by the use of 
mutated PI 3-kinase isoforms. Several cDNAs corresponding to PI 3-kinase have been 
engineered to produce active or inactive forms, to demonstrate either an effect of 
increased PI 3-kinase activity or an effect of blocking PI 3-kinase by using a dominant 
negative type approach. Mutated forms of p85 that lack the p i 10-binding site, have been 
shown to behave as dominant negative proteins that block activation of PI 3-kinase 
activity [Hara et al. (1994)], presumably by binding through their SH2 domains and 
forming non-productive complexes. Such a dominant negative mutant has previously 
been observed to inhibit insulin-stimulated PtdIns(3,4,5)P3 accumulation in U937 cells
[Stephens et al. (1995)]. An antisense cDNA vector to p85 has also been used to block 
class IA PI 3-kinase activation [Yin et al. (1998)]. Alternatively, a form of p i 10 
covalently attached to the inter SH2 domain (pi 10 binding domain) of p85, via a glycine 
linker region, has been shown to be active independently of p85-mediated regulation [Hu 
et al. (1995)]. Genetic approaches have also demonstrated membrane localisation of the 
p i 10 subunit by myristoylation, famesylation [Klippel et al. (1996)], or by fusing the 
catalytic domain of p i 10 with the extracellular domain and transmembrane region of rat 
CD2 [Reif et al. (1996)], as sufficient to result in a constitutively active PI 3-kinase 
mutant. Generally, the combined use of PI 3-kinase inhibitors and blocking or activation 
of PI 3-kinase using molecular reagents, allows for the construction of more robust 
arguments regarding the role of the enzyme in specific cellular events being studied.
1.5.6 PI 3-kinase dependent signalling cascades
The biochemical events downstream of PI 3-kinase are currently the subject of intense 
research. Recently, it has become increasingly apparent that PI 3-kinase may mediate its 
effect by the interaction of certain D-3 phosphoinositide lipids with pleckstrin homology 
(PH) domains. PH domains are protein modules of around 100 amino acids found in 
several proteins involved in signal transduction [Haslam et al. (1993)]. Although its 
specific function has yet to be elucidated, the carboxy terminal regions of many PH 
domains bind to the Py subunits of G proteins [Koch et al. (1993)]. A further clue to the 
function of PH domains lies in their ability to bind phosphoinositide lipids [Haslam et al. 
(1993); Harlan et al. (1994)], which may facilitate the localisation of the PH domain 
containing protein to phospholipid membranes. Indeed, many PH domain containing
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proteins need to be associated with membranes for their function, but lack classical 
membrane-anchoring groups such as a hydrophobic helix or sites for post-translational 
addition of lipid molecules. For example, pG-spectrin, which contains a PH domain, has
been shown to interact with brain membranes depleted of peripheral proteins [Davis and 
Bennett (1994)], but does not contain a classical membrane-anchoring group. Many of 
the reported downstream effectors of PI 3-kinase contain PH domains and these include 
PKB [Klippel et a l (1997)], PLCyl [Falasca et a l (1998)], tyrosine kinases such as ITK 
[August et a l (1997)] and Bruton’s tyrosine kinase [Salim et a l (1996)], and the guanine 
nucleotide exchange factor Vav [Han et a l (1998)]. Of the growing number of putative 
downstream targets of PI 3-kinase, a number are particularly relevant to T cell activation, 
and are discussed below.
1.5.6.1.1 Protein kinase B (PKB)
Protein kinase B was identified independently in 1991 by three groups, leading to a 
potentially confusing nomenclature of the molecule as protein kinase B [Coffer et a l
(1991)], RAC-protein kinase [Jones et a l  (1991)] or Akt [Bellacossa et a l  (1991)]. To 
avoid confusion the molecule is referred to herein as protein kinase B (PKB). The 
molecule is approximately 60 kDa consisting of a serine/threonine kinase domain 
stretching from residues 148-411, which displays 73% homology with the kinase domain 
of PKC 8, and 68% homology with the kinase domain of protein kinase A. Additional to 
the catalytic domain, there is a pleckstrin homolgy domain (PH) at the amino terminal 
end, which makes up the major part of the amino-terminal regulatory domain spanning 
residues 1-147, and has been referred to as the Akt homology (AH) domain. The 
carboxy-terminal tail region accounts for the rest of the protein, see Figure 1.8 below.
1 106 148 412 480
PH Kinase domain Tail
jAkt-Homology domain | Thr308 Ser473
Figure 1.8 Diagrammatic structure of human PKBa.
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1.5.6.1.2 R egulation of PKB.
PKB is activated in cells in response to a variety of growth stimuli including platelet 
derived growth factor (PDGF), epidermal growth factor (EGF), insulin, thrombin and 
nerve growth factor (NGF). A number of lines of evidence suggest a role for PI 3-kinase 
in the regulation of PKB: (i) Growth factor induced activation of PKB is inhibited by 
wortmannin [Franke et a l (1995)], and expression of a dominant negative form of p85 
[Burgering and Coffer (1995)]; (ii) PDGF receptor mutants which fail to activate PI 3- 
kinase, also fail to activate PKB [Burgering and Coffer (1995)]; and (iii) active mutants 
of PI 3-kinase activate PKB. Indeed, a wealth of publications have implicated PKB as an 











Protein kinase B DK 2
Phosphorylation of 
downstream targets
Figure 1.9 Schem atic model for activation of protein kinase B. Following 
growth factor receptor stimulation, PI 3-kinase is activated generating PtdIns(3,4,5)P3, 
hydrolysis of this lipid by 5-phosphatases leads to PtdIns(3,4)P2 formation. Both lipids 
interact with the PH domains of PKB and PDK1 inducing co-localisation at the plasma 
membrane where PKB is subject to phoshorylation by PDK1 at ^^^Thr and the putative 
PDK2 at 473$er? inducing full activation. Stress activation of the p38 MAP kinase 
pathway represents a potential route for PKB activation since MAPKAP K2 has been 
demonstrated to phosphorylate PKB at 473$er at least in vitro [Alessi et a l (1996)].
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PKB is activated synergistically by the dual phosphorylation of its 473$;er an(j 308xhr 
residues [Alessi et al. (1996)]. The amino acid sequences around these sites are very 
different, suggesting that two distinct kinases catalyse these phosphorylations. One PKB 
directed kinase has been identified in PtdIns(3,4,5)P3-dependent kinase 1 (PDK1) which
phosphorylates 308xhr [Alessi et al. (1997)]. The ^^Ser-kinase has been provisionally 
termed PDK2 by Alessi et a l although the molecule has not been cloned or purified to 
date. PDK2 also appears to be dependent on PI 3-kinase activity since phosphorylation of 
473Ser, in response to insulin, is inhibited by wortmannin [Alessi et a l (1996)].
PKB binds both PtdIns(3,4,5)P3 and PtdIns(3,4)P2 via its PH domain, although the 
interaction with PtdIns(3,4)P2 is about ten-fold weaker [James et al. (1996); Freeh et al. 
(1997)]. Neither lipid directly affects the activity of PKB [James et al. (1996); Alessi et 
al. (1997)], however, PKB is translocated to the plasma membrane as a result of lipid 
binding. PDK1 also binds both PtdIns(3,4,5)P3 and Ptdlns(3,4)7*2 via its PH domain,
and is consequently translocated to the plasma membrane [Anderson et al. (1998)]. 
Similar to PKB, the kinase activity of PDK1 is unlikely to be affected by the binding of 
lipids since PDK1 activity is not stimulated by insulin in vitro [Alessi et a l  (1997)]. 
Furthermore, the recently reported ability of PDK1 to phosphorylate p70 S6 kinase is not 
regulated by PtdIns(3,4,5)P3 [Pullen et al. (1998)]. The ability of the D-3
phosphoinositides to “activate” PDK1 may result from a substrate concentrating effect, 
and/or the induction of a conformational change in PKB that facilitates the 
phosphorylation of 308rflir After phosphorylation at both sites, activated PKB may 
detach from the membrane to phosphorylate cytosolic targets. Evidence also exists for the 
nuclear translocation of PKB isoforms within 20-30 minutes following stimulation of 
cells [Meier et al. (1997)].
Discrepancies from this model have arisen in the literature, suggesting that PtdIns(3,4)P2
may have a direct effect upon the activity of PKB [Freeh et al. (1996); Franke et al. 
(1997); Klippel et al. (1997)], and that whilst Ptdlns(3,4)7*2 is stimulatory, 
PtdIns(3,4,5)P3 may be inhibitory to PKB activity [Freeh et al. (1996); Franke et al.
(1997)]. These observations may be explained by PDK1 contamination of the PKB 
preparations, and inhibitory contaminants of synthetic phospholipids respectively.
In addition to PI 3-kinase-dependent PKB regulation, further pathways must clearly exist 
since cellular stresses, such as heat shock and hyperosmolarity (both of which activate the 
p38/HOGl cascade) can stimulate the PKB activity [Konishi et al. (1994)]. Mitogen- 
activated protein kinase (MAPK)-activated protein kinase 2 (MAPKAP kinase 2), a direct 
target of p38/HOGl, can phosphorylate PKB at least in vitro [Alessi et al. (1996)] and
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may represent a potential PKB activating pathway for cellular stresses by mechanisms 
independent of PI 3-kinase. A model of PKB activation representing these regulatory 
inputs is shown in Figure 1.9.
1.5.6.1.3 Downstream targets of PKB.
The downstream targets of PKB are currently the subject of keen interest since activation 
of the kinase has been shown to suppress the apoptotic death of a number of cell types in 
response to U.V. radiation [Kulik et al. (1997)], withdrawal of insulin like growth factor- 
1 (IGF-1) from neuronal cells [Dudek et al. (1997)] and detachment of cells from an 
extracellular matrix (anoikis) [Kwhaja et al. (1997)]. A direct substrate for PKB has been 
identified in glycogen synthase kinase 3 (GSK 3) [Cross et al. (1995]. Phosphorylation 
of GSK 3 by PKB, results in its inactivation and subsequent activation of glycogen 
synthesis [Cross et al. (1995)]. A further target for PKB is the ribosomal protein S6 
kinase p7 ()S6 K? although there is no evidence to suggest that this is a direct substrate 
[Burgering and Coffer (1995)]. Additionally PKB has been shown to stimulate glucose 
uptake and GLUT 4 translocation [Kohn et al. (1996)]. Recently a further target for PKB 
has been described, namely BAD, which is more relevant to the cell survival mechanism 
of PKB. BAD is a distant member of the Bel 2 family of proteins (see section 1.7) which, 
when unphosphorylated, interacts and inactivates the cell survival factors Bc1-Xl  and
Bcl-2, and can thus promote apoptosis [Zha et al. (1996)]. PKB can phosphorylate a 
critical serine residue, ^ ^ S e r  , on BAD causing it to dissociate from, and thus activate 
the cell survival factor Bel X l  [Datta et al. (1997)]. The serine phosphorylated BAD is
then bound preferentially to a cytosolic protein termed 14-3-3 [Zha et al. (1996)] and this 
may represent a specific mechanism for sequestration of BAD during cell survival.
1.5.6.2 p70 S6 kinase
A further target for PI 3-kinase is p70 S6  kinase, a ubiquitous, mitogen activated 
serine/threonine kinase, that is necessary for G1 to S-phase progression within the cell 
division cycle [Reinhard etal. (1994)]. On activation, the enzyme is subject to multi-site 
phosphorylation and in turn phosphorylates the 40S ribosomal subunit protein S6 , which 
correlates with increased translation, especially of mRNAs containing a polypyrimidine 
tract in their 5’ untranslated regions [Jefferies et al. (1997)]. Essentially two lines of 
evidence suggest that p70 S6  kinase is a downstream effector of PI 3-kinase. Firstly, PI 
3-kinase is required for the phosphorylation of ^52 jjir jn the catalytic domain of p70 S6
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kinase [Weng et a l (1995)], and secondly, activation of the enzyme by insulin or PDGF 
is sensitive to wortmannin [Chung et al. (1994)]. The mechanism of PI 3-kinase 
activation of p70 S6 kinase however, is unclear and in fact one study has suggested the 
effect of wortmannin in blocking p70 S6 kinase activation may not be due to inhibition of 
PI 3-kinase, since a dominant negative form of PI 3-kinase that blocked insulin stimulated 
PI 3-kinase activity, was unable to block activation of p70 S6 kinase [Hara et a l (1995)]. 
Studies of p70 S6 kinase regulation involving wortmannin may have been complicated by 
the fact that the genes encoding the targets of rapamycin in yeast TOR 1 and TOR 2 
[Kunz et a l (1993)], and the human homologue mammalian target of rapamycin (mTOR) 
or FKBP-rapamycin associated protein (FRAP), which are upstream regulatory proteins 
of p70 S6 kinase, show strong homology with domains of p i 10. Lipid kinase enzymatic 
activity of the TOR proteins has not been demonstrated, but the kinase domain has been 
shown to be important for their G1 cell cycle function [Zheng et a l  (1995)]. 
Furthermore, wortmannin and LY294002 have been demonstrated to inhibit autokinase 
activity of mTOR [Brunn et a l (1996)]. Therefore, it is possible that apparent effects of 
PI 3-kinase on p70 S6 kinase activity may be due to reported sequence homology 
between mTOR and PI 3-kinase.
Two studies have also suggested the recently cloned 3-phosphoinositide-dependent 
kinase 1 (PDK1) is an upstream p70 S6 kinase regulatory molecule [Alessi et a l (1997b); 
Pullen et a l  (1998)]. PDK 1 was isolated and cloned on the basis of its ability to 
phosphorylate PKB [Alessi et a l (1997a)]. Using purified recombinant forms of PDK 1 
and p70 S6 kinase, it has been demonstrated that PDK 1 specifically phosphorylates p70 
S6 kinase at residue ^29xjir in vitro [Alessi et a l (1997b); Pullen et a l  (1998)]. Although 
PKB and p70 S6 kinase differ structurally, their sequences show that 229Thr and ^ ^ T h r  
of p70 S6 kinase are analogous to 3 0 8 ^ ^  and 473ger 0f  PKB respectively [Pullen et al
(1998)], and this may reflect a regulatory mechanism conserved for PKB and p70 S6 
kinase [Reviewed by Downward (1998)]. The curent understanding of p70 S6 kinase 
activation [Reviewed more comprehensively by Pullen and Thomas (1997)] can be 
summarised in the following model: Proline directed kinases (such as MAP kinases) 
phosphorylate a number of sites in the COOH auto-inhibitory domain [Ferrari et a l
(1992)]. This relieves a conformational inhibition that may result from the interaction of 
the NH2 and COOH terminals of the protein. 389jhr is then phosphorylated by an 
unidentified PtdIns(3,4,5)P3-dependent kinase, suggested as the putative PDK 2 [Pullen 
et a l (1998)]. Both of these steps are required to expose 229xhr as a substrate for the 
constitutively active PDK 1, yielding active p70 S6 kinase. The multisite phosphorylation 
of p70 S6 kinase is suggestive of a complex control mechanism, however, clarification of 
the regulation of S6 kinase may be an important step in understanding how cell
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proliferation is controlled.
1.5.6.3 Mitogen activated protein kinase cascades.
Mitogen activated protein kinase (MAP kinase) was initially identified as a 
serine/threonine kinase, based on its ability to phosphorylate microtubule-associated 
protein [Ray and Sturgill (1987)]. Much investigation has revealed the MAP kinase 
family as a cascade of proteins, representing a major intracellular signalling system. MAP 
kinases are activated by a diverse array of extracellular stimuli and regulate a variety of 
cellular processes. Although, in mammalian cells, a degree of cross-talk exists, three 
cascades have been elucidated in the extracellular regulated kinases (ERKs), the c-jun 
NH2-terminal kinases (JNKs or stress activated protein kinases) and p38. These three
cascades are represented schematically in the Figure 1.10.
Evidence is accumulating that PI 3-kinase may be involved in the regulation of either or 
both of the signalling cascades that control ERK or JNK activity, and thus regulation of 
c-jun or c-fos. This is supported by the observation that fos transcription can be activated 
by a constitutively active p i 10 mutant [Hu et al (1995)]. Since this is a Ras dependent 
effect it implies that PI 3-kinase can modulate the p21ras pathway, and thus, the eventual 
modulation of ERKs that are thought to be involved in the transmission of signals from 
p21ras to the nucleus. Furthermore, the ras-related GTP-binding protein rac, which has 
been implicated as an upstream regulator of JNK [Minden et al. (1995)], appears to be a 
downstream effector for PI 3-kinase.
Interestingly JNK has been reported as synergistically activated by CD28 and TCR 
ligation in the leukaemic T cell line Jurkat [Su et al. (1994)]. This has led to the 
suggestion that JNK represents a point of integration of the signals for T cell activation 
and IL-2 production.
Similarly, a recent report also implicated p21-CDC42/Rac as a point of integration of the 
CD3 and CD28 signals [Kaga et al. (1998)]. Activation of PAK may be mediated via 
ceramide generation since treatment of Jurkat cells with C2-ceramide could mimic the 
activating effect of CD28 [Kaga et a l (1998)], correlating well with previous data 
[Westwick et al. (1995)], thus this pathway could potentially be independent of PI 3- 
kinase. The importance of this pathway has been demonstrated by the use of murine T 
cells deficient in the expression of SEK1, which show impaired CD28 mediated IL-2 
production and proliferation [Nishina etal. (1997)].
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Figure 1.10 Schem atic sum m ary of the mitogen activated protein k in a se s .
[Adapted from Kyriakis and Avruch (1996)]. Although represented here as linear, a 
degree of cross-talk does occur within mammalian cells. TEY, TPY and TGY are amino 
acid sequences characteristic to each pathway that are dually phosphorylated as a 
requirement for MAP kinase activation. SB203580 and PD98059 are pharmacological 
inhibitors. Activation of ERKs is induced by agonists for tyrosine kinase coupled 
receptors such as EGF, PDGF and TCR/CD3 complex can involve ras-mediated 
translocation to the plasma membrane, of the upstream kinase c-raf, which 
phosphorylates, thus activating the downstream kinase MAPK/ERK kinase (MEK, also 
known as MAPK kinase 1, MKK1). The JNK family of MAP kinases are activated by 
cellular stresses (such as U.V. light, y-irradiation and osmotic or heat stress), 
inflammatory cytokines (TNFa and interleukin-1) and ceramides. JNKs phosphorylate 
the NH2-terminal activation domain of c-jun and ATF 2, increasing their transcriptional 
activity. p38 MAP kinase is activated by osmotic stress and lipopolysaccharide (LPS). 
Substrates of p38 include MAPKAP kinase 2 [Pulverer et al. (1991)], and the ATF 2 
transcription factor. PAK 1 (p21 activated kinase) is activated directly on binding active 
Rac 1 and Cdc 42 in vitro. GCK is germinal center kinase [Katz et al. (1994)]. Max is a 
Myc binding protein phosphorylated in vitro by Mxi 2 (a p38 isoform) [Zervos et al. 
(1995)].
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1.5.6.4 PI 3-kinase regulates the phospholipase C pathway.
A large variety of extracellular signals stimulate the hydrolysis of PtdIns(4,5)P2 by the
activation of PLC isoforms [Rhee and Bae (1997)]. The two products of this hydrolysis, 
Ins(l,4,5)P3 and diacylglycerol, mediate the release of intracellular calcium [Berridge
(1993)], and activation of protein kinase C [Nishizuka (1995)], respectively. The critical 
role of these pathways in mammalian growth and development is demonstrated by the 
recent finding that targeted deletion of PLCyl causes embryonic lethality in mice [Ji et al.
(1997)]. It has been demonstrated that phosphorylation of ^ ^ T y r  0f  PLCyl is essential 
for stimulation of enzymatic activity in NIH-3T3 cells stimulated with PDGF [Kim et a l
(1991)]. However tyrosine phosphorylation does not strictly correlate with Ins(l,4,5)P3
production, since some extracellular signals induce weak tyrosine phosphorylation of 
PLCyl and extensive production of Ins(l,4,5)P3, whilst other signals cause strong 
tyrosine phosphorylation of PLCyl, yet only low levels of Ins(l,4,5)P3 production 
[Rhee and Bae (1997)]. Therefore, additional control mechanisms, independent of 
PLCyl tyrosine phosphorylation are likely to play a role in PLC enzymatic activity. 
Indeed, recent publications have suggested a role for Ptdlns(3,4,5)7*3 in the activation of
PLCyl via interactions of the lipid with both the PH domain [Falasca et al. (1998)], and 
the SH2 domain [Rameh et al. (1995); Bae et al. (1998)] of PLCyl, and this may 
represent an important means of regulation.
In common with the TCR, CD28 has been reported to regulate the tyrosine 
phosphorylation of PLCyl, Ptdlns hydrolysis and the cytosolic free calcium 
concentration [Ledbetter et al. (1986); Weiss et al. (1986)]. Discrepancies appear 
however in the relative ability of CD28 to elicit these responses, dependant upon the type 
of T cell model used, for example, in Jurkat cells, Ptdlns hydrolysis, increases in 
intracellular calcium and diacyglycerol generation can be elicited in the absence of cross 
Unking [Nunes et al. (1993)]. However, it has been noted that the abihty of anti-CD28 
mAbs to elicit these signals is dependent on the epitope recognised by the mAb [Nunes et 
al. (1993)]. Moreover, other groups have reported that CD28 cross-linking is a 
prerequisite for eliciting PLC activity in purified resting T cells, activated T cells and 
human CD28-transfected murine T cell hybridoma [Ledbetter et al. (1986); Weiss et al. 
(1986); Ledbetter et al. (1990); Couez et al. (1994)]. In marked contrast to anti-CD28 
mAbs, B7.1 failed to elicit any detectable activation of PLC as assessed by Ptdlns(4,5)7*2
degradation and phosphatidic acid generation [Ward et al. (1993)]. This suggests that 
PLC activation following mAb stimulation of CD28 may be functionally redundant.
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1.5.6.5 PI 3-kinase activates protein kinase C (PKC) family isoforms.
Members of the serine/threonine protein kinase family, protein kinase C have been 
shown to be activated by the second messenger diacylglycerol (DAG), which is formed 
following agonist-dependent turnover of inositol lipids. This is known to form the basis 
of a signalling pathway [Hokin (1985)]. However, the present family of PKC isozymes 
contains 11 members that differ in their structure and function, observations which form 
the basis of their grouping: Conventional PKC's a ,  (3 and y; Novel PKC’s 5, e, rj and 
0; Atypical X and i, and PKC p . Most PKC isotypes (with the exception of atypical 
isoforms) display DAG, or phorbol ester, dependence for activation. The family of PKC 
isozymes is summarised in Table 1.5. The PKC isozymes 8, 8, r| and C, have been 
shown to be activated, at least in vitro, by the lipid products of PI 3-kinase [Nakanishi et 
al. (1993); Toker et al. (1994)]. Palmer et al. (1995) suggested however, that this may be 
an in vitro artifact resulting from lipid vesicles in the assays that contained highly charged 
phospholipids. On comparing the in vitro activity of PKC(3, 8, T|, £ and a member of the 
PKC-related kinase family, PRK1, both PtdIns(4,5)P2 and PtdIns(3,4,5)P3 activated
each of the enzymes with similar activation constants, implying a lack of specificity in this 
in vitro analysis [Palmer et al. (1995)]. A few studies however, have linked the activation 
of PI 3-kinase to the activation of protein kinase C isoforms in whole cells. For example, 
the addition of PtdIns(3,4,5)P3 to permeabilised platelets, stimulated the phosphorylation
of pleckstrin, a major PKC substrate, and the lipid could bypass the block of PI 3-kinase 
activity by wortmannin [Zhang et al. (1995)]. Other studies have also demonstrated that 
insulin mediated activation of PKC£ can be blocked by PI 3-kinase inhibitors and 
expression of dominant negative p85 [Standaert et al. (1997)].
Sub group Isoforms DAG PdBu Ca2+
conventional «, P, Y + + +
novel 5, e, t|, e + + -
atypical CX.V - - -
PKC p n + + -
Table 1.5 The p ro te in  kinase C fam ily . The 11 members of the present family of 
PKC enzymes are grouped on a combination of structural and functional considerations. 
Sensitivity to diacylglycerol (DAG), Phorbol dibutyrate (PdBu), or calcium are indicated. 
PKC p is also referred to as protein kinase D [Van Lint et al. (1995)].
Additional to lipid mediated regulation of PKC, two groups have shown a direct 
association between PI 3-kinase and PKC isoforms, such as PKC8 and PKCs in human
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haematopoietic cells and platelets [Ettinger et a l (1996)], and PKC£ during IL-2 
stimulation of murine T cells [Gomez et a l (1996)]. This could enable the direct 
phosphorylation of PKC by PI 3-kinase, allowing for further complexity in PKC 
regulation.
Studies with phorbol esters have previously implicated PKC in the control of many 
signalling pathways including those mediated by p21ras and the mitogen activated protein 
(MAP) kinases such as extra cellular signal-regulated kinases (ERK) and c-jun N- 
terminal kinase (JNK). The PKC responsive element in the enhancer of the IL-2 gene 
contains sites for NF-kB, AP-1 and NF-AT1 [Genot et a l (1995)]. Although the role of 
specific isoforms is poorly understood, PKCe has been implicated in the induction of 
AP-1 and NF-AT1 [Genot et a l (1995)], whilst PKC£ has been suggested to play a role 
in NF-kB induction in fibroblasts (although not in T cells, to date). Interestingly, PKC£ 
has also been suggested as a direct target for ceramide and, thus may play a role in 
sphingomyelinase signalling. Thus PKC£ could represent a potential target for integration 
of the CD28-induced PI 3-kinase signals and sphingomyelinase signals.
1.5.7.1 Other signalling pathways activated by CD28: Protein tyrosine 
phosphorylation.
Analysis of the cytoplasmic domain of CD28 reveals no obvious inherent enzymatic 
activity, however ligation is followed by tyrosine phosphorylation of a number of 
substrates including CD28 itself, Vav and the adaptor protein p62^0^ [Klasen et al
(1998)]. Thus in common with the TCR, CD28 must recruit non-receptor tyrosine 
kinases. Extending this analogy, it was further proposed that src family tyrosine kinases 
such as p59fyn and p 5 6 ^  were coupled to CD28 [Prasad et a l (1994)]. Indeed, p 5 6 ^  
has been reported to be activated in Jurkat cells following CD28 ligation by cross linked 
antibody, but not by CD28 mAb alone [August and Dupont (1994)]. In lek deficient cell 
lines CD28 ligation by mAb elicits impaired calcium mobilisation and is unable to elicit 
tyrosine phosphorylation of certain substrates [Straus and Weiss (1992)]. Despite the pre­
requisite of tyrosine phosphorylation for its association with PI 3-kinase, CD28 has been 
demonstrated to couple to PI 3-kinase in lek deficient cell lines [Lu et a l (1994)]. Thus, 
it has been suggested that there are at least two PTK pathways activated in response to 
CD28 ligation, only one of which is dependent on p 5 6 ^  activity. Further to the 
proposed involvement src family protein tyrosine kinases in CD28 signal transduction, a 
member of the Tec family kinase p7 2 ^K /EM T has been shown to be associated with 
CD28, in the Jurkat T cell line following ligation by mAb, in the presence or absence of
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cross linking [August et al. (1994)]. ITK has been reported to negatively regulate T cell 
proliferation induced by the CD28 mediated costimulatory signal since proliferation in 
response to anti-CD28 antibody and sub-optimal CD3 stimulation, was enhanced in ITK 
deficient mouse T cells when compared to cells derived from normal animals [Liao et al 
(1997)].
Although the identity of the CD28-directed PTK remains to be convincingly demonstrated 
under in vivo conditions, baculovirus expression systems and in vitro phosphorylation of 
CD28 peptides reveal that lck and fyn are capable of phosphorylating l^ T y r  within the 
cytoplasmic tail of CD28 [Raab et al. (1995)]. Furthermore, ITK appears capable of 
phosphorylating all four tyrosine residues in the CD28 cytoplasmic domain [King et al. 
(1997)]. These studies are summarised in Figure 1.11. Additional to the tyrosine 
phosphorylation sites of CD28, several sites exist which may form potential sites for 
phosphorylation by protein kinase C [Hutchcroft and Bierer (1996)]. These are also 
indicated in Figure 1.11.
F igure 1.11 Schem atic m odel of potentia l tyrosine and se rin e /th reo n in e  
phosphory la tion  of CD28 cytoplasm ic dom ain. Baculovirus expression studies 
in insect cells have demonstrated tyrosine 173 as a substrate of both lck and fyn, and the 
binding of ITK to be dependent upon lck [Raab et al. (1995)]. CD28 mutation studies in 
Jurkat cells have demonstrated ITK to phosphorylate all four tyrosine residues of the 
cytoplasmic tails [King et al. (1997)].
1.5.7.2 CD28 couples to  p 2 1 r *s
Ras is a small, membrane bound, guanine nucleotide-binding protein that acts as a 
molecular switch linking receptor-associated tyrosine kinase activation to signalling 
events, with downstream effectors reported to include PI 3-kinase [Rodriguez-Vicinia et 






dissociation stimulator (Ral GDS) [Kikuchi et a l (1994)] (a GNEF for Ral). Ras cycles 
between an inactive GDP-bound state, and an active GTP-bound state. Thus Ras activity 
is regulated by proteins which influence the relative proportions of these bound guanine 
nucleotides. Guanine nucleotide exchange factors (GNEFs) activate Ras whilst GTPase- 
activating proteins (GAPs) down regulate Ras activity. Potentially, two routes couple 
CD28 to the p21ras pathway. Firstly, Vav is a 97 kDa GNEF identified as a substrate for 
CD28 induced tyrosine phosphorylation [Klasen et al. (1998)]. The Dbl domain of Vav 
confers GNEF activity and, although substrates for this activity are controversial, Vav 
has been demonstrated to have GNEF activity for Ras at least in vitro [Gulbins et a l 
(1993)], Secondly, Grb2 is an adaptor protein which associates with a GNEF known to 
activate p21ras namely, Sos. Grb2 has been shown to associate, albeit at low affinity, 
with CD28 via the PI 3-kinase binding motif (p)^^YM NM  [Schneider et a l (1995a)], 
which corresponds to the concensus binding motif (p)YXNX for Grb2 [Songyang et a l
(1993)].
The CD28 mAb, CD28.2 can activate the p21ras pathway since it has been shown to 
induce an increase in ras-GTP complexes and the phosphorylation of both Vav and the 
Grb2/Sos-associated protein p36 [Nunes et a l (1994)]. The functional relevance of CD28 
coupling to the p21ras pathway is called into question however, by the observation that 
binding of the natural ligand B7.1, fails to induce tyrosine phosphorylation of either Grb2 
or p36 [Nunes et a l (1994)], although tyrosine phosphorylation of Vav can be detected 
after both Ab or ligand stimulation of CD28. Thus CD28 can potentially couple to the 
p21ras pathway, as demonstrated by the CD28.2 mAb, however it may not activate Ras 
following ligation by B7.
1.5.7.3 CD28 activates acidic sphingomyelinase.
CD28 has been reported to activate acidic sphingomyelinase (A-SMase)[Boucher et a l
(1995)], catalysing sphingomyelin hydrolysis to phosphorylcholine and the putative 
signalling molecule ceramide. Pro-inflammatory cytokines such as TNF and IL-1, 
activate both A-SMase and N-SMase, whilst CD28 was observed to activate A-SMase in 
the absence of N-SMase activation, a property which distinguishes its signalling from that 
of pro-inflammatory cytokines. Many signalling pathways ascribed to CD28 also appear 
to be engaged by the TCR, however ligation of the TCR has not been demonstrated to 
activate A-SMase. Thus activation of A-SMase may donate an element of specificity to the 
CD28 derived signal. A number of putative targets for ceramide have been identified 
including ceramide activated protein phosphatase (CAPP) [Dobrowsky and Hannun
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(1992)], ceramide activated protein kinase (CAPK) [Mathias et a l (1991)], JNK 
[Westwick et a l (1995)], PKC£ [Hannun and Obeid (1995)], the proto-oncogenes vav 
and ras [Gulbins et a l (1995)], and caspase 3 [Smyth et a l (1996)]. Such a repertoire of 
downstream targets enable ceramide to influence a wide range of biological processes 
including apoptosis, inhibition of proliferation, differentiation and protein secretion 
[Hannun (1994)]. Whether ceramide signals trigger positive or negative outcomes are 
likely to be influenced by the context and location of ceramide generation, for example, 
ceramide induced apoptosis in Jurkat cells is converted to a proliferative response in the 
presence of DAG [Hannun (1994)].
1.6.1 Structure and function CD95.
CD95, also known as Apo-1 or Fas, comprises of 325 amino acids with a signal 
sequence at the N terminal and a central transmembrane domain [Nagata (1994)] 
indicative of a type 1 membrane protein. It has a molecular weight of 45 kDa and is 
encoded by a sequence which maps to human chromosome 10q24.21 [Nagata (1994)]. 
CD95 is a member of the TNFR/NGFR superfamily, comprising over more than twelve 
receptors, further members of which include TNFR 1/2, NGFR, PV-T2, CD40, CD27, 
0X 40 and 4-IBB [for review see Smith et al. (1994)]. They signal for broad spectrum of 
functional outcomes encompassing induction of thymocyte proliferation (TNFR 2) 
[Tartaglia et al. (1991)], immunoglobulin-class switching (CD40) [Kwabe et al. (1994)] 
and induction of apoptosis. CD95 triggers an apoptotic pathway when ligated [Itoh et a l 
(1991)]. The fundamental difference between this process and necrosis, or “accidental” 
cell death, lies in the fact that it is an active, gene directed process. Morphological and 
biochemical analyses of apoptotic cells indicate that apoptosis is accompanied by 
condensation of cytoplasm, loss of plasma membrane microvilli, segmentation of the 
nucleus and extensive degradation of chromosmal DNA into oligomers of about 180 bp. 
[Kerr et a l (1972)]. The apoptotic cells subsequently fragment into membrane bound 
apoptotic bodies which are rapidly phagocytosed and digested by macrophages or 
neighbouring cells. Apoptosis is believed to play an essential role in development, tissue 
homeostasis, defence against viral infection and clearance of damaged cells from 
multicellular organisms [Steller (1995)].
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1.6.2 CD95L: “A ligand to kill”.
Following the identification of CD95 as a receptor that could trigger apoptosis in 
susceptible cells, the identification and characterisation of a natural ligand became a key 
question. The ligand gene for CD95 (CD95L) was cloned and characterised by Suda and 
co-workers [Suda et al. (1994)], and found to encode a type II membrane protein 
comprising 270 amio acids with a molecular weight of 40 kDa. The expression of CD95L 
is relatively restricted and it is predomiantly found on activated T [Suda et a l (1995)] and 
Natural Killer (NK) cells [Arase et al. (1995)], although expression has been documented 
on neutrophils [Liles et al. (1996)], dendritic cells [Lu et al. (1997)] and macrophages 
[Badley et al. (1997)]. Chemical cross linking and gel filtration analysis have indicated 
that human soluble CD95L exists as a trimer [Tanaka et al. (1995)]. In addition to 
mediating apoptosis of target cells, T cell CD95L expression has also been implicated in 
the induction of cell suicide since T cells themselves express the CD95 receptor. A role 
for CD95L in cell suicide has been confirmed at the single cell level [Brunner et al.
(1995)] and one such physiological trigger for such suicide is believed to be TCR 
engagement [Wesselborg et al. (1993)]. The first evidence that TCR engagement might be 
linked to apoptosis induction came from studies in immature thymocytes in which anti- 
CD3 treatment was associated with the rapid induction of cell death [Smith et al. (1989)]. 
Later work demonstrated that whilst resting mature T cells were relatively resistant to 
TCR-induced apoptosis, previously activated T cells could be triggered to undergo cell 
death when stimulated in this manner [Ucker et al. (1992); Wesselborg et al. (1993)]. In 
fact, sensitivity to this form of apoptosis was enhanced by cytokines such as IL-2 and IL- 
4 which promoted S-phase entry [Lenardo (1991)]. This phenomenon was termed 
activation induced cell death (AICD).
1.6.3 CD95 signal transduction: associated molecules.
CD95-mediated apoptosis occurs independently of both RNA and protein synthesis [Itoh 
et al. (1991)], suggesting this pathway exists in a preformed state. The cytoplasmic 
domain of CD95 comprises of 145 amino acids but lacks any recognised motifs for 
enzymatic activity [Itoh et al. (1991)], thus presumably the molecule signals via the 
recruitment of cellular enzymes. A 68 amino acid sequence shared with the TNFR, 
termed the “death domain”, within the Fas cytoplasmic domain has been identified,which 
mediates association with other death domain containing proteins and is necessary for the 
transduction of death signals. The yeast two-hybrid system has been used to demonstrate 
CD95 interaction with death domain containing proteins such as FADD (Fas associated
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death domain containing protein), also known as MORT 1 [Chinnaiyan et a l (1995)] and 
RIP (receptor interacting protein) [Stanger et a l (1995)]. The binding of FADD to the 
death domain appears to be dependent on the trimerisation of CD95 molecules. This is 
concordant with the observation that self association of the CD95 death domains is 
sufficient to induce a death signal [Boldin et a l (1995)]. Further CD95 associated 
signalling molecules have been identified in the CAPS (cytotoxicity dependent Apo-1 
associated proteins) which associate with oligomerised, but not monomeric, CD95 
[Kischkel et a l (1995)]. Whilst CAP 1 and CAP 2 have been identified as serine 
phosphorylated forms of FADD, CAPS 3 and 4 may represent novel apoptosis 
transducing molecules [Kischkel et a l (1995)]. An additional protein DAXX has been 
recently demonstrated to interact with the CD95 cytoplasmic domain, despite the lack of a 
death domain, and is thought to be involved with CD95 JNK activation [Yang et al. 
(1997)]. The recruitment of death domain containing proteins such as FADD, RIP and 
CAPS to the CD95 death domain results in the formation of a signalling complex that is 
collectively called the DISC (death-inducing singalling complex) [Kischkel et a l (1995)].
The carboxy terminus of the CD95 cytoplasmic tail comprises a 15 amino acid “salvation 
domain” which negatively regulates CD95 signalling [Itoh and Nagata (1993)] by 
interaction with the tyrosine phosphatase FAP 1 (Fas associated phosphatase 1) [Sato et 
al (1995)]. Deletion of the salvation domain has been shown to enhance CD95 
interaction with FADD and expression of FAP-1 encoding DNA leads to reduction in 
CD95 sensitivity. This suggests that one or more tyrosine kinases may play a role in 
CD95 killing. Moreover, it has previously been demonstrated that CD95 activity is 
inhibited by tyrosine kinase inhibitors, and ligation of CD95 leads to the tyrosine 
phosphorylation of a number of cellular substrates [Eischen et a l (1994)]. Indeed, the 
tyrosine kinase fyn has been demonstrated to physically associate with CD95, and 
activated T lymphocytes from fyn knock out mice are less sensitive to killing on CD95 















Figure 1.12 Schem atic rep resen ta tion  o f CD95 m ediated death s ig n a llin g .
The DISC (death inducing signalling complex) is formed by recruitment of death domain 
containing proteins (such as FADD, RIP, and CAPS) to the CD95 death domain. FAP1 
is recruited to the salvation domain and may inhibit DISC formation. The DISC can 
recruit and activate caspase 8 (FLICE). DAXX associates with the CD95 cytoplasmic 
region and may be involved in JNK activation. Points of inhibition of death signalling are 
denoted by green border. The release of mitochondrial factors is thought to precede 
activation of caspase 3. Cyt c is cytochrome c, and AIF is Apoptosis Inducing Factor. 
Arrows do not necessarily indicate a direct link.
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1.6.4 CD95 activates caspases.
A key event in the execution of apoptotic pathways is the activation of a cascade of 
aspartate-specific cysteine proteases (caspases). A large number of genes relevant to the 
cell death pathway have been identified from work on the nematode Caenorhabditis 
elegans , termed ced genes (C. elegans death genes). These include ced-3 (homologous 
with mammalian caspase 1), ced-9 (homologous with mammalian BCL-2) and ced-4, for 
which no mammalian homologue has been identified. CD95 may activate caspases by 
recruitment of caspase 8, which interacts directly with the DISC via an interaction with 
the death effector domains of FADD, becoming proteolytically activated as a consequence 
[Medema et al. (1997)]. Which caspases participate in apoptosis appears to be highly cell 
type, and stimulus, dependent. CD95 killing of T cells however, is believed to involve 
sequential activation of caspase 8 (FLICE), caspase 1 (ICE), and caspase 3 (PRICE), see 
Figure 1.12. This is supported by the observation that caspase 1-deficient mice exhibit a 
defect in CD95-mediated apoptosis, yet still undergo apoptosis in response to 
dexamethasone or y irradiation [Cleveland and Ihle (1995)]. Furthermore, treatment with 
cell soluble fluoromethyl ketone caspase inhibitors such as Z-VAD-FMK (a pan-ICE 
nhibitor), inhibits CD95 killing in many cell types [Sarin et al. (1996)] implicating 
caspase activity as an essential step in the apoptotic pathway. Requirement of caspase 
activation in CD95-mediated apoptosis has also been demonstrated by the expression of 
crmA [Los et al. (1995); Enari et al. (1995)], a cytokine-response modifier gene encoded 
by cowpox virus that is a natural caspase inhibitor [Ray et al. (1992)].
A number of putative substrates for the caspases have been identified including (3-actin, 
a-fodrin and lamin B1 [Martin et al. (1995b); Neamati et al. (1995)], the substrate 
responsible for committing cells to apoptosis remains unknown. The early demonstration 
that poly (ADP-ribose) polymerase (PARP) was a substrate for caspase 3 [Lazebnik et al.
(1994)] suggested a possible role in the shut down of DNA repair processes. However, 
despite being a useful marker of apoptosis induction, PARP cleavage is dispensible for 
apoptosis [Wang et al. (1997)]. Interestingly, PKC5 represents an alternative substrate 
for caspase 3, and the caspase inhibitor YVAD has been reported block both PKC8 
activation and DNA fragmentation in U937 cells exposed to ionizing radiation [Emoto et 
al. (1995)], suggesting a role for PKC8 in apotosis.
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1.6.5 CD95 signals via ceramide.
The familial relationship of CD95 with TNFR prompted signalling comparisons which 
indicated some homology. One event reported to follow CD95, TNFR and CD28 ligation 
is the activation of certain forms of the lipid enzyme sphingomyelinase. The nature of the 
sphingomyelinase enzyme involved in CD95 signalling is still the subject of debate. 
Whilst the TNFR activates both acidic and neutral sphigomyelinase, and CD28 signalling 
only uses the acidic form [Boucher et a l (1995)], there is evidence for CD95 using both 
acidic [Gulbins et a l (1995)], and neutral sphingomyelinase [Tepper et a l (1995)]. 
Certainly, CD95 ligation is followed by sphigomyelin hydrolysis and an increase in 
ceramide generation [Gill et a l (1994)]. This appears to be necessary for cell death since 
cells expressing Fas, but defective in ceramide signalling, are resistant to Fas mediated 
apoptosis [Tepper et a l (1995)]. Treatment of these cells with synthetic ceramide 
analogues induced apoptosis, which was inhibited by treatment of cells with phorbol-12- 
myristate- 13-acetate, suggesting opposing roles for protein kinase C and ceramide in 
regulation of apoptosis [Tepper et a l (1995)].
1.6.6 Mitochondrial changes.
A further event recently implicated in apoptotic signalling is that of mitochondrial 
permeability transition (PT) involving a disruption of the mitochondrial inner 
transmembrane potential. In viable cells, the unequal distribution of ions across the inner 
mitochondrial membrane generates an electrochemical potential gradient which is 
intimately involved in the physiological transduction of chemical energy. The disruption 
of this transmembrane potential has recently been identified as an early marker of cells 
committed to apoptosis following diverse stimuli including CD95 ligation [Castedo et al
(1996)] and is believed to involve a process termed permeability transition during which 
mitochondrial protein can leak into the cytosol. Such proteins include cytochrome c and 
apoptosis inducing factor (AIF) [Zamzami e ta l  (1996)]. AIF is known to proteolytically 
activate caspase 3 and can induce characteristic apoptotic changes when applied to isolated 
nuclei [Susin et a l (1997)]. Interestingly, inhibition of caspase 1 prevented CD95- 
mediated disruption in the inner mitochondrial transmembrane potential [Castedo et al
(1996)], demonstrating that part of the caspase cascade occurs upstream of such 
mitochondrial changes, whilst the activation of other proteases (such as caspase 3) may 
lie downstream of this process [Susin et a l  (1997)].
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1.7 Negative regulation of CD95 signalling.
Apoptotic pathways are subject to regulation by a growing number of proteins. One of the 
first to be identified was Bcl-2, a 26 kDa protein, associated with mitochondrial and 
perinuclear membranes. Although initially thought to function via an anti-oxidant method 
[Hockenbery et a l (1993)], there is now evidence that this protein may operate by 
altering the mitochondrial release of apoptosis-inducing factors [Kluck et a l (1997)]. 
Subsequent to Bcl-2, a whole family of related, pro- and anti- apoptotic, proteins have 
been identified, these proteins share a common domain of approximately 66 amino acids, 
comprising the Bcl-2 homology regions 1 and 2 (BH1 and BH2). Pro-apoptotic 
intracellular proteins include Bax (21 kDa), Bak (23 kDa), Bcl-Xs (21 kDa) and BAD
[Gajewski and Thompson (1996)]. Anti- and pro-apoptotic proteins are summarised in 
Table 1.6.











Table 1.6 Bcl-2 R elated P ro te in s . Adapted from [Gajewski and Thompson 
(1996)]. A given family member may perform either function depending on the cell 
system utilised [Kiefer et a l (1995); Cotazzo et a l (1996); Middleton et a l (1996)]. 
Functional outcome may correlate with the ability to dimerise with further family 
members, or with how extra cellular signals regulate phosphorylation.
Proteins implicated in protection against apoptosis include BAG 1 and Bc1-Xl (29 kDa), 
although a given family member may perform either function, depending on the 
cellsystem utilised [Kiefer et a l (1995); Cotazzo et a l (1996); Middleton et a l (1996)]. 
Bcl-2 and Bc1-Xl have been suggested to function by heterodimerisation with Bax, thus
preventing the formation of toxic Bax homodimers [Gajewski and Thompson (1996)]. 
Conversely, the dimerisation of a further protein, BAD with Bcl-2 or Bc1-Xl , seems to
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liberate Bax and promote apoptosis induction [Gajewski and Thompson (1996)]. The 
relative role of the Bcl-2 family members in the modulation of mitochondrial events 
compared to the sequestration of pro-apoptotic proteins remains to be resolved.
Additional negative regulation of CD95 signalling is achieved by FLICE inhibitory 
proteins (FLIPS) [Irmler et a l (1997)]. FLIPS bind to the death affector domain (DED) 
of FADD, and inhibit the FADD-caspase 8 interaction [Thome et a l (1997)]. The FLIPS 
effectively act as dummy caspase 8 proteins and since they lack protease activity, prevent 
caspase activation inhibiting apototic signalling. Interestingly, FLIPS have been found in 
melanoma lesions suggesting that upregulation may occur during tumorigenesis [Irmler et 
al (1995)]. Further negative regulation is made possible by the death effector domain- 
containing protein CLARP (caspase-like apoptosis regulatory protein) which interacts 
with and regulates caspase 8 [Inohara et a l (1997)] and the death domain binding protein 
sentrin which can inhibit both CD95 and TNFR mediated apoptosis [Okura et a l  (1996)].
1.8 Costimulation of T cell activation by CD95.
Interestingly, there is evidence to support a positive, possibly costimulatory, role for 
CD95-derived signals, contrasting to its more widely accepted function in apoptosis 
induction. In this respect anti-CD95 antibodies have been reported to cooperate with sub 
optimal TCR stimulation in the induction of T cell proliferation [Alderson et a l (1993)], 
although these data await corroboration. Additionaly, T cells from CD95 defective Ipr 
mice are less responsive to antigenic stimuli than are normal T cells [Davignon et a l 
(1985)], which could be interpreted as implicating CD95 in a stimulatory role. 
Furthermore, recent reports studying murine T cells that fail to express FADD have 
shown these cells to be defective in activation induced proliferation [Zhang et a l  (1998)]. 
Two potentially divergent pathways must therefore be involved at the level of signal 
transduction in order for CD95 to be responsible for two such contrasting outcomes, 
proliferation or apoptosis. How this might be achieved under physiological conditions is 
currently unknown.
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1.9 Aims and objectives.
The intracellular signalling mechanisms employed by CD28 in preventing apoptosis and 
driving proliferation are poorly understood, however, the profound consequence of 
CD28 signalling make it an attractive point for therapeutic intervention in conditions 
where immunomodulation would be desirable. An understanding of the biochemical 
nature of costimulatory signalling is of fundamental importance in the design of such 
therapies, and therefore requires further investigation.
At the outset of this project previous work in the laboratory had demonstrated, by direct 
extraction of phosphorylated lipids from radiolabelled cells, that CD28 coupled and 
activated PI 3-kinase [Ward et a l (1993)]. This correlated well with the observation that 
the cytoplasmic domain of CD28 contained a (p)YMNM binding motif which, in its 
phosphorylated state, bound the SH2 domains of p85, the regulatory subunit of PI 3- 
kinase [Pages et a l  (1994); Prasad et a l (1994)]. There are however, a number of 
outstanding questions relating to the discrete biochemical events that he proximal and 
distal to CD28 recruitment and activation of PI 3-kinase, thus this study was intiated with 
the following aims:
1) To investigate the early biochemical events regulating recruitment and activation 
of PI 3-kinase with particular emphasis on the role of PKC and protein tyrosine 
kinase lck, in light of previous studies from other groups [Raab et a l  (1995); 
Hutchcroft et a l (1996)] that indicate these molecules exert a regulatory effect 
on CD28 signal transduction.
2) To investigate the effect of CD28 ligation on serine/threonine phosphorylation of 
CD28 and the role of PKC/ PI 3-kinase in this event, given i) the presence of a 
number of a number of serine/threonine residues within the CD28 cytoplasmic 
tail, some of which lie within potential PKC phosphorylation motifs, ii) the 
reported dual lipid and protein kinase activity of PI 3-kinase, and iii) that certain 
isoforms of PKC can be activated by PI 3-kinase.
3) To determine whether CD28-mediated activation of PI 3-kinase was sufficient to 
activate the known downstream effector targets of PI 3-kinase such as PKB and 
p70 S6 kinase.
4) To investigate the role, if any, of PI 3-kinase dependent signalling events in Fas 
signal transduction, given that Fas can act as a costimulatory molecule under 
certain conditions.
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SECTION TW O 
M ATERIALS AND M ETHODS
2.1.1 MATERIALS
The materials used in this project, together with their sources, are listed below:
R eagen t Source/C om m ent
Adenosine triphosphate Sigma, Poole, U.K. Stock stored at -20°C as 100 
mM diluted in 100 mM Tris-HCl pH 7.4
Ampicillin Sigma, Poole, U.K. Stock stored at -20°C at 100 
mg/ml dissolved in sterile filtered ddH20.
Biorad protein reagent Biorad, U.K. Used according to manufacturers 
instructions.
Bromophenol blue BDH, Poole U.K.
C2 ceramide Calbiochem Novabiochem, U.K. Stored at -20°C as 
1 mM stock dissolved in DMSO.
C2 dihydroceramide Calbiochem Novabiochem, U.K. Biologically 
inactive analogue. Stored at -20°C as 1 mM stock 
dissolved in DMSO.
Chloroform Fisher Scientific, U.K.
Electroporation cuvettes Northumbria Biologicals, U.K.
Enhanced Amersham International, Amersham U.K.
Chemiluminescence reagent Storage at 4°C.
Ethidium bromide Sigma, Poole U.K. Stock 10 mg/ml dissolved in 
ddH20 stored at 4°C
Ethyl formate Fisher Scientific, U.K.
soluble Fas-Ligand Generous gift of Dr David Sansom, University of 
Bath. U.K.
Flo-Scint IV scintillation fluid Canberra Packard, U.K.
GF/A filter paper Whatman, U.K.
Glacial acetic acid Fisher Scientific, U.K.
Glutathione Sepharose 4B Pharmacia U.K. Hydrated beads, stored at 4°C and 
washed in phosphate buffered saline (PBS) before 
use.
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H7 Calbiochem-Novabiochem, U.K. Stock stored at - 
20°C as 1 mM dissolved in ddH20.
Heparin Purchased as Monoparin, 5000 U/ml from C.P. 
Pharmaceuticals Ltd., Wrexham U.K.
Histone H2B Boehringer Manneheim, Germany. Stock stored at - 
20°C at 1 mg/ml in 20 mM Tris pH 7.5.
Hydrochloric acid BDH, Poole, U.K.
Human recombinant (hr) IL-2 Generous gift from Dr Ivan Lindley, Sandoz, Vienna, 
Austria.
Ionomycin Calbiochem-Novobiochem, U.K.
IPTG (Isopropyl P -D- 
thiogalactopyranoside)
Sigma, Poole, U.K. 1 M stock prepared by 
dissolving 238.3 mg in 1 ml water, stored at -20°C.
Lymphoprep Nycomed, Birmingham, U.K.
LY294002 Calbiochem Novabiochem, U.K. Stored at -20°C as 
5 mM stock dissolved in DMSO.
Molecular weight markers Gibco BRL, Paisley, U.K.
Methanol Fisher Scientific, U.K.
N-butanol BDH, Pool, U.K.
Nitrocellulose protran BA85 
blotting membrane
Schleicher and Schuell, Dassel, Germany.
NP40 Fisher Scientific, U.K.
Optiphase scintillation fluid Canberra Packard, U.K.
PD10 columns Pharmacia U.K. Desalting columns packed with 
sephadex G-25.
PD98059 Kind gift of Dr Alan Saltiel, Parke-Davis, USA. 
Stock stored at -20°C, 5 mM dissolved in DMSO.
Petroleum ether BDH, Poole, U.K.
Phenyl methylsulphonyl 
fluoride (PMSF)
Sigma, Poole, U.K. Dissolved in acetone, stored as 
100 mM stock at -20°C.
4a-phorbol Sigma, Poole, U.K. Stored as 5 mM stock in DMSO 
at -20°C.
Phosphate free DMEM Sigma, Poole, U.K.
Phorbol-12-myristate-13- 
acetate (PMA)
Calbiochem-Novabiochem, U.K. Stored as 5 mM 
stock in DMSO at -20°C.
Propan-l-ol Fisher Scientific, U.K.
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Protein A sepharose CL4B Pharmacia, U.K. Prepared according to the 
manufacturers instruction, stored sterile at 4°C.
Protein G beads Sigma, Poole, U.K.
Protein Kinase Inhibitor Sigma, Poole, U.K. Stored at -20°C as 5 \xM stock 
diluted in 0.05% BSA.
Protogel aciylamide Flowgen, U.K.
PVDF Polyscreen DuPont NEN research products, Boston, USA.
Rapamycin Generous gift of Dr Catherine Bansbach (Wyeth 
Ayerst, Princeton, USA). Stored as solid in dark, 
dissolved in ethanol when needed.
Ro31/8220 Generous gift of Dr J.S. Nixon, Roche, U.K.
Rubidium Chloride Fluka, Germany.
Silica Gel 60, TLC plates Whatman, U.K.
Sodium hydroxide Fisher Scientific, U.K.
Staurosporine Calbiochem-Novabiochem, U.K. Stock stored at - 
20°C as 1 mM dissolved in DMSO.




Trypan blue solution (0.4 %) Sigma, Poole U.K. Cell culture grade.
Wortmannin Sigma, Poole, U.K. Stored at -80°C, as 5 mM stock 
dissolved in DMSO.
ZVAD-FMK Calbiochem-Novabiochem, U.K. Stock stored at - 
20°C as 2 mM dissolved in DMSO.
PBS comprised: 80 mM N a2H P04,20 mM NaH2P04 and 100 mM NaCl, pH7.5 made 
up in ddH20. All other reagents were purchased from Sigma, Poole, U.K. unless 
otherwise stated. All sterile, cell culture grade plastics and culture media were purchased 
from Gibco BRL (Paisley, U.K.) unless otherwise stated.
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2.1.2 Antibodies
The antibodies used in this project, together with their sources, are listed below.
A ntibody S ource/C om m ents
9.3 anti-human CD28 Generous gift of Dr Carl June (NMRI, Bethesda, 
USA). Used for cell stimulations, Western blotting 
(diluted 1:1000) and I.P.’s coupled to protein A beads
CD28.2 anti-human CD28 Generous gift of Dr Daniel Olive (INSERM, 
Marseille, France). Used for cell stimulation.
anti-p85a Generous gift of Dr Doreen Cantrell (ICRF, London, 
U.K.) Used for Western blotting (diluted 1:1000) and 
I.P.’s coupled to protein G beads.
UCHT1 anti-human CD3 Generous gift of Dr Doreen Cantrell (ICRF, London, 
U.K.) Used for cell stimulation, Western blotting 
(diluted 1:1000) and I.P.’s coupled to protein A 
beads.
Anti-protein kinase B a Kind gift of Dr Brian Hemmings (FMI, Basel, 
Switzerland). Used for Western blotting (diluted 
1:100) and I.P.’s coupled to protein A beads.
Anti-protein kinase B PH, 
PKB(3 and PKBy
Generous gift of Dr Dario Alessi (MRC, Dundee, 
U.K.). Used for Western blotting (diluted 1:1000) 
and I.P.’s coupled to protein A beads.
Phosphospecific anti-PKB 
serine 473 (p) and anti PKB
Purchased in kit form from New England 




Purchased in kit form from New England 
Biochemicals (Beverly, MA, USA). Used according 
to the manufacturers instructions.
CH11 anti-CD95 Purchased from TCS biologicals U.K. IgM molecule. 
Used for cell stimulations.
Anti-p70 S6 kinase Purchased from Santa Cruz USA. Used for Western 
blotting according to manufacturers instructions.
12CA5 (Anti-HA) Generous gift of Dr D. Cantrell (ICRF, London. 
U.K.). Used for Western blotting (diluted 1:1000) 
and I.P.’s coupled to protein G.
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Anti-SHIP Generous gift of Dr Mark Coggleshall (Ohio State 
University, USA). Ab raised in rabbits to SHIP 
residues 872-941. Used for Western blotting (diluted 
1:1000) and I.P.’s coupled to protein A beads.
Goat anti-rabbit IgG-HRP 
Rabbit anti-goat IgG-HRP 
Rabbit anti-sheep IgG-HRP 
Goat anti-mouse IgG-HRP
Purchased from DAKO, Denmark. Used as 
secondary antibodies in chemiluminescent protein 
detection protocol diluted at 1:5000.
Goat anti-mouse-FITC Purchased from Sigma, used as secondary antibody 
in FACS according to manufacturers instructions.
Sheep anti-mouse IgG coated 
magentic beads.
Purchased from Dynal, Norway. Used according to 
the manufacturers instructions.
2.1.3 Plasmids
The plasmids used in this study are listed below, together with their sources.
P lasm id S ource/C om m ent
PK C a Generous gift of Dr Peter Parker (ICRF London, 
U.K.) Constitutively active mutant generated by 
substitution of a E for an A residue at position 25, 
expressed in pCC>2 vector.
PKCC Generous gift of Dr Peter Parker (ICRF London, 
U.K.) Constitutively active mutant produced by 
substitution of a E for an A residue at position 119, 
expressed in pMT-2 vector.
rCD2pllO Generous gift of Dr Doreen Cantrell (ICRF London, 
U.K.). Constitutively activated, myc tagged, p i 10 by 
linking to extracellular and transmembrane regions of 
rCD2. pEF-BOS vector. [Reif et al. (1996)].
rCD2pllOR/P Generous gift of Dr Doreen Cantrell (ICRF London, 
U.K.). PI 3-kinase inactivated by point mutation 
R1130P in kinase domain, myc tagged. pEF-BOS 
vector [Reif et al. (1996)].
HA-PKB Generous gift of Dr B. Burgering (Utrecht, 
Netherlands) pEF-BOS vector.
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HA-PKB kinase dead Generous gift of Dr P. Tsischlis (Fox-Chase Cancer 
Centre, USA) pcmv-6 vector.
Ap85 Generous gift of Dr C.P. Downes (Dundee, U.K.) 
pcDNA3.1 vector.
2 .1 .4  R ad io iso topes.
Radioisotopes used in this study are listed below, together with their sources. All assays 
utilising radio-isotopes were carried out in 1.5 ml screw capped micro tubes (Sartedt, 
Germany).
R ad io iso to p e Source/C om m ent
[y_32p]_ATP (5 jiCi/ml, 3000 Ci/mmol, in aqueous solution) 




(5 mCi/ml, 8500-9120 Ci/mmol) purchased from 
NEN DuPont (Stevenage, UK). Stored at room 
temperature.
Phosphatidyl [2-^H] inositol- 
4-monophosphate
(37 GBq/mmol, 1.0 Ci/mmol) purchased from 




(37 GBq/mmol, 1.0 Ci/mmol) was purchased from 





(1.1 lTBq/mmol, 30 Ci/mmol) was purchased from 
NEN DuPont (Stevenage, U.K.). Stored at 4°C.
[^H] thymidine (1 mCi/ml, 2 Ci/mmol) was purchased from 
Amersham International (Little Chalfont, U.K.)
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2.2 METHODS
2.2.1 Cell cu ltu re
All cells were grown at a constant 37°C in an humidified atmosphere of air supplemented 
with 5% C02- Cells were routinely passaged every two days. To maintain stocks, cell
lines were frozen for long term storage under liquid nitrogen, as follows. Cells were 
pelleted (500 g, 10 min) and resuspended at 10^ cells/ml in 20% FBS/10% DMSO and 
aliquoted into freezing vials. Vials were lowered into liquid nitrogen over a number of 
hours, using a Handi-Freeze freezing tray (Taylor-Wharton). When necessary, cells were 
rapidly thawed in a water bath (37°C), washed three times in fresh medium and returned 
to culture. Cell viability was determined by trypan blue exclusion, 100 pi of cells were 
removed from culture and diluted with 400 p,l RPMI and 100 pi trypan blue solution. 
Cells were placed on a haemocytometer and examined under a light microscope, viable 
cells were those which excluded the trypan blue stain.
The cell lines used in this study are outlined below:
Cell line S ource /C om m ents
Jurkat J6 Generous gift of Dr Andres Alcover (INSERM, Paris, France). 
Leukaemic T cell line, cultured in RPMI 1640 supplemented with 
10% FBS, streptomycin (50 pg/ml) and penicillin (50 U/ml).
Jurkat J16 Obtained from American Type Culture Collection (ATCC) 
(Rockville, USA). Grown in RPMI 1640 supplemented with 10% 
FBS, streptomycin (50 pg/ml) and penicillin (50 U/ml).
CTLL Obtained from ATCC (Rockville, USA). Murine T cell line, 
cultured in RPMI-1640 supplemented with 10% FBS, hr-IL-2 (20 
ng/ml) streptomycin (50 pg/ml) and penicillin (50 U/ml), in upright 
25 cm^ flasks.
DC27.1 Generous gift of Dr Daniel Olive (INSERM, Marseille, France). 
Murine hybridoma cell line stably transfected to express wild type 
and mutated human CD28 (as described in Figure 2.1). Cells were 
cultured in DMEM supplemented with 10% FBS, streptomycin (50 




Generous gift Dr D. Sansom (Bath University, U.K.). Chinese 
Hamster Ovary (CHO) cells, used as parental (control) cells or 
stably transfected to express CD80 [Sansom et a l (1993)]. 
Cultured in DMEM supplemented with 10% FBS, streptomycin 
(50 pg/ml), penicillin (50 U/ml), 25 mM HEPES, 0.375% (w/v) 
NaHC03, and the nucleosides adenosine, cytidine, uridine,
thymidine and guanosine (all at 20 pM). These are adherent cells 
and when confluent, were passaged by trypsinisation. Briefly, cells 
were washed twice by rinsing with PBS (pH 7.3), before 
incubation with Trypsin-EDTA (Gibco BRL, U.K.) for five 
minutes at 37°C. Trypsinisation was terminated by the addition of 
20 ml fresh culture medium, cells were passaged (routinely 1:5), 
washed twice and returned to culture.
CD28 (wild type)
Transm em brane 173 188 191 200
dom ain y  ▼ Y Y
FflFWV RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS




f iif w v | r s k r s r l l h s d y m n m t p r r p
A30
FIIFWV RSKRSRLLHSD
173 188 191 200
DYF173 y y y y
FIIFWVlRSKRSRLLHSDFMNMTPRRPGPTRKHYQPY APPRDFAAYRS
173 188 191 200
DYF2 0 0  y y y y
FIIFWV RSKRSRLLHSD YMNMTPRRPGPTRKH Y QPY APPRDFAAFRS
Figure 2.1 D iagram m atic rep resen ta tion  of hum an CD28 m utants s tab ly  
transfected  into DC27.1 cell lin e . To examine the contribution of regions or 
residues of the cytoplasmic tail of CD28 to its signalling function, the above mutations 
were made, in human CD28, which was then expressed in DC27.1 cells. Substitution of 
tyrosine for phenyl alanine is structurally conservative. Transfected cell lines were found 
to express equivalent amounts of CD28, and routinely checked for CD28 expression, by 
FACS analysis.
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2.2.2 Preparation of T cell blasts.
T lymphoblasts were produced essentially as described by Smith and Cantrell (1985). 
Samples of peripheral blood were collected aseptically via a 19-guage butterfly cannula 
from normal healthy donors into sterile disposable 60 ml syringes containing 50 U/ml 
blood heparin. After collection the blood was mixed thoroughly by gentle inversion of the 
syringe before dilution with an equal volume of RPMI 1640. 35 ml of the diluted blood 
was layered onto 15 ml of Lymphoprep in a sterile disposable 50 ml tube. The samples 
were centrifuged at 500 g, for 30 minutes at room temperature, and the rotor allowed to 
stop without braking. The mono-nuclear cell rich interface was carefully removed with a 
sterile pipette and washed three times by centrifugation at 500g for five minutes. The 
peripheral blood mononuclear cells (PBMCs) were then resuspended, in the original 
blood volume, in RPMI 1640 supplemented with 10% heat inactivated FBS, 
streptomycin (50 pg/ml), penicillin (50 U/ml) and Phytohaemaglutinin A (PHA) 1 pg/ml. 
After 72 hours culture at 37°C, the cells were washed three times by centrifugation at 
500 g and resuspended in RPMI 1640 supplemented with 10% heat inactivated FBS, 
streptomycin (50 pg/ml), penicillin (50 U/ml) and hrBL-2 (20 ng/ml). Thereafter, the cells 
were treated with fresh medium supplemented with IL-2 every third day. Cells were 
starved of IL-2 for 48 hours before use. These cells, having been induced to express the 
IL-2 receptor by PHA treatment, and maintained with IL-2, no longer produce 
endogenous IL-2, but retain an ability to respond to exogenous IL-2 [Smith and Cantrell 
(1985)].
2.2.3 Purification of peripheral blood primary T cells.
T cells were purified by immunomagnetic depletion as described by Sansom et al. (1993). 
PBMCs were isolated from the blood of normal healthy donors as above. These were 
then further purified by resuspension, in the original blood volume, in RPMI 1640 
supplemented with 10% FBS and incubated in sterile culture flasks at 37°C for 60 
minutes. Non-adherent cells were pelleted and resuspended in 15 ml centrifuge tubes in 1 
ml RPMI 1640 for each 100 ml original blood volume supplemented with the following 
antibodies at 1 pg/ml: monoclonal anti-CD19 (B-lymphocyte marker), anti CD14 clone 
UCHM-1 (monocyte and macrophage marker), and anti-MHC-II DR- clone L243 
(antigen presenting cell marker). The cells were incubated with the antibodies for 60 
minutes at 4°C with gentle rotation. Antibody tagged cells were then washed twice, to 
remove unbound antibody, and resuspended in RPMI (2 ml/100 ml original blood
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volume) with 2-4x 10^/ml magnetic beads M-450, 4.5 pm  diameter, coated with sheep 
anti mouse IgG antibody (Dynal, Merseyside, U.K.). After 45 minutes rotation at 4°C , 
the cells were diluted in 10 ml RPMI 1640 and passed over a magnet three times for one 
minute. Unbound cells were removed with a sterile pipette and counted under a light 
microscope. FACS analysis confirmed that the resultant cell population were >95% T 
cells as judged by positive staining with UCHT1.
2.2.4 Preparation of electrocompetent cells.
All molecular biology techniques were carried out with reference to protocols contained in 
“Molecular cloning: A laboratory manual.” (1989) Sambrook et al. Bacterial Eschericia 
coli DH5a cells were streaked onto a warmed Luria broth (LB) agar plate, from frozen 
stocks, and grown at 37°C overnight. A single colony was used to inoculate 5 ml of 
Luria broth, and grown in a shaking incubator at 37°C overnight. The overnight culture 
was subcultured 1:100 in 100 ml LB and grown until the OD550 nm reached 0.48. The 
cells were incubated on ice for 5 minutes before centrifugation at 6000 rpm in a Beckman 
JA14 rotor, for 5 minutes at 4°C. Cells were resuspended in 40 ml solution I (30 mM 
KC1, 100 mM RbCl, 10 mM CaCl2, 50 mM MnCl2, 15% glycerol pH 5.8) and
incubated on ice for 5 minutes, before pelleting by centrifugation at 6000 rpm for 5 
minutes at 4°C and resuspension in 4 ml solution II 10 mM MOPS, 75 mM CaCl2, 10
mM RbCl, 15% glycerol pH 6.5). The cells were aliquoted at 200 pl/tube, snap frozen in 
liquid nitrogen and stored at -80°C until use.
2.2.5 Isolation of plasmid DNA.
Electrocompetent DH5a cells were thawed and left on ice for 10 minutes. Plasmid DNA 
to be isolated was added to the cells at 100 ng/200 pi cells, mixed gently and incubated 
on ice for 30 minutes. The cells were heat shocked at 37°C for 2 minutes and returned to 
ice for 2 minutes. 800 pi of LB was added to the cells which were then incubated at 
37°C for a further hour before plating onto an agar plate containing 100 pg/ml ampicillin. 
The plates were inverted and incubated overnight at 37°C. A single colony was then 
cultured, overnight at 37°C with shaking, in 5 ml of LB containing 100 pg/ml ampicillin. 
500 pi of the preculture was added to 250 ml of LB containing 100 pg/ ml ampicillin and 
incubated overnight at 37°C with shaking. The bacteria were harvested by centrifugation 
at 5000 rpm in a Beckman JA14 rotor, for 5 minutes at 4°C and resuspended in 20 ml ice 
cold GTE (glucose 50 mM, Tris-HCl 25 mM, EDTA 10 mM pH 8.0). 40 ml of freshly
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prepared solution II (200 mM NaOH, 1% SDS) was added the solutions mixed well and 
left on ice for 5 minutes. 20 ml of ice cold solution HI (3 M potassium acetate, 2 M acetic 
acid) was added, the solutions mixed well and left on ice for 15 minutes. The mixture 
was then centrifuged at 8000 rpm for five minutes at 4°C and the rotor allowed to stop 
without braking. The supernatant was then filtered through four layers of cheesecloth into 
a 250 ml centrifuge bottle, 50 ml of propan-2-ol added and the bottle incubated at room 
temperature for 10 minutes. Nucleic acids were then recovered by centrifugation at 5000 
rpm in a Beckman JA14 rotor, for 15 minutes. The supernatant was decanted and drained 
by inverting the open bottle. The pellet was dried by letting the botde stand at room 
temperature for 30 minutes. The pellet was resuspended in 3 ml: 10 mM Tris-HCl, 1 mM 
EDTA pH 8.0 (TE pH 8.0) and the plasmid DNA purified by equilibrium centrifugation 
in a caesium chloride-ethidium bromide gradient.
2.2.6 Purification of plasmid DNA.
Caesium chloride was added to the crude preparations of plasmid DNA, obtained as 
above, at 1 g/ml and mixed gently at 30°C. 80 pi from a stock solution of 10 mg/ml 
ethidium bromide in water was added to each ml of the CsCl/DNA mixture. This solution 
was centrifuged at 8000 rpm for 5 minutes at room temperature. The clear red solution 
produced from this spin was removed to a Quick-Seal tube (Beckman) using a pasteur 
pipette. The tube was filled with paraffin oil and heat sealed. The tubes were then 
centrifuged in a Beckman Ti 70.1 rotor at 60000 rpm for at least 24 hours at 20°C. Two 
bands were visible in the middle of the gradient following centrifugation, the lower, 
containing closed circular plasmid DNA, was collected using an 18G hypodermic needle. 
An equal volume of water-saturated isobutanol was then mixed with the DNA solution, 
and the phases mixed by vortexing. The mixture was then centrifuged in a benchtop 
microfuge at 1500 rpm for 3 minutes at room temperature, and the lower aqueous phase 
removed to a fresh tube. This organic extraction of ethidium bromide was repeated five 
times to remove ethidium bromide. CsCl was then removed from the plasmid DNA by 
dialysis against TE pH 8.0.
2.2.7 Transient transfection of Jurkat cells.
Cells to be transfected were removed from culture, washed three times and aliquoted at 
1.5x10^/500 pi RPMI 1640. Samples were placed in an electroporation cuvette with 10 
pg of desired DNA prior to electroporation at 310V, 960 pF  in a BioRad Gene Pulser.
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Cell samples were pooled, resuspended in RPMI 1640 supplemented with 10% FBS and 
cultured over night. Plasmid expression was determined according to the plasmid. HA- 
tagged proteins were detected by immunoblotting with the 12CA5 Ab, and iCD2 
containing chimaeras were detected by flow cytometry analysis with the 0x34 Ab.
2.2.8 Cell lysis and immunoprecipitation
Cell lysis was carried out essentially as described by Ward et a l (1992). Cultured cells 
were harvested, washed three times in RPMI 1640 and resuspended at the desired 
concentration. After appropriate stimulation the cells were lysed by the addition of an 
equal volume of 2 x ice cold lysis buffer: 137 nM NaCl, 20 mM Tris pH 7.5, 1 mM 
MgCl2, 1 mM CaCl, 1% Nonidet-P40, supplemented with phosphatase and protease
inhibitors 150 pM sodium orthovanadate, 100 pg/ml leupeptin, 100 pg/ml pepstatin A 
and 200 pM phenylmethylsulphonyl fluoride (PMSF). The samples were rotated at 4°C 
for ten minutes before centrifugation for 5 minutes at 13,000 g at 4°C and removal of the 
supernatant (cellular lysate) to a fresh tube. All cellular lysates and purified proteins were 
kept at 4°C, unless otherwise stated.
Where whole cellular lysates were required for analysis, the cellular proteins were 
precipitated by addition of 600 pi ice-cold acetone to 500 pi cellular lysate, incubation at 
4°C for 15 minutes before centrifugation for 5 minutes at 13,000 g in a Beckman F2402 
rotor at 4°C. The supernatant was aspirated and proteins dried of acetone in vacuo. 
Where immunoprecipitates were required, the protein of interest was isolated from the 
cellular lysate by incubation with protein A or G beads coupled to an appropriate 
antibody. Protein A sepharose beads were obtained from Pharmacia as a dried powder 
which was hydrated by the addition of 12.5 ml distilled water to 1.5g dried beads. 
Protein G sepharose beads were obtained from Sigma in a prehydrated form, stored in 
methanol. When required, 500 pi suspensions of protein A or G sepharose beads were 
washed three times with 1 ml PBS and then resuspended as a 50% suspension in PBS. 
Antibodies were coupled to protein A or G sepharose beads by incubating 50 pg of the 
required antibody with 500 pi of a 50% suspension of beads and 500 pi PBS. This 
mixture was rotated at 4°C for two hours. Unbound antibody was removed from the 
beads by washing three times with 1 ml PBS. Antibody coupled beads were resuspended 
as a 50% suspension in PBS and stored at 4°C until required. Cellular lysates were pre­
cleared by rotation with 20 pi of a 50% suspension of protein A or G beads, at 4°C for 
one hour. The beads were then sedimented by centrifugation and the supernatants 
removed to fresh tubes. To immunoprecipitate a protein of interest, a 20 pi 50%
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suspension of protein A or G sepharose beads, coupled with the appropriate antibody, 
was rotated with the pre-cleared cellular lysate at 4°C for two hours. Beads were 
sedimented by centrifugation and supernatant removed by aspiration.
2.2.9 SD S-Polyacrylam ide gel e lec trophoresis  (SDS-PAGE).
Protein samples were resolved essentially as described by Laemmli (1970), according to 
protocols previously established in our laboratory. Proteins to be analysed were 
solubilised by boiling for 5 minutes in SDS-PAGE sample buffer consisting: 3% SDS 
(w/v), 10% glycerol (v/v), 200 mM Tris-HCl pH 6.8, 5% 2-mercaptoethanol coloured as 
appropriate with bromophenol blue.
Where large (15 cm vertical slab) gels were required , 7-17% acrylamide gradient gels 
were prepared using vertical slab gel units (model SE400), Hoefer Scientific Instruments, 
San Francisco). These gels were run at 75V overnight. The aciylamide gels were 
prepared as below. Where minigels were required BioRad Mini Protean II equipment was 
used (BioRad laboratories, Hemel Hempstead, UK) and 10% homogeneous gels were 
run, prepared as detailed in the Table 2.1. These gels were electrophoresed at 75V for 
two hours.
C om ponent 7%  (ml) 17% (ml) 10% (ml) S tacking gel
Protogel 3.5 8.5 10 1.6
1M Tris pH 8.8 5.6 5.6 11.25 -
Water 5.8 - 8.15 7.6
xl Upper buffer - - - 3.1
Sucrose - l-5g - -
10% SDS 0.075 0.075 0.3 -
10% APS 0.15 0.15 0.3 0.063
TEMED 0.015 0.015 0.012 0.012
Table 2.1 P rep a ra tio n  of solutions fo r casting SDS-PAGE gels. Minigels 
were run as 10% homogeneous acrylamide. 15 cm vertical slab gels were run as 7-17% 
acrylamide gradient gels prepared with a 30 ml SG series gradient mixing chamber 
(Hoeffer Scientific Instruments).
Upper buffer was prepared as a x4 stock consisting: 0.5 M Tris, 0.4% SDS pH 6.8. APS 
and TEMED were added immediately prior to casting the gels. Once cast, the gels were 
overlayered with water-saturated isobutanol and left to polymerise. The isobutanol was
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then washed off with water and stacking gels poured with appropriate combs in place. 
For both gel systems stacking gels were prepared as above and running buffer consisted 
192 mM glycine, 25 mM Tris and 0.01% SDS.
Gels to be fixed were incubated in fixing solution (propan-2-ol:water:glacial acetic acid, 
25%:65%:10%, v/v/v) for two hours. The gels were then placed on Whatman 3MM filter 
paper and dried on a BioRad gel dryer (model 583) for two hours. Radiolabelled proteins 
were visualised by autoradiography. Gels to be stained with Coomassie blue were 
immersed in Coomasie blue stain (0.1% (w/v) Coomassie brilliant blue R, dissolved in 
40% methanol/7% acetic acid/53% distilled water) for four hours with gentle agitation. 
Destaining was achieved by decanting the Coomassie stain and immersing the gel in 
copious changes of destaining solution (20% ethanol/7.5 % acetic acid/72.5% distilled 
water v/v/v).
2.2.10 Detection of proteins by Western blotting.
15 cm gels were transferred to “Polyscreen” PVDF membrane (pre-wetted according to 
the manufacturers instructions) in a BioRad Transblot cell at 200 mA overnight in transfer 
buffer consisting 192 mM glycine and 25 mM Tris. Mini gels were transferred to 
nitrocellulose membranes under semi-dry conditions in transfer buffer consisting 39 mM 
glycine, 48 mM Tris base, 0.0375% SDS and 20% methanol. The proteins were 
transferred at 0.8 mA/cm^ of gel for 90 minutes. Non-specific protein interactions were 
blocked by incubating the membranes in 5% Marvel milk powder in PBS for two hours at 
room temperature. Membranes were washed by rinsing at least three time for ten minutes 
in 0.05% Tween 20 (v/v) diluted in PBS (PBS-T). All antibodies were diluted into a 
sterile filtered solution of 0.05% marvel in PBS with 0.1% NaN3. The membranes were
incubated with primary antibody for at least two hours with gentle agitation, followed by 
recovery of the primary antibody and rinsing, as before, prior to incubation with the 
secondary antibody for at least 45 minutes. The membranes were then washed with 
copious changes of PBS-T before visualisation with Amersham ECL western blotting 
reagents, according to the manufacturers instructions.
Western blots to be reprobed with a second antibody were submerged in membrane 
stripping buffer (100 mM 2-mercaptoethanol, 2% (w/v) SDS, 62.5 mM Tris-HCl pH 
6.7) and incubated at 60°C for one hour with occasional agitation. The blots were 
washed with copious changes of 200 ml PBS-Tween at room temperature, before 
reprobing as above.
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2.2.11 Metabolic labelling of cells with [32p] Pi.
Cells were labelled with [32p] Pi as previously described [Ward et al. (1993)]. Cells to 
be labelled were removed from culture and depleted of intracellular phosphate by 3x 10 
min incubations in phosphate free Dulbeccos Modified Eagle Medium supplemented with 
20 mM HEPES, pH 7.2 at 37°C. The cells were then incubated in 10ml phosphate free 
DMEM supplemented with 5% FBS (previously dialysed against saline), 50 pM HEPES 
and 100 pCi/ml ^^P-labelled orthophosphoric acid, at 37°C for 3 to 4 hours.
2.2.12 Phosphoamino acid analysis of proteins
Proteins of interest were immunoprecipitated from cells radiolabelled with [32p] Pi as 
above (section 2.2.11) separated by SDS-PAGE and using 15 cm gels and transferred to 
PVDF membrane as previously described (section 2.2.6). The blot was then 
autoradiographed to determine the position of the labelled bands, which were then 
excised, soaked in methanol and washed in distilled water. Bound protein was 
hydrolysed in 6M HC1 (150-250 pi) for one hour at 110°C. The hydrolysate was dried in 
a speedvac (Savant), and redissolved in 5 ml of 0.1 M acetic acid containing 3 mg each of 
unlabelled phosphoserine, phosphothreonine and phosphotyrosine as standards. The 
phosphoamino acids were separated at 20 mA for 80 minutes on a cellulose TLC 
(Polygram Cell 300, Macherey-Nagel, Duren, Germany) in acetic acid/pyridine/water 
(10/1/189, v/v/v). The standard phosphoamino acids were detected by spraying with 
ninhydrin followed by baking at 110°C for 30 minutes. The labelled phosphoamino acids 
were visualised by autoradiography at -80°C.
2.2.13 Extraction of [32p]-labelled phosphoinositide lipids.
[32pj_iabelled phosphoinositide lipids were extracted as previously described [Jackson et 
al. (1992); Ward etal. (1993)]. Cells metabolically radiolabelled (as described in section 
2.2.11) were washed three times in phosphate free DMEM, resuspended in RPMI 1640 
and aliquoted into 1.5 ml screw capped tubes at 2xl0^/120pl. The cells were stimulated 
as appropriate at 37°C and the reactions quenched by the addition of 0.5 ml ice cold 
chloroform/methanol/water (32.65%/65.3%/2.15%, v/v/v) vortexing and incubation on 
ice for ten minutes. Phases were separated by the addition of 100 pi chloroform 
containing Folch lipids (20 pg/100 ml), and 100 pi 5 mM tetrabutylammonium sulphate,
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2.4 M HC1. The samples were vortexed and centrifuged at 14000g for five minutes. The 
lower chloroform layer was carefully removed to a fresh tube containing 400 pi of 25 
mM EDTA, 100 mM HC1 mixture before further vortexing and centrifugation. The lower 
phases were removed to fresh tubes and dried in vacuo. The samples were then 
deacylated by the addition of 1 ml 25% w/v methylamine in water/methanol/butanol 
(44.4%/44.4%/l 1.1%, v/v/v). Samples were vortexed, incubated for 40 minutes at 53°C 
and cooled on ice for five minutes before drying in vacuo. This deacylation procedure 
renders the glycerophosphorylinositol (GroPtdlns) derivatives of PtdIns(3)P, 
PtdIns(3,4)P2 and PtdIns(3,4,5)P3 (namely GroPtdIns(3)P, GroPtdlns(3,4)P2 and 
GroPtdIns(3,4,5)P3 respectively) water soluble. The deacylated lipids were then 
resuspended in 0.5 ml sterile water and washed by the addition of 0.6 ml n-butanol/40- 
60% petroleum ether/ethyl acetate (80%/16%/4% v/v). After vortexing and centrifugation 


























F igure  2.2 E lution program m e for separa tion  of phospho inositides by 
anion exchange ch rom atog raphy . Samples were applied to a Partisphere SAX 
column (Whatman) at a constant flow rate of 1 ml/min. Initial mobile phase (ddH20) was 
progressively replaced by 1.25 M (NH4)2HP04 (pH 3.8) as represented above. 
Retention times for PtdIns(4)P and PtdIns(3,4,5)P3 are represented.
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2.2.14 High performance liquid chromatography (HPLC).
Deacylated lipid samples, prepared as above (section 2.2.13), were resuspended in 120 
pi sterile water in a sonicating water bath before being applied to an anion exchange 
Partisphere-SAX column (Whatman) at a flow rate of 1 ml/min. Lipids were eluted from 
the column using the following gradient programme represented in Figure 2.2.
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Figure 2.3 R epresentative trace showing the retention times of the 
phosphoinositides isolated from  Ju rk a t cells. The retention times of the lipid 
products of PI 3-kinase were compared to previously published data [Stephens et al. 
(1991)]. Retention times can vary slightly depending on room temperature and age of 
column.
The anion exchange column eluate was fed into a Canberra Packard A-500 Flo-One on­
line beta-radio detector where it was mixed with three volumes of Flo-Scint IV 
scintillation cocktail (Packard) and the results recorded and analysed using Flo-One data 
software (Radiomatic, USA). An example trace of the elution of lipids isolated from 
Jurkat cells is given in Figure 2.3. The identity of the various peaks has been previously 
defined [Stephens et al (1991)].
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2.2.15 In vitro lipid kinase assay
This assay was used to detect the lipid kinase activity that is present in either anti-p85a 
immunoprecipitates or that is co-associated with other proteins such as CD28. Cells were 
aliquoted at 2xl0^/point and lysed and immunoprecipitates prepared as described in 
section 2.2.4. Immunoprecipitates were washed sequentially, once in NP40 lysis buffer, 
once in PBS, twice in 0.5 M lithium chloride, 100 mM Tris pH 7.6, once in water and 
finally into lipid kinase buffer (5 mM M gCl2,0.25 mM EDTA, 20 mM HEPES pH7.4). 
Lipid kinase activity was determined by the modified method of Whitman et a l (1988). 
The washed immunoprecipitates were resuspended in 30 pi of kinase buffer before 
addition of 50 pi of a mixture of Ptdlns 0.1 mg/ml and phosphatidyl serine 0.1 mg/ml, 
dispersed by sonication in 1 mM EDTA, 25 mM HEPES pH 7.4. The reactions were 
initiated by the addition of 20 pCi of [y32p] a x p  and too mM ATP, this reaction is 
represented schematically in Figure 2.4. After 15 minutes at 30°C the reactions were 
terminated by the addition of 100 pi 1M HC1 and 200 pi chloroformimethanol (1:1). 
After vortexing and centrifugation to separate the phases, the lower organic layer was 
removed to a fresh tube and dried in a speedvac. The extracted phospholipids were then 






Figure 2.4 Schematic diagram of in vitro lipid kinase reaction.
2.2.16 Thin Layer Chromatography
Laned silica gel 60 plates (Whatman) were pre-treated by spraying with 1% sodium 
oxalate in water and allowed to dry. The extracted phospholipid samples, that had been 
re-dissolved in chloroform (section 2.2.15), were loaded onto the plates in 10 pi aliquots 
and placed in a pre-equilibrated solvent tank containing propan-l-ol :acetic acid (2N) 
(65%:35% v/v). The samples were resolved overnight and visualised by exposure to
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iodine vapour prior to autoradiography. Phospholipids were identified by comparison 
with non-labelled standards. The phosphoiylated lipid product visualised by 
autoradiography had been previously identified as PtdIns(3)P by extraction from the TLC 
plate and HPLC analysis by Dr Stephen Ward.
2.2.17 In vitro protein kinase assay
This assay was used to detect protein kinase activity associated with immunoprecipitated 
molecules. Immunoprecipitates were prepared as in section 2.2.8 washing three times in 
lysis buffer and twice in protein kinase assay buffer (100 mM NaCl, 25 mM HEPES pH 
7.4, 10 mM MgCl2, 5 mM MnCl2, 100 pM sodium ortho vanadate). In vitro kinase
assays were initiated by the addition of 20 pi of kinase buffer containing 10 pM ATP and 
10 pCi [y32p] ATP. After 10 minutes at 37°C the reactions were terminated by the 
addition of 1 ml of kinase buffer containing 20 mM EDTA. The immunoprecipitates were 
then washed three times in this buffer prior to solubilisation in SDS-PAGE sample 
buffer. Phosphorylated proteins were separated on 7-17% acrylamide gradient gels, dried 
down and visualised by autoradiography.
2.2.18 Protein kinase B assay
Cells were washed, aliquoted at 10^/point and equilibrated at 37°C prior to appropriate 
stimulation and lysis as above (section 2.2.8). Cell lysates were pre-cleared with protein 
A (or protein G, where appropriate) sepharose beads. Samples were pulsed in a benchtop 
microfuge and supernatants removed to a fresh tube containing either lpg/m l anti-protein 
kinase B (PKB) Ab or 1 pg/ml 12CA5 Ab, before further rotation at 4°C for 60 minutes. 
Immunoprecipitates were produced by adding 20 pi of a 50% suspension of protein A 
sepharose beads to the samples and further rotation for 60 minutes. Immunoprecipitates 
were then washed sequentially, twice in NP40 lysis buffer, twice in LiCl 500 mM, 100 
mM Tris, 1 mM EDTA pH 7.5, and finally into protein kinase B assay buffer (50 mM 
Tris, 10 mM M gC l2,1 mM DTT). Once in assay buffer the beads were removed to screw
capped tubes, pulsed in a benchtop microfuge and supernatants aspirated. The beads were 
taken to dryness using a Hamilton syringe and kinase reactions initiated by addition of 15 
pi kinase reaction mixture comprising as follows: 10 mM MgCl2, 1 mM DTT, 50 mM 
Tris pH 7.5, 0.5 pM protein kinase inhibitor, 150 pg/ml H2 B, 50 pM ATP, 200 pCi/ml 
[32p] y-ATP. After 30 minutes at room temperature the reactions were quenched by the 
addition of 30 pi SDS-PAGE sample buffer and boiling for five minutes.
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Proteins were then subjected to SDS-PAGE overnight as above (section 2.2.9), using 15 
cm gel apparatus. Following electrophoresis the gel was cut horizontally at 40 kDa. The 
upper half was western blotted as above and immunoblotted with anti-PKB antibody 
(section 2.2.10) to demonstrate equal loading of protein. The lower half containing 
phosphorylated H2 B was stained with coomassie blue, destained, dried (section 2.2.9)
and phosphoproteins visualised by autoradiography at -80°C.
2.2.19 Determination of JNK activity.
JNK activity was determined essentially as described by Hibi et a l (1993). JNK binds c- 
jun between residues 33-79 [Hibi et al. (1993)], thus a glutathione sepharose transferase 
(GST)-c-jun (1-135) fusion protein was used to immunoprecipitate JNK from Jurkat 
cells. JNK activity was subsequently assessed by the ability of JNK to phosphorylate the 
c-jun fusion protein, with which it was immunoprecipitated. GST-c-jun fusion proteins 
were prepared as follows. Eschericia coli cells, transfected with plasmid DNA for 
recombinant GST-c-jun, were grown from frozen stock overnight in 25 ml Luria broth 
supplemented with 50 pg/ml ampicillin (LB-amp), at 37°C in a shaking incubator. 12 ml 
overnight culture was inoculated into 400 ml LB-amp and grown in a shaking incubator 
for three hours. Expression of the recombinant protein was induced by adding isopropyl 
(3-D-thiogalactopyranoside (IPTG) to a final concentration of 0.4 mM. The cultures were 
grown for a further 4 hours at 37°C in a shaking incubator. The bacterial cultures were 
centrifuged at 4000 rpm in a Beckman JA14 rotor, for 20 minutes at 4°C. The bacterial 
pellet was resuspended in 10 ml lysis buffer consisiting: PBS supplemented with 1% 
Triton X-100, EDTA 2 mM, PMSF 1 mM, 100 pg/ml leupeptin and 100 pg/ml pepstatin 
A. The pellet was resuspended completely by mixing the lysate with a pipette. The lysate 
was transferred to a 50 ml tube and sonicated 4x 40 seconds, with 1 minute intervals on 
ice. The lysate was then centrifuged at 10 000 rpm in a Beckman Ti 70.1 rotor for 10 
minutes at 4°C. The supernatant was removed to a 50 ml tube and 1 ml of 50% 
suspension of glutathione sepharose beads in PBS was added, before the tube was 
rotated on a blood tube rotator for 2 hours at 4°C. The tube was centrifuged for 15 
seconds at 1200 rpm and the glutathione beads washed in lysis buffer by rotation for a 
further five minutes. The beads were subsequently washed once in lysis bufer and three 
times in PBS supplemented with 2 mM EDTA. After the final wash, the glutathione beads 
were transferred to the top of a PD-10 column (Pharmacia). The fusion protein was eluted 
from the beads by competition with reduced glutathione (25 mM glutathione, 50 mM 
Tris-HCl pH 8.0). The glutathione solution cannot be stored, thus was prepared fresh as
64
required. The GST-c-jun fusion protein was eluted with 7-10 ml glutathione solution, 
collecting 1 ml fraction from the column. Elution fractions containing protein were pooled 
and dialysed against dialysis buffer (HEPES 20 mM pH 8.0, EDTA 0.2 mM, KC1 0.1 
M, DTT 0.5 mM, PMSF 0.5 mM and glycerol 20% v/v) to remove the glutathione. The 
dialysed fusion proteins were recoupled to glutathione beads, at 1 mg protein/ 100 pi 
50% suspension of beads, by rotation with the beads for two hours. The coupled beads 
were washed by centrifugation for 15 seconds at 1200 rpm and removal of the 
supernatant as before, three times in PBS and resuspended as a 50% suspension in 
storage buffer (HEPES 50 mM pH 7.0, NaCl 50 mM, Glycerol 50% v/v) for aliquoting 
at 5 pl/tube and storage at -20°C.
Cells to be used in the JNK assay were removed from culture and washed three times 
with R PM I1640. Cells were aliquoted at 5x 10^/point and stimulated as required. Cells 
were pulsed in a benchtop microfuge, the supernatant removed by aspiration and 200 pi 
whole cell extract buffer added (HEPES 25 mM pH 7.7, NaCl 0.3 M, MgCl2 1.5 mM,
EDTA 0.2 mM and Triton X -100 0.1% v/v supplemented with phosphatase and protease 
inhibitors 150 pM  sodium orthovanadate, leupeptin 100 pg/ml, pepstatin A 100 pg/ml 
and PMSF 200 pM). Cells were rotated at 4°C for 30 minutes before centrifugation at 13 
000 rpm for ten minutes at 4°C. The supernatants were collected and 600 pi dilution 
buffer added (HEPES 20 mM pH7.7, EDTA 0.1 mM, MgCl2 2.5 mM, Triton X-100
0.05% v/v supplemented with phosphatase and protease inhibitors sodium orthovanadate 
150 pM, leupeptin 100 pg/ml, pepstatin A 100 pg/ml and PMSF 200 pM ). The 
supernatants were incubated on ice for ten minutes and centrifuged at 13000 rpm for ten 
minutes to clean the lysates. The supernatants were then removed to 1.5 ml microtubes 
containing 5 pi GST-c-jun glutathione beads, prepared as above. The beads were rotated 
for 4 hours at 4°C. The beads were then washed four times with washing buffer (HEPES 
20 mM pH7.7, NaCl 50 mM, EDTA 0.1 mM, MgCl2 25 mM, Triton x-100 0.05% v/v).
Kinase reactions were intiated by the addition of 30 pi kinase buffer (HEPES 20 mM pH 
7.6, DTT 2 mM, P-glycerophosphate 20 mM, MgCl2 20 mM, sodium orthovanadate 0.1
mM, ATP 20 pM, 3 pCi [32p]y-ATP/reaction). Reactions were carried out at 30°C for 
20 minutes, with occasional agitation. Beads were washed with 1 ml dilution buffer and 
proteins solubilised by boiling in 30 pi SDS-PAGE sample buffer. Proteins were 
resolved by SDS-PAGE and visualised by autoradiography.
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2.2.20 Determination of inositol polyphosphate 5-phosphatase activity.
Murine DC27.1 cells were aliquoted at lO^/ml, stimulated as required and lysed in 1 ml 
ice cold NP40 lysis buffer (section 2.2.8). SHIP was immunoprecipitated from the 
cellular lysates using 20 pi of a 50% suspension of anti-SHIP polyclonal antibody 
coupled to protein A sepharose beads (section 2.2.8). Immunoprecipitates were washed 
twice in lysis buffer and once with phosphatase buffer: 50 mM Tris-HCl (pH 7.5), 10 
mM MgCl2- Sedimented beads were resuspended in 25 pi phosphatase buffer 
supplemented with 5 pl/point stock [^H]-Ins(l,3,4,5)P4. Reactions were performed at 
37°C for 20 minutes and quenched by the addition of 500 pi acidified chloroform 
(l):methanol(2). A single phase was obtained to which was added 250 pi chloroform and 
250 p i 0.01 M HC1, the phases were separated by centrifugation. The upper (aqueous) 
phase was dried in vacuo and resuspended in 100 pi dH20. Samples were then analysed 
by anion exchange HPLC and the levels of [^H]-Ins(l,3,4,5)P4 and [^H]-Ins(l,3,4)P3 
were quantitated using an on-line radiodetector (Canberra Packard).
2.2.21 Proliferation assay
Purified T cells were resuspended in complete medium and aliquoted at 5x10^ cells in 
150 pi medium/well in 96 well tissue culture plates. The cells were stimulated as 
appropriate in quintuplicate to minimise internal variation. The TCR/CD3 complex was 
stimulated by UCHT1 mAb cross linked with Mouse IgG Fab fragments. The plates were 
incubated at 37°C in humidified air supplemented with 5% C02 for 72 hours before
being “pulsed” with 0.5 pCi/well [^HJ-thymidine and returned to incubation After 18 
hours, the cells were harvested onto Whatman GF/A filters using an automated cell 
harvester. The incoporation of [^H]- thymidine was measured by placing the dried 
radioactive filter into 4 ml scintillation fluid (Optiphase) and counted on a P-scintillation 
counter (LKB).
2.2.22 IL-2 bioassay.
Quantitation of IL-2 was carried out essentially as described by Rayter et al. (1992). 
Briefly, three days after feeding, CTLL cells were removed from culture and washed 
twice in RPMI 1640 by 5 min centrifugation at 500 g. Cells were resuspended at 10^ 
cells/ml in RPMI 1640 containing 10% FBS. A serial dilution of standard IL-2, starting at 
40 U/ml was prepared and 50 pi of supernatant samples were placed in the wells of a 96
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well microtitre plate. 50 pi of the CTLL cell suspension was added to each well and the 
plate placed in an incubator. After 18 hrs incubation 0.5 pCi [^Hj-thymidine was added 
to each well and the plate returned to the incubator. After 4 hrs the cells were harvested 
and [^HJ-thymidine incorporation measured as above (section 2.2.19). Unknown 
samples of IL-2 were quantitated by comparison with a standard curve prepared from the 
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F igure  2.5 R epresentative  s tan d a rd  curve fo r IL -2 b ioassay . Data are mean 
and SEM of quintuplicate replicates from single representative experiment.
2.2.23 A nnexin-F IT C  apoptosis assay.
This assay uses FITC-conjugated annexin-V to detect phosphatidyl serine, which is 
rapidly externalised during apoptosis [Martin et al. (1995)]. Briefly, 3x 10^ cells were 
exposed to the experimental treatment for four hours at 37°C. The cells were then washed 
once in ice cold PBS and resuspended in 100 pi HEPES buffer (5 mM CaCl2, 140 mM
NaCl, 10 mM HEPES pH 7.4) containing annexin-FITC (2 pi neat/sample) and 
propidium iodide (final concentration 2 pg/ml). After a ten minute incubation at room 
temperature in the dark, samples were diluted 1:5 with HEPES buffer. Apoptotic cells 
were those which bound the annexin-FITC, yet excluded propidium iodide, as 
determined by flow cytometry analysis.
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2.2.24 Flow cytometry.
Cells to be analysed by flow cytometry were removed from culture and washed three 
times in PBS. Cells (5x lO^/sample) were aliquotted into FACS tubes (Beckton 
Dickinson) and resuspended in 50 pi primary antibody (10 pg/ml) and 25 pi FBS, 
antibodies used are detailed in section 2.1.2. Samples were incubated at 4°C for 30 
minutes with occasional agitation. Samples were washed of unbound antibody by 
resuspension in 3 ml PBS and centrifugation at 500 g for 5 minutes. Samples were then 
incubated with 50 pi FTTC-conjugated secondary antibody and 25 pi FBS, at 4°C for 30 
minutes with occasional agitation. Cells were washed of unbound antibody in PBS as 
before, and resuspended in 200 pi PBS. Subsequent flow cytometric analysis was 




Early biochemical events regulating recruitment and 
activation of phosphatidylinositol 3-kinase by CD28
3.1 CD28 ligation results in recruitment and activation of PI 3-kinase
Signal transduction events elicited in response to CD28 ligation are relatively poorly 
defined in comparison to those of the TCR. CD28 has been demonstrated however, to 
recruit and activate the putative signalling molecule PI 3-kinase [Ward et al. (1993); Pages 
et al. (1994)], resulting in rapid and strong accumulation of the lipid products of PI 3- 
kinase which may be sufficient to activate downstream effector molecules. Activation of 
PI 3-kinase has been demonstrated as a pivotal event in CD28-mediated T cell 
proliferative reponses and IL-2 production [Ward et al. (1996)]. Experiments were 
conducted therefore, to further characterise the recruitment and activation of PI 3-kinase 
by CD28, before examining the activation of downstream targets.
Studies of biological functions dependent upon the activity of PI 3-kinase have been 
greatly advanced by the use of pharmacological inhibitors of the kinase such as 
wortmannin, a fungal metabolite which covalently binds to the p i 10 subunit [Thelen et al. 
(1995)], inhibiting both its lipid and protein kinase function. Before attempting to identify 
a role for PI 3-kinase in the regulation of downstream effector signalling molecules, it 
was important to confirm the inhibitory action of wortmannin. Accordingly, PI 3-kinase 
was immunoprecipitated from Jurkat cells using an anti-p85a antibody and both in vitro 
lipid and in vitro protein kinase function was evaluated in the presence of wortmannin. 
Figure 3.1.1a demonstrates that the protein kinase activity of PI 3-kinase was inhibited by 
wortmannin. In the absence of wortmannin (control), both the p85 and p i 10 subunits of 
PI 3-kinase are substrates for in vitro phosphorylation. Incubation of Jurkat cells, for ten 
minutes, with wortmannin at concentrations greater than 10 nM however, is observed to 
inhibit the phosphorylation of these proteins. An inhibitory effect on phosphorylation 
was also observed on addition of wortmannin to the washed immunoprecipitated proteins 
just prior to assay for kinase activity (Figure 3.1.1b).
Lipid kinase activity of p85 immunoprecipitates, derived from Jurkat cells, was also 
found to be sensitive to inhibition by wortmannin (Figure 3.1.1c). Lipid kinase activity 
associated with p85 immunoprecipitated from Jurkat cells, resulted in considerable 
phosphorylation of exogenous Ptdlns substrate forming PtdIns(3)P. Incubation of Jurkat
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cells with wortmannin (0.1 to 100 nM) was observed to inhibit PtdIns(3)P formation, 
and complete inhibition of lipid kinase activity was achieved using higher concentrations 
of wortmannin.
Ligation of CD28 by its natural ligand, namely B7.1, is followed by recruitment of PI 3- 
kinase as demonstrated in Figure 3.1.2a. CD28 immunoprecipitates from unstimulated 
(control) Jurkat cells do not show any co-association with p85, whilst ligation of CD28 
with B7.1 however, induces rapid co-association with PI 3-kinase, as evidenced by p85 
detected in CD28 immunoprecipitates from cells stimulated for one minute. This co­
association with PI 3-kinase is seen to be sustained for at least 15 minutes. Recruitment 
of PI 3-kinase to CD28 results in an up-regulation of the enzymatic activity of PI 3- 
kinase, as evidenced by increased in vitro lipid kinase activity in CD28 
immunoprecipitates. Figure 3.1.2b shows B7 treatment of Jurkat cells to induce a large 
increase over basal, of lipid kinase activity associated with CD28 immunoprecipitates, 
which is sensitive to inhibition by wortmannin (1 nM to 10 |iM). Further evidence that 
the lipid kinase activity observed is resultant from PI 3-kinase is provided since inhibition 
is achieved by LY294002 (1.5 to 30 pM) [Vlahos et al. (1994)], another PI 3-kinase 
inhibitor that is structurally unrelated to wortmannin.
An alternative approach to studying the activation of PI 3-kinase is to metabolically 
radiolabel cells with 32p inorganic phosphate, and directly extract the cellular 
phosphoinositide lipids in chloroform. Separation of lipids, solubilised in water by 
deacylation, using anion exchange HPLC methodology enables their qualitative and 
quantitative detection, allowing for the study of changes in concentrations of lipids 
induced on cellular stimulation. This may be a preferable technique since it allows for the 
study of kinase activity under more physiological conditions, avoiding some of the 
potential artifacts involved with in vitro kinase methodologies. Figure 3.1.2c details 
CD28 mediated accumulation of PtdIns(3,4,5)P3> which is thought to be the major
signalling molecule produced by PI 3-kinase activation. Lipid samples extracted from 
unstimulated cells reveal modest levels of PtdIns(3,4,5)P3, indicating a basal production
of the lipid in Jurkat cells. Ligation of CD28 by the natural ligand B7.1 results in a rapid 
accumulation of PtdIns(3,4,5)P3. This is maximal after five minutes, and the levels of 
PtdIns(3,4,5)P3 produced on receptor ligation are approximately eight-fold above basal 
levels. Levels of PtdIns(3,4,5)P3 tend to decrease slightly after five minutes but remain 
elevated above basal levels for up to twenty minutes. Transient transfection of a dominant 
negative p85 (Ap85) in which the inter-SH2 domain required for interaction with the 
p i 10 catalytic subunit has been deleted, also inhibited both basal and CD28-stimulated 
levels of PtdIns(3,4,5)P3 in Jurkat cells, when compared to responses obtained in cells
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subjected to mock transfection conditions (Figure 3.1.2d). It is dificult however to 




Figure 3.1.1a Pro tein  phosphorylation of PI 3-kinase is w ortm annin
sensitive. Jurkat cells (2xl0^cells/point) were pre-treated with wortmannin at the 
concentrations indicated, for 10 minutes. PI 3-kinase was immunoprecipitated using an 
antibody to the p85 regulatory subunit. Immunoprecipitates were washed, as described, 
before in vitro protein kinase assays were performed in 20 pi kinase buffer containing 10 
pM ATP and 10 pCi [y32p] a t p  (see section 2.2.17). Phosphorylated proteins were 
resolved by SDS-PAGE and visualised by autoradiography.
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Figure 3.1.1b In vitro  P rotein kinase activity of PI 3 -k in ase
im m unoprecipitates is w ortm annin sensitive. Jurkat cells (2xl0^/point) were 
lysed, and p85 immunoprecipitates were prepared and washed, as described (section 
2.2.4). Immunoprecipitates were pre-treated with wortmannin at the concentrations 
indicated, for 10 minutes. In vitro protein kinase assays were performed in 20 pi kinase 
buffer containing 10 pM ATP and 10 pCi [y32p] ATP (see section 2.2.17). 






Figure 3.1.1c Lipid kinase activity associated with im m unoprecipitated  
p85 is inhibited by w ortm annin . Jurkat cells were aliquoted (107/point) and 
pretreated with wortmannin, at the concentrations indicated in the annotation, for ten 
minutes. Cells were then lysed in ice-cold NP40 lysis buffer and p85 immunoprecipitated 
with anti-p85a Ab. Lipid kinase activity was assessed by the ability of the immuno­
precipitates to phosphorylate added lipid substrate (section 2.2.15), which was then 
separated by thin layer chromatography and visualised by autoradiography. Lysate 







Figure 3.1.2a CD28 ligation is followed by recruitm ent of PI 3 -k in a se .
Jurkat (2xl07) cells were co-sedimented with CHO-B7+ (107) cells, where indicated, for 
the times described in the annotation. Cells were then lysed in ice-cold NP40 lysis buffer 
and CD28 immunoprecipitated with 9.3 mAb. Immunoprecipitated proteins were then 
subjected to SDS-PAGE using a 7-17% acrylamide gradient gel. Resolved proteins were 
transferred to PVDF membrane as described (section 2.2.10) and recuitment of PI 3- 
kinase demonstrated by immunoblotting for the p85 subunit as described (section 
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Figure 3.1.2b PI 3-kinase activity associated with CD28 is inhibited by 
w ortm annin and LY 294002. Jurkat cells (2xl0^/point) were co-sedimented with
CHO-B7.1+ cells (lO^/point) for 5 minutes before lysis in ice-cold NP40 lysis buffer. 
CD28 was immunoprecipitated using 9.3 anti-CD28 mAb. Immunoprecipitates were 
washed as described and resuspended in 30 fil kinase buffer with added Ptdlns as 
exogenous substrate. Reactions were intiated by the addition of 100 mM ATP and 20 p.Ci 
[y-32p] ATP. After 15 minutes at 30°C, as described in section 2.2.15. Phosphorylated 
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Figure 3.1.2.C Time course of CD28-m ediated P td In s (3 ,4 ,5 )P 3  
accum ulation in Ju rk a t cells. [32p]_radiolabelled Jurkat cells (2xl07cells/point)
were co-sedimented with CHO-B7.1"1" cells (lO^cells/point). After incubation at 37°C, 
cellular lipids were extracted in chloroform, deacylated and analysed by HPLC as 
described (see section 2.2.14). Data expressed as absolute counts from single 
representative experiment
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F igure  3.1.2.d CD28 m ediated  accum ulation of P td In s (3 ,4 ,5 )P 3  in J u rk a t 
cells is inh ib ited  by w ortm ann in , LY294002 and Ap85 expression . Jurkat 
cells were subjected to transfection conditions or transfected with Ap85 DNA as 
described (see section 2.2.7) and incubated ovemight.The cells were then radiolabelled 
and aliquoted at 5xl0^cells/point and incubated with wortmannin (100 nM) or LY294002
(30 pM) as above, prior to stimulation by co-sedimentation with CHO-B7.1+ cells. 
Cellular lipids were extracted in chloroform, deacylated and analysed by HPLC as 
described, (see section 2.2.14). Data expressed as absolute counts from single 
representative experiment.
3.2 The role o f Lck in  P I 3-kinase recru itm en t and  activation by CD28.
CD28 recruitment of PI 3-kinase has been demonstrated to be dependent upon the prior 
tyrosine phosphorylation of the YMNM binding motif, which has specificity for the SH2 
domains of PI 3-kinase [Pages et a l (1994)]. Since analysis of the CD28 cytoplasmic 
domain reveals it to encode no recognised enzymatic motifs, the requirement for tyrosine 
phosphorylation implicates an intervening tyrosine kinase in coupling CD28 to 
downstream signalling cascades, and thus effectual function. Despite the influential role 
for this phosphorylation event in human T cells, the identity of the kinase responsible for 
this phosphorylation in human T cells remains to be defined. JCaMl is a mutant of the 
Jurkat leukaemic T cell line, which has previously been shown to be defective in tyrosine 
phosphorylation and intracellular calcium mobilisation following stimulation of the T cell 
antigen receptor [Straus and Weiss (1992)]. This aberrant cell signalling was found to
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represent a failure to express functional lck and transfection of JCaMl cells with cDNA 
encoding lck restored TCR function, at least in terms of calcium signalling [Straus and 
Weiss (1992)]. Given that lck appears to fulfil a dual function in the signal transduction 
repertoire of both the TCR and CD28, experiments were performed using the JCaMl cell 
line to examine the role of this tyrosine kinase in costimulatory signalling.
Firstly, it was important to confirm that the Jurkat leukaemic cell line and subclone 
JCaMl, expressed equivalent levels of CD28 and that JCaMl cells failed to express lck. 
This was done by flow cytometry and immunoblot analyses of cells respectively. Flow 
cytometric analysis of the two cell lines showed them to express equivalent levels of 
CD28 (Figure 3.2.1a), whilst immunoblot analysis of cellular lysates derived from Jurkat 
and JCaMl cells (Figure 3.2.1b), revealed Lck to be present in Jurkat cell lysates, but 
absent in lysates derived from identical numbers of JCaMl cells, confirming previous 
observations [Straus and Weiss (1992)]. Ligation of CD28 by B7.1 in both Jurkat and 
JCaMl cells, was found to induce co-association of the p85 subunit of PI 3-kinase with 
CD28 (Figure 3.2.1c). Following the demonstration that lck deficient JCaMl cells 
display ligation-dependent recruitment of PI 3-kinase to CD28 (Figure 3.2.1c), further 
experiments were performed to examine whether or not the subsequent activation of the 
lipid kinase function of the enzyme was impaired by the absence of lck. Analysis of the 
[32p]-labelled Ptdlns(3,4,5)P3  formed in response to CD28 ligation by B7.1, revealed
an impaired lipid kinase function in JCaMl cells (Figure 3.2.2). Co-sedimentation of 
Jurkat cells with CHO-B7.1+ cells, was followed by an eight to ten-fold increase above 
basal levels of PtdIns(3,4,5)P3. However, co-sedimentation of JCaMl cells with CHO- 
B7.1+ cells was followed by a four-fold increase in PtdIns(3,4,5)P3 above basal levels 
(Figure 3.2.2). The discrepancy in levels of PtdIns(3,4,5)P3 extracted from Jurkat and 
JCaMl cells is unlikely reflect any general difference in cellular metabolism since the 
average total CPM extracted from these cells were 2.4±0.5 xlO^ (n=4) and 2.5±0.2 xlO^ 
(n=4), respectively. Thus, although PI 3-kinase recruitment to CD28 is not affected by 
the absence of lck, the subsequent activation of the lipid kinase function of the enzyme, is 
severely impaired.
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Figure 3.2.1a J u rk a t and JC a M l cells express equivalen t levels of CD28.
5x 1 C)6 cells/point were incubated with primary antibodies, control anti-mouse IgG (10 
pg/ml) (blue histograms), and anti-CD28 mAb 9.3 (10 pg/ml) (green histograms). Data 




Figure 3.2.1b JC aM l cells do not express Lck. Lysates of the Jurkat and 
JCaMl cell lines were resolved by SDS-PAGE, using 10% homogeneous acrylamide 
gels, and transferred to nitrocellulose membranes. Immunoblotting was then performed 






































Figure 3.2.1c Failure to express Lck does not prevent liga tion -dependen t 
recruitm ent of PI 3-kinase to CD28. Jurkat cells (2xl07/point) were co- 
sedimented with CHO-B7.1+ cells (10^/point), for the times indicated, before lysis with 
ice-cold NP40 lysis buffer. CD28 immunoprecipitates were then prepared using the 9.3 
mAb. Immunoprecipitated proteins were subjected to SDS-PAGE, using 15cm, 7-17% 
acrylamide gradient gels. Resolved proteins were transferred to nitrocellulose 
membranes. Association of PI 3-kinase was assessed by immunoblotting for the presence 














F igure 3.2.2 F a ilu re  to express Lck im pairs CD28 m ediated  
P td In s (3 ,4 ,5 )P 3  accum ulation . Cells of the Jurkat and JCaMl cell lines were
radiolabelled with 32ps as described (see section 2.2.11). Jurkat cells (2xl0^/point) were
then co-sedimented with CHO-B7.1+ (10^/point) for five minutes before chloroform 
extraction of cellular lipids. Lipids were then solubilised in water by deacylation and 
subjected HPLC analysis, as described (see section 2.2.14). Data expressed as absolute 
counts from single representative experiment
3.3 Effect of phorbo l este r trea tm en t on CD28 recru itm en t and ac tiv a tio n  
of P I 3-kinase.
PMA is capable of supplying cellular signals additional to CD28 ligation, sufficient to 
drive IL-2 production in combination with CD28 mediated signals. It may also modulate 
the enzymatic activity or physical association of proteins coupled to the CD28 cytoplasmic 
tail. In particular, the PKC phosphorylation site around l ^ T h r  m a y  serve to modulate 
the PKC-mediated regulation of PI 3-kinase binding to CD28 given its close proximity to 
the 173YMNM binding motif.
In order to assess the effect of PKC activation on CD28:PI 3-kinase associations, 
immunoblotting experiments were performed on CD28 immunoprecipitates derived from 
resting or B7.1 stimulated cells that had been pretreated with PMA, a pharmacological 
activator of PKC. These immunoprecipitates were then immunoblotted using an antibody
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to the p85 subunit of PI 3-kinase. These experiments revealed that the association of the 
p85 subunit of PI 3-kinase with CD28 following treatment with the natural ligand, B7.1 
was partially inhibited by treatment of the cells with PMA (100 ng/ml) (Figure 3.3.1a). 
The decreased association of PI 3-kinase with CD28, in the presence of PMA, correlated 
with a decrease in the amount of PI 3-kinase activity associated with CD28 
immunoprecipitates (Figure 3.3.1b). The inhibition by PMA of both the ligation- 
dependent association of CD28 with PI 3-kinase (Figure 3.3.1c) and the lipid kinase 
activities associated with CD28 immunoprecipitates (Figure 3.3. Id) were prevented by 
pretreatment of the cells with the PKC inhibitor Ro 31/8220. It should be noted however 
that Ro 31/8220 exerted a greater degree of protection against PMA driven down- 
regulation of p85 association with CD28 (Figure 3.3.1c) than it did for PMA driven 
down-regulation of in vitro lipid kinase activity associated with CD28 immunoprecipitates 
(Figure 3.3.Id).
Additionally, the effect of PMA treatment upon B7.1/CD28 driven PI 3-kinase activation 
was assessed by measuring the accumulation of PtdIns(3,4,5)P3. The previously 
reported increase in PtdIns(3,4,5)P3 after CD28 ligation can be inhibited by pretreatment
of the cells with PMA (5-500 ng/ml) (Figure 3.3.2a). However the non-PKC acting 
phorbol ester 4 -a  phorbol, was without effect on CD28 mediated PtdIns(3,4,5)P3
accumulation, a further demonstration that PMA exerts its effect via activation of PKC. 
Optimal inhibition was induced after 5-10 minutes of pretreatment and was sustained for 
at least 30 minutes (Figure 3.3.2b). Concordant with previous results (Figure 3.3.1), 
pretreatment of the Jurkat cells with the PKC inhibitor Ro31/8220 (5 pM) prior to 
addition of PMA reduced the inhibitory effects of PMA. Neither PMA or Ro 31/8220 had 
any detectable effect on basal levels of PtdIns(3,4,5)P3 (Figure 3.3.2c).
PMA and CD28 are known to provide stimuli sufficient to drive T cell proliferation . 
Given the observation that PMA disrupts the coupling of CD28 to PI 3-kinase, it was 
important to establish whether PI 3-kinase activation is required for CD28 dependent 
activation of normal T cells in the presence of PMA. The effect of PI 3-kinase inhibitors 
has therefore been investigated on [3H]-thymidine incorporation by normal T cells driven 
by PMA and CD28. In this study, concentrations of PMA greater than 0.05 ng/ml were 
sufficient to support [3H]-thymidine incorporation in the presence of CHO-B7.1+ 
(Figure 3.3.3a). Moreover, [3H]-thymidine incorporation driven by PMA and CHO- 
B7.1+ is optimal in the presence of 0.5 ng/ml PMA (Figure 3.3.3a), whilst sub-optimal 
responses are induced in the presence of higher concentrations of PMA (5-50 ng/ml). The 
PI 3-kinase inhibitors wortmannin and LY294002 induced partial inhibition (<60% and 
<50% inhibition respectively) of [3H]-thymidine incorporation induced by CHO-B7.1+
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in the presence of 0.5 ng/ml PMA (Figure 3.3.3b and Figure 3.3.3c). Interestingly the 
sub-optimal [^H]-thymidine incorporation observed in response to CHO-B7.1+ and 5 
ng/ml PMA is only weakly inhibited (less than 20% inhibition) by either wortmannin 
(Figure 3.3.3b and Figure 3.3.3c), whilst [^H]-thymidine incorporation induced by 50 
ng/ml PMA in combination with CHO-B7.1+ was completely resistant to wortmannin 
and LY294002. In contrast, wortmannin or LY294002 completely inhibited [^H]- 
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Figure 3.3.1 PMA disrup ts CD28 coupling and activation of PI 3 -k inase .
Panels A and C: Western blots. Jurkat cells (2x 10^/point) were pre-incubated as 
appropriate with PKC inhibitors prior to treatment with PMA, as shown above. Cells
were then co-sedimented with CHO-B7.1+ cells (lO^/point), before lysis in ice-cold 
NP40 lysis buffer. CD28 immunoprecipitates were prepared using the 9.3 mAb. Proteins 
were resolved by SDS-PAGE, transferred to nitrocellulose membranes. PI 3-kinase 
association was assessed by immunoblotting for the presence of the p85 subunit. P ane ls
B and D: in vitro lipid kinase assays. Jurkat cells (2xl0^/point) were pre-incubated as 
appropriate with PKC inhibitors, prior to incubation with PMA as shown above. Cells
were then co-sedimented with CHO-B7.1 + cells (10?) before lysis with ice-cold NP40 
lysis buffer. CD28 immunoprecipitates were prepared using the 9.3 mAb and associated 
kinase activity assayed by phosphorylation of exogenous Ptdlns as described (see section 
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Figure 3.3.2a CD28 mediated P td In s (3 ,4 ,5 ) />3 accum ulation in Ju rk a t
cells is inhibited by PMA but not 4 - a  phorbol. MetabolicaUy radiolabelled
Jurkat cells (2x 10^) were pretreated with PMA (solid bars) or 4 -a  phorbol (hatched
bars), at the concentrations described in the annotation, for fifteen minutes at 37°C. Cells
were then co-sedimented with CHO-B7.1+ cells for five minutes (except basal samples 
which were sedimented alone). Phospholipids were then extracted in chloroform, 
deacylated and analysed by HPLC as described (see section 2.2.14). Data expressed as 
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F igure  3.3.2b: Time course of PMA inhibition of CD28 m ediated
P td In s (3 ,4 ,5 )P 3  accum ulation . Metabolically radiolabelled Jurkat cells (2x10^) 
were pretreated with PMA (100 ng/ml) for times as shown above, prior to co­
sedimentation with CHO-B7.1+ cells (1x10^). Phospholipids were then extracted in 
chloroform, deacylated and analysed by HPLC as described (see section 2.2.14). Results 



















F igure 3.3.2c: PMA inh ib ition  of CD28 m ediated P td In s (3 ,4 ,5 )P 3
accum ulation is reversed  by an inh ib ito r of p ro te in  kinase C . Jurkat cells 
(2x10^) were pretreated with Ro31/8220 (30pM), as shown, before pre-incubation with 
PMA (50 ng/ml) for fifteen minutes. Jurkat cells were then co-sedimented with CHO- 
B7.1+ cells (107), at 37°C for five minutes. Following stimulation, phospholipids were 
extracted in chloroform, deacylated and analysed by HPLC as described (section 2.14). 





F igure 3.3.3a Effect of PM A on [^H ]-thym idine in co rp o ra tio n . Peripheral
blood T cells (5x1 O^cells/point) derived form normal healthy donors were treated as
indicated. CHO-B7.1+ cells were included, where indicated, at (2x10^). Cells were
harvested and assayed for [3 H]-thymidine incorporation as described (see section 
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Figure 3.3.3c Effect of LY294002 on [^H]-thymidine incorporation in 
purified primary T cells. Peripheral blood T cells ( 5 x 1 0^) derived form normal 
healthy donors were treated as indicated or with anti-CD3 antibody UCHT1 (1 jug/ml) in 
the presence of cross linking antibody (1 pg/ml). CHO-B7.1+ cells were included, where
indicated, at (2x10^). T cells were preincubated with wortmannin (Figure 3.3.3b) or 
LY294002 (Figure 3.3.3c) for 20 minutes prior to the addition of stimulatory agents.
Cells were harvested and assayed for [^Hj-thymidine incorporation as described (see 
section 2.2.21). Results in b and c are expressed as percentage of inhibition of the 
thymidine incoporation induced by each treatment in the absence of wortmannin or
LY294002. [^H]-thymidine incorporation driven by CD3/B7, 0.5 ng/mlPMA/B7 and 5 
ng/ml PMA/B7 were 69,92914201 CPM, 55,10013327 CPM and 40,26013421 CPM 




1) CD28 ligation by B7.1 resulted in a rapid activation of PI 3-kinase. The 
subsequent accumulation of PtdIns(3,4,5)P3 was maximal at an eight-fold
increase over basal levels, after five minutes and followed by a slight decrease in 
lipid levels.
2) The accumulation of the lipid products of PI 3-kinase induced by B7.1 ligation 
of CD28, in Jurkat cells, was inhibited by wortmannin (100 nM), LY294002 (30 
pM) and transient transfection of cells with Ap85.
3) The absence of lck does not inhibit the recruitment of PI 3-kinase to CD28 in 
JCaMl cells. However, the subsequent activation of the enzyme, as demonstrated 
by the accumulation of its lipid product PtdIns(3,4,5)P3> was severely impaired.
4) Pre-treatment of Jurkat T cells with PMA, inhibited CD28 association with the 
p85 subunit of PI 3-kinase after ligation by B7.1. Approximately 30% of 
stimulated PI 3-kinase activity, as assessed by the quantitation of its lipid 
products, was insensitive to the presence of the phorbol ester.
5) The effects of PMA on CD28 recruitment and activation of PI 3-kinase were not 
mimicked by the non-PKC activating phorbol ester 4 -a  phorbol, and were 
prevented by pretreatment of cells with the PKC inhibitor Ro31/8220.
6) PMA treatment of normal T cells in combination with B7 was sufficient to 
stimulate proliferation as measured by incorporation of [^H]-thymidine. 
Proliferation was maximal at PMA concentrations of 0.5 ng/ml whilst higher 
concentrations still induced reduced proliferative responses.
7) Proliferation of normal T cells induced by CD3 and CD28 stimulation of cells was 
completely inhibited by inhibitors of PI 3-kinase wortmannin and LY294002. 
Proliferation of normal T cells induced PMA (0.5 ng/ml) in combination with B7 
was partially inhibited by wortmannin and LY294002, whilst the reduced 
proliferative responses induced by higher concentrations of PMA (5 ng/ml) in 
combination with B7 were increasingly resistant to the effects of these PI 3-kinase 
inhibitors.
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SECTIO N  FO U R
Ligation stimulated phosphorylation of CD28
4.1 P hosphory la tion  of CD28 following stim ulation  by B 7.I.
Ligation of CD28, by monoclonal antibody, has previously been reported to be followed 
by the phosphorylation of 173y within its cytoplasmic tail, which allows for the 
recruitment of PI 3-kinase [Pages et al. (1994); Prasad et al. (1994)]. Significant 
differences have been reported however, between CD28 mediated signals transduced 
following ligation by antibody or the natural ligand B7 [Nunes et al. (1994)]. Initial 
attempts to demonstrate the ligation dependent tyrosine phosphorylation of CD28 
following ligation by B7.1 using Western blotting however, yielded inconclusive data, 
thus a metabolic labelling approach was adopted, in which CD28 was immunoprecipitated 
from Jurkat cells previously radiolabelled with 32p inorganic phosphate. This procedure 
revealed the major component of CD28 phosphorylation to reside within serine and 
threonine residues. Since the serine/threonine phosphorylation of CD28 is a ligation 
dependent event it may be assumed to carry a physiological relevance either regulating the 
association of CD28 with PI 3-kinase or facilitating the coupling of CD28 to further 
signalling pathways. Experiments were therefore conducted to determine the nature of 
CD28 serine/threonine phosphorylation with respect to structural requirements of CD28 
and sensitivity to pharmacological inhibitors.
Concordant with previously published data for CD28 phosphorylation following 
antibody stimulation [Pages etal. (1994); Prasad et a l  (1994)], stimulation of CD28 by 
B7.1, the natural ligand, induced phosphorylation of CD28 which displayed rapid and 
sustained kinetics between 1 and 10 minutes, followed by a small decrease at 15 
minutes (Figure 4.1.1a). Phosphoaminoacid analysis of the phosphorylated CD28, 
subsequent to ligation by B7.1 however, revealed the molecule to be heavily 
phosphorylated on serine and threonine residues, whilst tyrosine phosphorylation 
represented only a minor component of total phosphorylated residues (Figure 4.1.1b). 
This ligation-dependent phosphorylation was found to be specific to B7 ligation of 
CD28 since treatment of cells with CHO cells, UCHT1 mAb or phorbol ester, did not 













products ^  
o r i g i n  ►











Figure 4.1.1a and b: B7.1 ligation of CD28 is followed by
phosphorylation , predom inantly  on serine/threonine residues. Panel a:
[32p]_radiolabelled Jurkat cells (2x10^) were co-sedimented with CHO B7.1 + cells
(10^) and incubated at 37°C. Cells were lysed in ice-cold NP40 lysis buffer and CD28 
immunoprecipitated with 9.3 mAb. Immunoprecipitated proteins were then resolved by 
SDS-PAGE using a 7-17% acrylamide gradient gel (section 2.2.9) and transferred to 
PVDF membrane as described (section 2.2.10). Phosphorylated proteins were located 
on the membrane by overnight autoradiography. Panel b: The appropriate portion of the 
PVDF membrane was excised, bound proteins hydrolysed and phosphoamino acids 
were separated as described (section 2.2.12) and visualised by autoradiography.
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Figure 4.1.1c CD28 phosphorylation is specifically induced by CHO-B7.1 
treatm ent of Ju rk a t cells. [32p]-radiolabelled Jurkat cells (2x 10^) were co- 
sedimented with CHO cells (10^), CHO-B7.1+ cells (10^) or treated with PMA (50 
ng/ml) or UCHT1 mAh (10 pg/ml) and incubated at 37°C for the times indictaed. Cells 
were lysed in ice-cold NP40 lysis buffer and CD28 immunoprecipitated with 9.3 mAb. 
Immunoprecipitated proteins were then resolved by SDS-PAGE using a 7-17% 
acrylamide gradient gel (section 2.2.9). Phosphorylated proteins were visualised by
autoradiography at -80°C.
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4.2 The role of protein kinase C in mediating ligation-dependent 
phosphorylation of CD28.
The presence of three potential sites for phosphorylation by the serine/threonine protein 
kinase, protein kinase C, within the cytoplasmic domain of CD28 around residues 
163ser, l^ T h r  184xhr strongly suggested a role for PKC in ligation stimulated 
CD28 phosphorylation. Moreover, PKC has previously been implicated in the threonine 
phosphorylation of CD28 [Hutchcroft et al. (1996)]. In order to investigate the role of 
PKC in CD28 phosphorylation therefore, [32p].pi radiolabelled Jurkat cells were 
preincubated with 50 and 100 ng/ml PMA for fifteen minutes, conditions known to 
affect the signal transduction capabilities of CD28 (section 3.3), prior to sedimentation 
with or without CHO-B7+ cells. Immunoprecipitation of CD28 (Figure 4.2.1), revealed 
that pretreatment with PMA did not result in the phosphorylation of unstimulated CD28, 
nor was the ligation-stimulated phosphorylation of CD28 potentiated by the presence of 
phorbol esters in Jurkat cells.
In an alternative approach used to attempt to demonstrate a role for PKC in CD28 
phosphorylation, radiolabelled Jurkat cells were incubated with the PKC inhibitor 
Ro31/8220 for ten minutes prior to stimulation with B7.1, conditions demonstrated to 
protect against the inhibitory action of PMA on CD28 coupling and activation of PI 3- 
kinase (Figure 3.3.1 B and D). Inhibition of PKC by Ro31/8220 was found not to inhibit 
B7.1 stimulated ligation-dependent phosphorylation of CD28 (Figure 4.2.2). Moreover, 
further inhibitors of PKC function such as Calphostin C (0.001-1 jiM) and Bisindolyl 
maleimide (0.001 -1 pM) were found to be without effect upon the phosphorylation 
profile of CD28 (summarised in Table 4.1). These data strongly suggest that PKC does 
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Figure 4.2.1 Effect of PMA on phosphorylation  profile of CD28. [32pj-
radiolabelled Jurkat cells (2x10^) were pre-incubated with PMA (lanes 3 to 7) as 
indicated for 15 minutes prior to co-sedimentation with CHO B7.1+ cells ( 10^) (lanes 
2 to 5) and incubated at 37°C. Cells were lysed in ice-cold NP40 lysis buffer and CD28 
immunoprecipitated with 9.3 mAb. Immunoprecipitated proteins were then subjected to 
SDS-PAGE using a 7-17% acrylamide gradient gel (section 2.2.9), and phosphorylated
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Figure 4.2.2 Effect of Ro31/8220 on ligation-dependent p h o sp h o ry la tio n  
of CD28. [32p]-radiolabelled Jurkat cells (2 x 1 0^) were pre-incubated with 
Ro31/8220 (lanes 2 to 6) for 10 minutes prior to co-sedimentation with CHO-B7.1 + 
cells (107) (lanes 1 to 6) and incubation at 37°C. Cells were lysed in NP40 lysis buffer 
and CD28 immunoprecipitated with 9.3 mAb. Immunoprecipitated proteins were then 
subjected to SDS-PAGE using a 7-17% acrylamide gradient gel (section 2.2.9), and
phosphorylated proteins were visualised by autoradiography at -80°C.
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4.3 Effect of CD28 cytoplasm ic tail trunca tion  m utation on lig a tio n  
stim ulated  phosphorylation .
To further characterise the nature of CD28 phosphorylation induced by B7.1 ligation, a 
murine T cell hybridoma DC27.1, stably transfected with wild type human CD28 
[Pages et al. (1994)], or various cytoplasmic tail mutants which had been truncated by 
21 (A 21) or 30 (A 30) C-terminal residues, were used. The cell surface expression of 
these CD28 mutants in DC27.1 cells was analysed by flow cytometry, and CD28 
expression was found to be equivalent for each mutation. In murine T cell hybridomas 
transfected with human wild type CD28, B7.1 ligation resulted in the phosphorylation 
of CD28. In contrast to the phosphorylation observed in Jurkat, the ligation-induced 
phosphorylation of CD28 in DC27.1 cells was of shorter duration, such that 
phosphorylation was at a maximum after one minute post stimulation, and had declined 
to basal levels at ten minutes post stimulation (Figure 4.3.1). In T cell hybridomas 
transfected with del 21 CD28, B7.1 ligation induces phosphorylation, albeit to a lesser 
extent than that observed in wild type expressing cells (Figure 4.3.2). In cells 
expressing the CD28 del 30 truncation mutation however, B7.1 ligation did not induce 
any detectable phosphorylation of CD28 (Figure 4.3.2).
Figure 4.3.1 L igation-dependent phosphorylation  of hum an CD28 in
m urine DC27.1 cells. [32p]-radiolabelled murine DC27.1 cells (2x10^),
expressing wild type CD28, were co-sedimented with CHO B7.1 + cells (10^) as
indicated, and incubated at 37°C. Cells were lysed in ice-cold NP40 lysis buffer and 
CD28 immunoprecipitated with 9.3 mAb. Immunoprecipitated proteins were then 
subjected to SDS-PAGE using a 7-17% acrylamide gradient gel (section 2.2.9), and
phosphorylated proteins visualised by autoradiography at -80°C.
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Figure 4.3.2 Effect of CD28 truncation  m utations on liga tio n -d ep en d en t 
phosphorylation. [32p]_radiolabelled murine DC27.1 cells (2x 10^), expressing wild 
type or truncated CD28 as indicated, were treated with PMA for 15 minutes, as
indicated. Cells were then co-sedimented with CHO B7.1+ cells ( 10^), as indicated,
and incubated at 37°C for one minute. Cells were lysed in NP40 lysis buffer and CD28 
immunoprecipitated with 9.3 mAb. Immunoprecipitated proteins were then subjected to 
SDS-PAGE using a 7-17% acrylamide gradient gel (section 2.2.9), and phosphorylated
proteins were visualised by autoradiography at -80°C.
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4.4 Site m utagenesis of Tyr 173 prevents ligation-stim ulated CD 28 
p h o sp h o ry la tio n .
PI 3-kinase exhibits a unique dual specificity as both a lipid and protein serine/threonine 
kinase [Dhand et al. (1995)], and associates directly with CD28 (section 3.1) 
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Figure 4.4.1 Effect of DYF173 point m utation on CD28 liga tion  
dependent phosphory lation . [32p].radiolabelled murine DC27.1 cells 
(2xl0^/point) were co-sedimented with CHO-B7.1 + cells (10^ cells/point) (lanes 2, 4, 
6 and 8) for one minute before lysis with NP40 lysis buffer. CD28 was 
immunoprecipitated with 9.3 mAb and immunoprecipitated proteins resolved by SDS- 
PAGE on a 7-17% acrylamide gradient gel. Phosphorylated proteins were then 
visualised by autoradiography.
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3-kinase bound to the (p)^-^YMNM motif may mediate ligation-stimulated 
phosphorylation of the CD28 cytoplasmic tail. To investigate this possibility, 
experiments were performed on the murine T cell hybridoma DC27.1 expressing either 
wild type human CD28 or a site-specific CD28 mutant in which l^ T y r  had been 
mutated to Phe (DYF173), since previous studies have reported that mutation of l^ T y r  
is sufficient to completely abolish binding of PI 3-kinase to CD28 [Pages et a l (1994)].
In murine T cell hybridomas stably transfected with human wild type CD28, stimulation 
of CD28 by B7.1 resulted in the phosphorylation of CD28 (Figure 4.3.1). 
Interestingly, we were unable to detect ligation-stimulated phosphorylation of CD28 in 
DC27.1 cells expressing the DYF173 mutants, suggesting that the ligation dependent 
phosphorylation of CD28 is dependent upon the integrity of the YMNM motif.
4.5 Evidence that phosphorylation of CD28 on serine/threonine residues 
is independent of PI 3-kinase activity.
Since mutation of l^ T y r  has previously been shown to abolish CD28 coupling to PI 3- 
kinase [Pages e ta l  (1994)], the demonstration that engagement of B7.1 did not stimulate 
CD28 phosphorylation of the DYF173 mutant initially suggested the possible 
involvement of PI 3-kinase in modulating ligation-dependent CD28 serine/threonine 
phosphorylation. To further investigate this possibility, another site specific mutant CD28 
was used in which 20Opyr was mutated to Phe (DYF200) and stably expressed in the 
murine T cell hybridoma. Although 200pyr does not he within a recognised consensus 
binding motif for the SH2 domains o f the p85 subunit of PI 3-kinase, mutation of this 
residue has previously been reported to inhibit PI 3-kinase association with CD28 by 
approximately 90% [Pages et a l  (1996)]. However, the precise role of 200j y r jn the 
recruitment of PI 3-kinase to CD28 remains unclear. Given the observations that mutation 
of ^^T y r disrupts both CD28 coupling to PI 3-kinase [Pages et a l (1994)] and ligation 
stimulated CD28 phosphorylation (Figure 4.4.1) it was surprising to note that mutation of 
200ryr to Phe had no effect on the phosphorylation of CD28 after ligation by B7.1 
(Figure 4.5.2).
The effects of wortmannin and the structurally unrelated PI 3-kinase inhibitor LY294002 
on ligation-stimulated CD28 phosphorylation were also examined, since they act as 
inhibitors of both the protein kinase and lipid kinase activities of PI 3-kinase [Vlahos et 
al (1994); Lam et a l (1994)]. However, concentrations of wortmannin and LY294002, 
which are known to inhibit CD28-stimulated PtdIns(3,4,5)P3 accumulation, had no effect
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Figure 4.5.1 Ligation dependent phosphorylation of CD28 is resistan t to 
inhibitors of PI 3-kinase. [32p]_radiolabelled Jurkat cells (2x10^) were pre­
incubated for ten minutes with wortmannin (lanes 3 to 6) or LY294002 (lanes 7 to 10), 
at the concentrations indicated. Cells were then co-sedimented with CHO-B7.1 + cells 
(10^) (lanes 2 to 5 and 7 to 9) and incubated at 37°C for five minutes, followed by lysis 
in ice-cold NP40 lysis buffer. CD28 was immunoprecipitated with 9.3 mAb and 
proteins subjected to SDS-PAGE using a 7-17% acrylamide gradient gel (section
2.2.9). Phosphorylated proteins were visualised by autoradiography at -80°C.
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Figure 4.5.2 Effect of DYF200 point m utation on CD28 liga tion
dependent phosphorylation. [32p]-radiolabelled murine DC27.1 cells (2xl07/point)
were co-sedimented with CHO-B7.1 + cells (lanes 2 and 4) for one minute before lysis 
with NP40 lysis buffer. CD28 was immunoprecipitated with 9.3 mAb and 
immunoprecipitated proteins resolved by SDS-PAGE on a 7-17% acrylamide gradient
gel. Phosphorylated proteins were then visualised by autoradiography -80°C.
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4.6 Effect of inhibitors or activators of protein serine/threonine k inases
on the phosphorylation profile of CD28.
In a further attempt to elucidate the identity of the protein serine/threonine kinase that 
phosphorylates CD28 subsequent to B7.1 ligation, Jurkat cells were treated with 0.001- 
1 pM staurosporine [Davis et a l (1989)], 0.2-200 pM H8 [Hidaka et a l (1984)] or 
0.5-50 pM calphostin C [Tamaoki (1991)], which are known to inhibit several kinases 
including PKC, cAMP-dependent protein kinase and/or cGMP-dependent protein 
kinase. Treatment of Jurkat cells with these inhibitors however, did not detectably 
modify the phosphorylation profile of CD28. Moreover, treatment of Jurkat cells with 
agents known to activate cAMP-dependent protein kinase such as 5 pM  forskolin in 
combination with 500 pM  isobutylmethylxanthine for one hour; or 0.1-100 pM 8- 
bromo-cAMP for 5-15 minutes and cGMP-dependent protein kinase such as 100 pM 
sodium nitroprusside or 0.1-100 mM 8-bromo-cGMP for 15 minutes, had no detectable 
effect on either basal or ligation-stimulated phosphorylation of CD28. The activators 
and inhibitors of serine/threonine kinases that were used without effect on ligation- 
stimulated phosphorylation of CD28, along with the concentrations and incubation 
times are summarised in Table 4.1.
One serine/threonine residue of the CD28 cytoplasmic domain lies within a potential 
site for phosphorylation by the proline-directed ERK serine/threonine kinases (namely 
1 7 7 tp r) . This is particularly interesting given the observation that truncation mutants 
lacking this site exhibited markedly impaired ligation-stimulated phosphorylation of 
CD28 (Figure 4.3.2), therefore, the effect of PD98059, which inhibits MAP kinase 
kinase (MEK) and thus ERK activation was studied. One hour pretreatment with 
PD98059 0.1-50 pM  [Dudley et a l (1995)] however, had no effect on the 
phosphorylation of CD28 after B7.1 ligation (Figure 4.6.1). Similarly, SB203580 (30 
pM) which inhibits the related, but distinct p38 MAP kinase [Cuenda et a l (1995)], 
also had no effect on ligation stimulated CD28 phosphorylation. The data is summarised 
in Table 4.1.
Ligation of CD28 has been demonstrated to result in the activation of the acidic form of 
sphingomyelinase [Boucher et a l (1995)], which elevates ceramide levels activating 
serine/threonine kinases including ceramide activated protein kinase (CAPK) [Matthias 
et a l (1991)], and PKC£ [Lozano et a l (1994)]. Therefore, experiments were 
performed to determine whether ceramide analogues could stimulate the 
phosphorylation of CD28. Accordingly, radiolabelled Jurkat cells were incubated for an
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hour with active C2, (2S,3R)-D-e/yt/zro-./V-Acetylsphingosine, and inactive C2H2 (DL- 
erythro-Dihydro-C2-ceraimde) cell permeable analogues of ceramide [Cifone et al
(1993); Westwick et al (1995)], both at 10 and 50 pM (Figure 4.6.1). It was not 
possible to detect any CD28 phosphorylation induced by ceramide under these 
conditions. Furthermore, B7.1 stimulated ligation dependent phosphorylation of CD28 
was found to be insensitive to the presence of chloroquine (20 pM to 2mM, an inhibitor 
of the activation of acidic sphingomyelinase [Boucher et al (1995)] (Table 4.1). These 
data suggest that ceramide signalling is not responsible for the serine/threonine 
phosphorylation of CD28.
Figure 4.6.1 Effect of a MAP kinase inhibitor and ceram ide analogues 
on phosphorylation profile of CD28. [32p]-radiolabelled Jurkat cells (2x 10^) 
were pre-incubated with agents indicated, where PD is PD98059, C2 is active ceramide 
and C2H2 is the inactive analogue, co-sedimention with CHO B7.1 + cells ( 10^),
indicated as B7, and incubation at 37°C. Cells were lysed in ice-cold NP40 lysis buffer 
and CD28 immunoprecipitated with 9.3 mAb. Immunoprecipitated proteins were then 
subjected to SDS-PAGE using a 7-17% acrylamide gradient gel (section 2.2.9), and 
phosphorylated proteins were visualised by autoradiography at -80°C.
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Table 4.1 Serine/threonine kinase inhibitors and activators without effect







Staurosporine 0.001-0.1 20 PKC, PKA, MLCK, Casein
Ro31/8220 0.5-50 5-10
kinase 1, Ca^+ZCaM dependent 
kinase, PKG
PKC, Ca2+/CaM dependent
Calphostin C 0.5-50 20
kinase, PKA 
PKC, PKA, PKG
H89 5-50 nM 10 PKA
H7 0.2-200 10 PKA, PKC, PKG, MLCK
PD98059 0.1-50 60 MEK
SB203580 0.3-30 60 p38
Chloroquine 0.02-2 mM 10 Acidic sphingomyelinase
activators
Forskolin 5 30-60 PKA
Forskolin/IBMX 5/500 60 PKA
8-bromo-cAMP 100 5-15 PKA
Rp-cAMPs 0.5-1 15 PKA
8-bromo-cGMP 100 5-15 PKG
Na nitroprusside 0.2-20 5-15 PKG
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4.7 Role of protein tyrosine kinases in ligation-stim ulated
phosphorylation of CD28.
Since previous results had suggested that the integrity of l^ T y r  residue, within the 
CD28 cytoplasmic tail, was a prerequisite to serine/threonine phosphorylation of CD28 
(Figure 4.4.1), an experiment was performed to determine if inhibition of protein 
tyrosine kinase activity also inhibited ligation-dependent phosphorylation of CD28. 
Jurkat cells were incubated overnight (16 hours) with or without Herbimycin A (1 pM), 
prior to metabolic labelling with 32p inorganic phosphate. Cells were then stimulated by 
co-sedimentation with CHO-B7.1+ cells, and CD28 immunoprecipitated with 9.3 mAb. 
CD28 phosphorylation was found to be markedly reduced in cells that had been treated 
with Herbimycin A (Figure 4.7.1) compared to vehicle treated cells. Difficulties arise in 
the interpretation of this experiment however since the observed inhibition of 
phosphorylation may be due to a non-specific effect of Herbimycin on the metabolism 
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Figure 4.7.1 Effect of herbim ycin A on liga tion -dependen t 
phosphorylation of C D 28. Jurkat cells were incubated with (lanes 4 to 6) or 
without (lanes 1 to 3) Herbimycin A (1 pM) overnight. Cells were then metabolically 
radio-labelled with [32p] as described (section 2.2.11). Radiolabelled cells (2x10^)
were then co-sedimented with CHO-B7.1 + cells (10^) and incubated at 37°C. Cells 
were lysed in NP40 lysis buffer and CD28 immunoprecipitated with 9.3 mAb. 
Immunoprecipitated proteins were then subjected to SDS-PAGE using a 7-17% 




1) Ligation of CD28 is followed by heavy phosphorylation of its cytoplasmic 
serine and threonine residues, whilst tyrosine phosphorylation represents only a 
minor component of the detectable phosphorylated amino acid residues.
2) Despite the presence of several consensus site for phosphoryation by PKC 
within the cytoplasmic domain of CD28, no phosphorylation was induced by 
PMA and ligation-dependent phosphorylation of CD28 was found to be 
insensitive to inhibition of PKC.
3) Phosphorylation of CD28 requires the integrity of the l^Y M N M  motif since 
site-specific mutagenesis or truncation mutation of 173y severely abrogated 
ligation-dependent phosphoiylation.
4) Ligation dependent phosphorylation of CD28 occurs independently of the 
protein or lipid kinase function of PI 3-kinase since inhibitors of PI 3-kinase did 
not inhibit this response, and site specific mutagenesis of 200y, which prevents 
PI 3-kinase association with CD28, was without effect on CD28 ligation- 
stimulated phosphorylation.
5) Studies with a range of pharmacological inhibitors indicate that ligation- 
dependent phosphorylation of CD28 occurs independently of PKA, PKG, as 
well as ERK and p38 MAP kinase and ceramide generated signals.
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SECTION FIVE
CD28 activation of downstream effectors and regulators 
of PI 3-kinase-dependent signalling cascade
5.1. CD28 mediates activation of protein kinase B.
The demonstration that ligation of CD28 resulted in the recruitment and strong activation 
of PI 3-kinase, suggested that CD28-mediated activation of PI 3-kinase may be sufficient 
to induce activation of downstream effector molecules of PI 3-kinase. Additionally, the 
demonstration that ligation of CD28 was followed by heavy phosphorylation of CD28 on 
serine and threonine residues (as discussed in section four) revealed that CD28 ligation by 
B7.1 is followed by activation of serine/threonine kinases. The recently identified 
serine/threonine kinase PKB has been implicated as a downstream effector of PI 3-kinase 
by a number of lines of evidence (discussed in section 1.5.6.1.2). Furthermore, since 
activation of PKB has been widely reported as protective against apoptosis [Dudek et al. 
(1997); Kulik et al. (1997); Kwhaja et al. (1997); Hausler et al. (1998)], activation of 
PKB would fit well as a downstream effector of CD28. Accordingly, a number of 
experiments were performed to examine the effects of CD28 ligation on the activity of 
PKB.
5.1.1 PKB activation by constitutively active PI 3-kinase in Jurkat cells.
To demonstrate the expression of CD28 and/or rCD2 on transiently transfected cells and 
the effectiveness of both the transfection and the PKB assay, Jurkat cells were transfected 
with plasmid DNA for HA-PKB and the constitutively active PI 3-kinase chimaeric 
construct which consisted of the rCD2 extracellular and transmembrane domain linked to 
p i 10 or a kinase dead version of this construct, rCD2pllOR/P. The cell viability after 
transfection was found by trypan blue exclusion after transfection to be consistent at 
approximately 40% viability for each transfection condition. Flow cytometric 
immunofluorescence analysis of the viable Jurkat cells 16 hours after transfection 
confirmed expression of CD28 on Jurkat cells transfected with either HA-PKB alone or 
with rCD2pl 10 or rCD2pl 10R/P (Figure 5.1.1a). Furthermore, cell surface expression 
of the different rCD2-PI 3-kinase chimaeras was confirmed by flow cytometric 
immunofluorescence with the anti-rCD2 mAb 0x34 (Figure 5.1.1a). Considerable 
amounts of PKB activity were detected in the anti-HA immunoprecipitates derived from
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Jurkat cells co-transfected with HA-PKB and rCD2pllO, compared to cells transfected 
with HA-PKB alone (Figure 5.1.1b). Whilst some PKB activity was detected in anti-HA 
immunoprecipitates derived from Jurkat cells co-transfected with the kinase dead 
rCD2pllOR/P construct (which contains an inactivating arginine to proline mutation at 
position 1130) and HA-PKB, this was considerably less than that detected in cells co­
transfected with rCD2pllO and HA-PKB (Figure 5.1.1b). Since cells transfected with 
HA-PKB alone exhibit some basal PKB activity in HA-PKB immunoprecipitates (Figure 
5.1.1b), the increased expression of HA-PKB in cells co-transfected with rCD2pllOR/P 
(Figure 5.1.1b middle panel). Additionally, there appears to be more protein 
immunoprecipitated in the rCD2pllOR/P lane (Figure 5.1.1b upper panel). These 
observations may explain the increased PKB activity of cells co-transfected with 
rCD2pl 10R/P and HA-PKB.
5.1.2 Activation of PKB in Jurkat cells following CD28 ligation.
To assess the effects of CD28 ligation on PKB activation in T cells, cells of the leukaemic 
T cell line Jurkat that had been transfected with HA-tagged PKB were intially used. 
Ligation of CD28 by either its natural ligand B7.1 or the anti CD28 mAb 9.3 resulted in 
the rapid and transient activation of PKB in transiently transfected Jurkat cells (Figure 
5.1.2a). Moreover, the activation of PKB following CD28 ligation by B7.1 could be 
prevented by pretreatment of the Jurkat cells with the PI 3-kinase inhibitors wortmannin 
and LY294002 (Figure 5.1.2.a/b). Although parental CHO cells increased PKB activity 
above that seen under basal unstimulated conditions this was not time dependent and only 
partially sensitive to wortmannin (Figure 5.1.2a). It is nevertheless surprising to note that 
wortmannin suppresses the PKB activity stimulated by B7.1 ligation of CD28 to a level 
that is much lower than the observed PKB activation by parental CHO. Immunoblotting 
revealed that this observation is unlikely to be explained by discrepancies in HA-PKB 
expression and the reasons for this observation remain unclear. Since the histone H2B 
substrate used to detect PKB activity can be phosphorylated by many protein kinases in 
cell extracts [Burgering and Coffer (1995); Franke et a l (1995); Alessi et a l (1997)], this 
observation may simply reflect discrepancies in the washing of the individual 
immunoprecipitates, and hence the amount of kinase activity non-specifically associated 
with the protein G-sepharose beads.
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Figure 5.1.1 a Flow cytom etry o f  
transiently  transfected Ju rk a t cells fo r 
expression of CD28, rC D 2pllO  and 
rC D pllO R /P  and activation of PKB by 
PI 3-kinase, (a) Jurkat cells which had been 
transiently transfected with HA-PKB, 
rCD2pl 10 or rCD2pl 10R/P were stained with 
either a control mouse IgG (dotted lines), or 
anti-CD28 mAb 9.3 or the anti-rCD2 0x34 
(solid lines) as indicated, (b) Jurkat cells
(10^/point) which had been transiently 
transfected with HA-PKB or co-transfected 
with either rCD2pllO or rCD2pllOR/P were 
lysed and immunoprecipitates prepared with 
anti-HA mAb. The immunoprecipitates were 
subjected to a PKB assay using histone H2B 
as a substrate. The reactions were stopped and 
proteins resolved by SDS-PAGE. The upper 
part of the gel was transferred to PVDF and 
immunoblotted with anti-PKBa polyclonal 
antibody (upper panel). The lower part of the 
gel was dried and histone H2B 
phosphorylation was detected by 
autoradiography at -80°C (middle panel) 
followed by densitometric analysis (lower 







The specificity of the CD28 stimulated PKB activation which was observed after ligation 
by B7.1 was investigated using the CTLA4-Ig fusion protein. Incubation of CHO-B7.1+ 
cells with CTLA4-Ig fusion protein prior to co-sedimentation with Jurkat cells also 
prevented the activation of PKB (Figure 5.1.2b). No PKB activity was detectable in 
either untreated control or CD28-activated Jurkat cells which had been transfected with 
the plasmid DNA for HA-PKB(-) (Figure 5.1.2c). Expression of HA-PKB or HA- 
PKB (-) and efficiency of immunoprecipitation was confirmed by immunoblotting of the 
immunoprecipitates with anti-PKBcc Ab (Figure 5.1.2b upper panel).
5.1.3 Activation of PKB in normal T lymphocytes by CD28.
Given that the signalling pathways relating to CD28 activation in normal T lymphocytes 
are still poorly defined, and that the signalling mechanisms observed in cell lines do not 
necessarily faithfully reflect those which operate in normal in normal T lymphocytes, it 
was investigated whether or not ligation of CD28 in freshly isolated primary T cells also 
resulted in the activation of PKB. For these studies, endogenous PKB was 
immunoprecipitated using an anti-PKBa polyclonal Ab. Accordingly, endogenous PKB 
activity present in anti-PKB immunoprecipitates derived from normal T lymphocytes 
stimulated with anti-CD28 mAb 9.3 was enhanced above that observed under resting 
conditions (Figure 5.1.3). Moreover, the increase was inhibited by pretreatment of the 
cells with the PI 3-kinase inhibitor wortmannin (Figure 5.1.3). Immunoblotting analysis 
with anti-PKB Ab at 1:1000 dilution confirmed the efficiency of immunoprecipitation 
(Figure 5.1.3 upper panel).
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Figure 5.1.2 Activation of PKB in 
Ju rk a t cells following CD28 
ligation. Jurkat cells were transiently 
transfected with HA-PKB (a, b and c) or 
kinase dead HA-PKB(-) (c). The Jurkat 
cells were left unstimulated (control/C) or 
stimulated with lpg/ml anti-CD28 mAb 9.3 
(a), 0.5x106 CHO-B7.1+ (a, b and c) or 
parental CHO cells (a) for the times
indicated, (b) CHO-B7.1+ cells were 
incubated for 5 min with lpg/ml CTLA4- 
Ig fusion protein prior to cosedimentation 
and incubation with Jurkat cells which had 
been transfected with HA-PKB. Where 
indicated, the Jurkat cells were pretreated 
for 10 minutes with 100 nM wortmannin or 
10 pM LY294002. After cell lysis and 
immunoprecipitation with anti-HA mAb, 
the immunoprecipitates were subjected to a 
PKB assay using histone H2B as a 
substrate. The reactions were stopped and 
proteins resolved by SDS-PAGE. The 
upper part of the gel was transferred to 
PVDF and immunoblotted with anti-PKB a  
polyclonal antibody (upper panel). The 
lower part of the gel was dried and histone 
H2B phosphorylation was detected by 
autoradiography at -80°C (middle panel) 
followed by densitometric analysis (lower 
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Figure 5.1.3 B7 ligation activates PKB in norm al T lymphocytes. Normal T 
lymphocytes were purified by negative selection (as described section 2.2.3). The cells 
were either left unstimulated (control) or stimulated with 10 pg/ml anti-CD28 mAb 9.3 
for the times indicated. Where indicated T lymphocytes were pretreated with 100 nM 
wortmannnin. After cell lysis and immunoprecipitation with anti-HA mAb, the 
immunoprecipitates were subjected to a PKB assay using histone H2B as a substrate. The 
reactions were stopped and proteins resolved by SDS-PAGE. The upper part of the gel 
was transferred to PVDF and immunoblotted with anti PKBa polyclonal antibody (upper 
panel). The lower part of the gel was dried and histone H2B phosphorylation was 
detected by autoradiography (middle panel) followed by densitometric analysis (lower 
panel). Data are from single representative experiment.
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5.1.4 PKB co-immunoprecipitates an unidentified phosphoprotein.
In an attempt to generate PKB phosphorylated with 32p for phosphopeptide mapping to 
verify that CD28 could also stimulate phosphorylation of 308yhr, Jurkat cells were 
transiently transfected with HA-PKB or co-transfected with HA-PKB and the rCD2pl 10 
chimaera and incubated for sixteen hours. The transiently transfected cells were then 
radiolabelled with [32p] Pi before treatment with various stimuli, prior to lysis and 
immunoprecipitation of HA-PKB. A phosphorylated protein was observed to co- 
immunoprecipitate with the HA-PKB however, which migrated with an apparent 
molecular weight of approximately 180 kDa. Phosphorylation of this protein was induced 
by co-transfection of Jurkat cells with constitutively active PI 3-kinase, or treatment of 
cells with either anti-CD28 or anti-CD95 mAb (Figure 5.1.4). This unidentified 
phosphoprotein may represent a PKB interacting protein.
Figure 5.1.4 PKB co- 
im m unoprecipitates with a 
phosphoprotein o f
approxim ately 180 kDa. Jurkat 
cells were transiently transfected with 
HA-PKB or co-transfected with HA- 
PKB and rCD2pllO. The Jurkat cells 
were left unstimulated (control) or 
stimulated with lpg/ml anti-CD28 
mAb 9.3 or anti-CD95 mAb (CH11) 
for five minutes as described in the 
annotation. After cell lysis and 
immunoprecipitation with anti-HA 
mAb, the immunoprecipitated proteins 
were resolved by SDS-PAGE. The gel 
was dried and phosphorylated proteins 
visualised by autoradiography at -









5 .2  CD28 mediates activation of p70 S6 kinase
P70 S6 kinase is a mitogen activated serine/threonine kinase that is indicated as a 
downstream effector of PI 3-kinase by a number of lines of evidence, i) PI 3-kinase is 
required for the phosphorylation of 2 5 2 j in the catalytic domain of p70 S6 inase [Weng 
et al. (1995)] and ii) activation of the enzyme by insulin or PDGF is sensitive to 
wortmannin [Chung et al. (1994)]. Furthermore, p70 S6 kinase has been demonstrated as 
necessary for G1 to S phase progression within the cell division cycle [Reinhard et al. 
(1994)], thus p70 S6 kinase would fit well as a downstream effector of CD28. 
Accordingly, experiments were performed to examine the effects of CD28 activation on 
p70 S6 kinase activity.
In this study the PI 3-kinase inhibitor wortmannin has been used to assess the role of PI 
3-kinase signalling to couple CD28 to p70 S6 kinase. Jurkat cells were removed from 
culture, washed and aliquoted at 7.5x 10^ cells/point prior to stimulation. After 
appropriate vehicle/drug stimulations, the Jurkat cells were lysed and cell lysates assayed 
for p70 S6 kinase activity by immunoblotting using a polyclonal antibody which 
recognises both the a l  and a l l  isoforms of p70 S6 kinase. p70 S6 kinase activity was 
determined by the appearance of a slow mobility a l l  isoform on SDS-PAGE 7-17% 
acrylamide gradient gels. Initial attempts to demonstrate CD28 mediated activation of p70 
S6 kinase were hampered by the high basal activity of the enzyme. Accordingly, cells 
were serum starved overnight, prior to stimulation. Serum starvation did not affect 
viability as assessed by trypan blue exclusion. Treatment of Jurkat cells with the PKC- 
activating phorbol ester, phorbol-12-myristate-13-acetate (50 ng/ml) resulted in the 
activation of p70 S6 kinase (Figure 5.2.1). Activation of p70 S6 kinase, following 
stimulation of Jurkat cells with 9.3 mAb (10 pg/ml) or PMA (50 ng/ml), was observed in 
the time range 1-30 minutes (Figure 5.2.1). This CD28-dependent activation of p70 S6 
kinase was inhibited by a ten minute pretreatment with rapamycin (0.1-20 ng/ml), but 
was resistant to pretreatment with cyclosporin A (0.1-10 pg/ml) (Figure 5.2.2). 
Pretreatment of Jurkat cells with nanomolar concentrations of wortmannin, previously 
shown to inhibit CD28-induced accumulation of the lipid products of PI 3-kinase (section
3.1), resulted in inhibition of CD28 induced activation of p70 S6 kinase (Figure 5.2.3). 
Rapamycin, which potently inhibited CD28 mediated p70 S6 kinase activation, had no 
effect on the accumulation of PtdIns(3,4,5)P3 (Figure 5.2.4), suggesting that the effects
of rapamycin on CD28-stimulated p70 S6 kinase activation were not due to upstream 
inhibition of PI 3-kinase. These data indicate that activation of p70 S6 kinase is at least 
one downstream target for the PI 3-kinase signalling pathway following CD28 ligation on 
T cells.
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Figure 5.2.1 Activation of p70 S6 kinase by CD28 and PMA. Jurkat cells
(7.5x 10^) were treated with 10 ng/ml PMA or 10 pg/ml CD28.2 (anti-CD28) mAb, as 
detailed in the legend. Cells were lysed in ice-cold NP40 lysis buffer and subjected to 
SDS-PAGE on a 7-17% acrylamide gradient gel. Separated proteins were transferred to 
PVDF membrane as described (section 2.2.10). Western blots were then analysed by 
immunoblotting with anti p70 S6 kinase antibody and activation state of the enzyme 
assessed by the appearance of electrophoretically retarded a ll  isoforms.
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Figure 5.2.2 CD28 m ediated activation of p70 S6 kinase is inhibited  by
rapam ycin but not cyclosporin A. Serum starved Jurkat cells (7 .5x 10^) were pre­
incubated with cyclosporin A or rapamycin (as detailed in the annotation) for thirty 
minutes. Cells were then treated with CD28.2 (anti-CD28) mAb (except lane 10), for 
thirty minutes at 37°C. Cells were lysed in ice-cold NP40 lysis buffer and subjected to 
SDS-PAGE on a 7-17% acrylamide gradient gel. Separated proteins were transferred to 
PVDF membrane as described (section 2.2.10). Western blots were then analysed by 
immunoblotting with anti p70 S6 kinase antibody and activation state of the enzyme 
assessed by the appearance of electrophoretically retarded a ll  isoforms.
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Figure 5.2.3 CD28 m ediated activation p70 S6 kinase is inhibited by
w ortm annin. Serum starved Jurkat cells (7.5x lOfypoint) were pretreated with 
wortmannin (lanes 3 to 6, 100 nM, 10 minutes) before treatment with CD28.2 mAb for 
thirty minutes, (lanes 1 and 3 to 6) as detailed in the legend. Cells were lysed in ice-cold 
NP40 lysis buffer. Proteins were then resolved by SDS-PAGE on 7-17% acrylamide 
gradient gels and transferred to PVDF membrane, as described (section 2.2.10). Western 
blots were then immunoblotted with anti-p70 S6 kinase antibody and activation assessed 
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Figure 5.2.4 Rapam ycin does not inhibit CD28 m ediated P td In s(3 ,4 ,5 )P 3  
accumulation in Ju rk a t cells. Jurkat cells were radiolabelled with 3^P, as described 
(section 2.2.11). Cells were then aliquoted (2xl0^/point) prior to stimulation with 9.3 
mAb (10 pg/ml) for five minutes before chloroform extraction of cellular lipids. Lipids 
were then solubilised in water by deacylation and subjected HPLC analysis, as described 
(see section 2.2.14). Data are absolute counts from single representative experiment.
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5.3 CD28 activates an SH 2 containing inositol 5-j)hosphatase.
Since PtdIns(3,4,5)P3 is the major lipid product of CD28-activated PI 3-kinase, it is 
important to understand the mechanisms by which levels of this signalling molecule are 
regulated. In this respect experiments were performed to assess the role of the D-5 
phosphatase SHIP in CD28 signal transduction. This study has used immunoblotting 
techniques to show that SHIP is expressed in DC27.1 cells but not Jurkat (Figure
5.3.1). Thus, in subsequent experiments designed to investigate SHIP function, murine 
hybridoma DC27.1 cells, stably transfected with cDNA for human wild type CD28 
[Pages et a l (1994)] have been used. The anti-SHIP antibody also cross-reacted with 
bands of approximately 100 kDa and 190 kDa (Figure 5.1.3) and these may represent 
alternative isoforms of SHIP. Previous studies have demonstrated SHIP to be heavily 
tyrosine phosphorylated in response to treatment with macrophage-colony stimulating 
factor (M-CSF), in 32D cells expressing Fms, a tyrosine kinase growth factor receptor, 
closely related to the platelet derived growth factor receptor (PDGF), which binds 
homodimeric M-CSF [Lioubin et al. (1996)]. Accordingly, it was investigated as to 
whether CD28 ligation induced tyrosine phosphorylation of SHIP in DC27.1 cells. 
Firstly, DC27.1 cells were stimulated with the anti-CD28 mAb 9.3, prior to 
immunoprecipitation of SHIP, and in vitro protein kinase assays were performed. 
CD28 ligation was found to induce rapid and sustained phosphorylation of a 145 kDa 
substrate (Figure 5.3.2), which is assumed to be SHIP. Phosphorylation of the 145 
kDa substrate was accompanied by phosphorylation of further molecules of 
approximately 40 and 100 kDa, the identity of which are unknown (Figure 5.3.2). In an 
alternative strategy to demonstrate SHIP as tyrosine phosphorylated in response to 
CD28 ligation, DC27.1 cells were stimulated with 9.3 mAb and 2C11 mAb (which 
ligates murine CD3), and SHIP immunoprecipitated. Phosphorylated proteins were then 
detected by immunoblot analysis with 4G10 mAb. Ligation of human CD28 and murine 
CD3 were both found to induce tyrosine phosphorylation of SHIP within 1 minute 
which was sustained for at least 10 minutes, in DC27.1 cells (Figure 5.3.3 a and c). 
Furthermore, these induced phosphorylation events were demonstrated as antigen- 
specific since treatment of cells with rabbit anti-mouse immunoglobulins and UCHT1 
did not induce detectable tyrosine phosphorylation of SHIP (Figure 5.3.3 a and c). 
Blots were stripped and reprobed with anti-SHIP Ab to demonstrate equal loading of 
proteins (Figure 5.3.3.b and d) and verify that the position of the tyrosine 
phosphoprotein correlated with the position of SHIP on SDS-PAGE.
Having demonstrated the tyrosine phosphorylation of SHIP in response to CD28 and 
CD3 ligation, further experiments were performed to determine if tyrosine
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phosphorylation of the molecule correlated with activation of its catalytic function. 
Accordingly, SHIP activity was assessed by measuring the ability of the SHIP 
immunoprecipitates to hydrolyse [^H]-Ins(l,3,4,5)P4. Hydrolysis of [^H]- 
Ins(l,3,4,5)P4 by SHIP should result in the formation of Ins(l,3,4)P3? and it is 
possible to separate and measure these water soluble inositol polyphosphates using 
HPLC, and on-line (3-scintilation counting. Figure 5.3.4 demonstrates that SHIP 
immunoprecipitates, derived from unstimulated DC27.1 cells, display a basal ability to 
degrade [^H]-Ins(l,3,4,5)P4. Treatment of cells with 9.3 mAb (10 pg/ml) for 1 to 10
minutes however, results in an increased ability to hydrolyse the substrate as 
characterised by the decrease in Ins(l,3,4,5)P4 and formation of Ins( 1,3,4)^ 3.
Similarly, ligation of the murine T cell antigen receptor with 2C11 mAb resulted in an 
increased hydrolysis of the Ins(l,3,4,5)P4 substrate. These experiments demonstrate
that ligation of CD28 or the CD3, results in increased activity of the newly identified 
SH2 containing inositol polyphosphate 5-phosphatase in murine hybridoma cells.
Since ligation of CD28 clearly induces tyrosine phosphorylation and activation of 
SHIP, CD28 immunoprecipitates from murine DC27.1 cells were immunoblotted with 
anti-SHIP antibody in an attempt to demonstrate a direct association between the two 
molecules. Under conditions where it was possible to detect p85 associated with CD28 
however, no SHIP could be detected in CD28 immunoprecipitates (Figure 5.3.5). This 
suggests that SHIP does not directly interact with CD28.
DC27.1 Jurkat
106 105 IP IP 106 105 IP IP
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Figure 5.3.1 SHIP is expressed in m urine DC27.1 cells but not Ju rk a t.
Cellular lysates (cell density shown in annotation) and SHIP immunoprecipitates from 
(lO?) DC27.1 or Jurkat cells ( 10^) were resolved by SDS-PAGE on 10% 
homogeneous acrylamide gels. Separated proteins were transferred to nitrocellulose 
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Figure 5.3.2 In vitro  kinase assays on SHIP im m unoprecipitates show  
phosphorylation of 145 kDa, 100 kDa and 40 kDa substra tes. SHIP (lanes 1 
to 8) and p85 positive control (lane 9) immunoprecipitates were prepared from DC27.1 
cells expressing wild type human CD28, that had been stimulated with 10 pg/ml 2C11 
mAb (lanes 2 to 4) or 10 pg/ml 9.3 mAb (lanes 6 to 8). Immunoprecipitates were washed 
and in vitro protein kinase assays carried out as described (section 2.2.17). Proteins were 
subjected to SDS-PAGE on a 7-17% acrylamide gradient gel which was subsequently
fixed and dried. Phosphorylated proteins were visualised by autoradiography at -80°C. 
Data are from single representative experiment.
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Figure 5.3.3 SHIP is tyrosine phosphorylated in response to CD28 and
CD3 ligation. SHIP was immunoprecipitated from 10^ wild type human CD28 
expressing DC27.1 cells which had previously been stimulated according to the 
annotation. 9.3 mAb ligates CD28, RaM (rabbit anti-mouse) was used as a general non­
specific Ig to test specificity of the 2C11 and 9.3 reponses (panels a and b), 2C11 mAb 
ligates the mouse T cell antigen receptor and UCHT1 mAb ligates the human T cell 
antigen receptor (panels c and d). Immunoprecipitated proteins were resolved by SDS- 
PAGE and transferred to nitrocellulose membranes. Immunoblotting was then carried 
out to identify tyrosine phosphorylated proteins using the 4G10 mAb (panels a and c). 
The western blots were then stripped and reprobed with anti-SHIP antibody (panels b 
and d) to demonstrate equal loading of the proteins. Data are fdrom single representative 
experiment.
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Figure 5.3.4 Effect of CD28 ligation on SHIP activity. SHIP was 
immunoprecipitated from 2C11 mAb (CD3) or 9.3 mAb treated murine DC27.1 cells. 
SHIP activity was then assessed by the ability of the immunoprecipitates to hydrolyse
[^H]-Ins(l,3,4,5)P4 substrate (see section 2.2.20). Substrate and products from the 5- 
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Figure 5.3.5 SH IP does not co-associate with CD28. Murine DC27.1 cells,
stably transfected to express human CD28 (10^ cells/point), were co-sedimented with
CHO-B7.1+ cells (0.5x 10^ cells/point). After the times indicated, cells were lysed in ice 
cold NP40 lysis buffer and CD28 immunoprecipitated with 9.3 mAb. Proteins were 
resolved in duplicate by SDS-PAGE and transferred to PVDF membrane before 
immunoblot analysis with anti-p85 mAb (left hand panel) or anti-SHIP antibody (right 
hand panel).
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5.4.1 CD28 activation of MAP kinases.
The MAP kinase family of protein represents a major intracellular signalling system with 
three pathways delineated in mammalian cells, controlling the activation of the ERKs, 
JNKs and p38 [for review see Kyriakis and Avruch (1998)]. Evidence exists for the 
involvement of PI 3-kinase in either or both of signalling cascades that control ERK or 
JNK, for example fos transcription, which is regulated by ERK or JNK activity, can be 
activated by a constitutively active p i 10 mutant [Hu et al. (1995)]. Since this is a ras 
dependent effect, it implies that PI 3-kinase may modulate the p21ras pathway and thus 
the eventual activation of the ERKs. Interestingly JNK has been reported as 
synergistically activated by CD28 and TCR ligation in Jurkat cells. [Su et a l (1994)]. 
Additionally, CD28 regulatory input into the MAP kinases has been reported via p21- 
CDC42/Rac which he upstream of PAK. This has been suggested as a point of 
integration for CD3 and CD28 generated signals [Kaga et al. (1998)]. Given that CD28 
may be able to regulate MAP kinases such as JNK, experiments were performed to 
examine the effect of CD28 ligation on JNK activity and the effect of MAP kinase 
inhibitors on proliferative signalling.
5.4.2 CD28 activates JN K .
In this study c-jun N-terminal kinase (JNK) has been immunoprecipitated using a 
recombinant protein corresponding to residues 1-135 of c-jun. JNK activity was then 
assessed by the ability of the immunoprecipitated protein to phosphorylate the co- 
asociated c-jun N-terminal protein in an in vitro kinase assay [Hibi et al. (1993)]. To 
demonstrate the effectiveness of the assay, cells were stimulated with UV light since JNK 
is activated by environmental stress, or PMA (10 ng/ml) in combination with ionomycin 
(1 pg/ml). Exposure to UV light was demonstrated to result in the activation of JNK 
(Figure 5.4.2a), as did PMA (10 ng/ml) in combination with ionomycin (1 pg/ml) 
(Figure 5.4.2a). Alone, PMA or ionomycin induced little or no JNK activation (Figure 
5.4.2b). Similarly CD28 mAb alone had little or no activating effect on JNK activity, 
whilst in combination, PMA (10 ng/ml) and ionomycin (1 mg/ml) induced JNK activation 
which was potentiated by anti-CD28 mAb CD28.2 (10 pg/ml) (Figure 5.4.2b). Pre­
incubation of cells with wortmannin was found to inhibit CD28 potentiation of JNK 
activity whilst no affect on PMA/ionomycin stimulated JNK activity was detected (Figure 
5.4.2c).
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Figure 5.4.2a Activation of JN K  by UV and PM A/ionom ycin. Jurkat cells
(5x lOfypoint) were stimulated, as detailed in the annotation, and lysed as described (see 
section 2.2.19). JNK was immunoprecipitated in complex with GST-c-jun, JNK activity 
was subsequently assessed by the ability of JNK to phosphorylate the GST c-jun fusion 
protein in an in vitro kinase assay (see section 2.2.19). Phosphorylated proteins were
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Figure 5.4.2b Effect of CD28 ligation by mAb on JN K  activation. Jurkat
cells (5x lOfypoint) were stimulated, as detailed in the annotation, and lysed as described 
(see section 2.2.19). JNK was immunoprecipitated in complex with GST-c-jun, JNK 
activity was subsequently assessed by the ability of JNK to phosphorylate the GST c-jun 
fusion protein in an in vitro kinase assay (see section 2.2.19). Phosphorylated proteins
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Figure 5.4.2.C Effect of w ortm annin  on JNK activation. Jurkat cells (5x 
lOfypoint) were stimulated, as detailed in the annotation, and lysed as described (see 
section 2.2.19). JNK was immunoprecipitated in complex with GST-c-jun, JNK activity 
was subsequently assessed by the ability of JNK to phosphorylate the GST c-jun fusion 
protein in an in vitro kinase assay (see section 2.2.19). Phosphorylated proteins were
resolved by SDS-PAGE and visualised by autoradiography at -80°C.
5.4.3 The effect of M AP kinase inhibitors on T cell proliferation.
The availability of a selective and potent pyrinidyl imidazole inhibitor of p38 MAP kinase 
in SB203580 has enabled the identification of functional activities mediated by p38. Since 
CD28 may be implicated as regulating at least some MAP kinase activity (Figure 5.42c), I 
have used SB203580 to assess the importance of p38 in CD28 dependent T cell 
proliferation. The [^Hj-thymidine incorporation induced by anti-CD3 mAb and B7.1 
treatment of cells was inhibited (>70%) in a concentration dependent manner (Figure 
5.4.3.a) by one hour pretreatment of with SB203580 (IC50=10± 2.5 pM, n=4). The
[^H]-thymidine incorporation induced by PMA and CD28 was also inhibited by 
SB203580 at similar concentrations. In contrast SB203580 was much less effective at 
inhibiting [^Hj-thymidine incorporation induced by the combination of 5 ng/ml PMA and 
1 pM ionomycin (Figure 5.4.3b). Activation of the extracellular regulated kinases 
(ERKs) is mediated by MEK, which can be selectively inhibited by PD98059 [Dudley et 
al (1995)]. Experiments were performed to determine the effect of PD98059 o-n CD28 
mediated T cell proliferation. An hour pretreatment with PD98059 (0.1 to 50 pM)) had no 
effect on [^H]-thymidine incorporation induced by PMA and B7.1 treatment of cells 
(Figure 5.4.4a) however, [^HJ-thymidine incorporation induced by CD3 and CD28 
(Figure 5.4.4a) was slightly inhibited (<50%), albeit at a lesser extent than the inhibition 
observed with similar concentrations of SB203580. PD98059 did not inhibiit [^H]-
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thymidine incorporation in response to 5 ng/ml PMA and ionomycin (Figure 5.4.4b).
The effect of SB203580 on CD28-dependent IL-2 production was assessed by taking 
supernatants from human T cell cultures 24 hours after treatment with UCHT1 and CHO- 
B7.1+ cells, in the absence or presence of SB203580. These supernatants were assayed 
for IL-2 production by a bioassay using the IL-2 dependent cell line CTLL [Rayter et al 
(1992)]. This revealed that SB203580 inhibited EL-2-production from the T cells 
stimulated with anti-CD3 Ab and B7.1+ (Figure 5.4.5a). The IC5 0  for inhibition of IL-2
production by SB203580 was 3± 1.4 |lM , n -4, and was similar to that required for 
inhibition of [^HJ-thymidine incorporation (Figure 5.4.5b).
These data may indicate a role for p38 in CD28 driven IL-2 production. However, the 
SB203580 may be carried over in the supernatant assayed for IL-2, and may therefore 
inhibit IL-2 driven biochemical pathways, thus the observed inhibition of IL-2 production 
may be an artifact. Moreover a similar inhibition of IL-2 driven T cell proliferation may 
also explain the observed inhibition of CD28-dependent T cell proliferation. To 
investigate this possibility, human T lymphoblasts were stimulated with IL-2 (20 ng/ml) 
in the presence or absence of both SB203580 and PD98059 (Figure 5.4.6a+b). 
SB203580 was found to inhibit IL-2 driven proliferation of T lymphoblasts at 1-30 |iM . 
In contrast 50 pM  PD98059 had no effect on IL-2 stimulated T lymphoblast proliferation 
(Figure 5.4.6a+b). The IC5 0  for inhibition by SB203580 of sub-optimal IL-2 stimulated
T lymphoblast proliferation was 5± 2.5 pM , n=4 (Figure 5.4.6b), and therefore similar 
to the IC5 0  values calculated for inhibition of anti-CD3 Ab and B7.1 driven IL-2



















Figure  5.4.3 a: Effect of SB203580 on B7/CD3 o r B7/PM A driven T  cell
proliferation. Peripheral blood T cells (5x10^ cells/point) derived from normal healthy 
donors were preincubated with SB203580 (at the concentrations indicated in the
annotation) for one hour before treatment with CHO-B7.1+ cells (2x10^ cells/point) in 
combination with either anti-CD3 mAb UCHT1 (1 pg/ml) or PMA 5 ng/ml. Cells were 
pulsed with [^HJ-thymidine as described (section 2.2) before being harvested and
assayed for [^HJ-thymidine incorporation, as described (see section 2.2.21). Data are 




















F igure  5.4.3 b: Inh ib ition  of T cell p ro lifera tion  by SB203580. Peripheral
blood T cells (5x10^ cells/point) derived from normal healthy donors were preincubated 
with SB203580 (at the concentrations indicated in the annotation) for one hour before
treatment with stimuli as indicated. CHO-B7.1+ cells were included at 2x1 cells/point,
anti-CD3 mAb UCHT1 at 1 pg/ml or PMA 5 ng/ml and ionomycin at 1 jaM. [^H]- 
thymidine incorporation assays were performed, as described (see section 2.2.21). Data 
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F igure 5.4.4 a: Effect of PD98059 on CD3/B7 o r PMA/B7 driven T ce ll
proliferation. Peripheral blood T cells (5x10^ cells/point) derived from normal healthy 
donors were pre-incubated with PD98059 (at the concentrations indicated in the
annotation) for one hour before treatment with CHO-B7.1+ cells (2x10^ cells/point) in 
combination with either anti-CD3 mAb UCHT1 (1 pg/ml) or PMA 5 ng/ml. Cells were
harvested and assayed for [^HJ-thymidine incorporation after 72 hours incubation, as 















Figure 5.4.4 b: Inh ib ition  of T  cell p ro life ra tio n  by PD98059. Peripheral
blood T cells (5x10^ cells/point) derived from normal healthy donors were preincubated 
with PD98059 (at the concentrations indicated in the annotation) for one hour before
treatment with combinations of CHO-B7.1+ cells (2x10^ /point), anti-CD3 mAb UCHT1 
(1 pg/ml), PMA 5 ng/ml or ionomycin (1 pM). Cells were harvested and assayed for
[^H]-thymidine incorporation after 72 hours incubation, as described (section 2.2.21). 
Proliferation driven by each treatment in the absence of inhibitors +/- S.E.M was 
CD3/B7= 27249± 3882 CPM, PMA/B7= 40883± 2380 CPM and PMA/Ionomycin= 
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Figure 5.4.5 a: Effect of SB 203580 on CD3/B7 driven IL-2 production.
Peripheral blood T cells (5x10^ cells/point) derived from normal healthy donors were 
treated with anti-CD3 mAb UCHT1 (1 pg/ml) and CHO-B7.1+ (2x10^ /point) in the 
presence of SB203580 at the concentrations indicated. Supernatants from the cell cultures 
were harvested after 24 hours and IL-2 production detected by a bioassay technique using 
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Figure 5.4.5 b: Effect of SB203580 on CD3/B7 driven T cell activation.
Peripheral blood T cells (5x10^ cells/point) derived from normal healthy donors were 
incubated for one hour in the presence of SB203580, at the concentrations indicated,
prior to activation with anti-CD3 mAb UCHT1 (1 pg/ml) and CHO-B7.1+ (2x10^ /point) 
in two parallel experiments. Supernatants were harvested, from one plate, at 24 hours and
assayed for IL-2 production (section 2.2.22). From the second plate [^HJ-thymidine 
incorporation was determined after 72 hours (section 2.2.21). Data are mean of 
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F igure  5.4.6 a  Effect of SB203580 and PD98059 on IL-2 d riv en  
pro lifera tion  of T  cell lym phoblasts. T cell lymphoblasts prepared as described 
(section 2.2.2) were preincubated with PD98059 (50 pM), SB203580 (10 pM) or 
untreated (vehicle), for one hour before incubation with IL-2 at the concentrations
indicated. Cells were harvested and assayed for [^H]-thymidine incorporation after 72 
hours incubation, as described (see section 2.2.21). Data are mean of quintuplicate 






F igure  5.4.6 b: Effect of SB203580 and PD98059 on IL -2 -s tim u la ted
[^H ]-thym idine incorpora tion  in T lym phoblasts. T cell lymphoblasts prepared 
as described, were preincubated with PD98059 or SB203580 (at the concentrations 
indicated) for one hour before incubation with IL-2 (3 ng/ml). Cells were harvested and
assayed for [^H]-thymidine incorporation after 72 hours incubation, as described (see
section 2.2.21). [^HJ-thymidine incorporation in unstimulated cells was 499± 69 CPM 
and IL-2 (3 ng/ml) stimulated cells was 4031± 579 CPM. Data are mean of quintuplicate 
replicates from a single representative experiment.
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5.4.4 Effect of SB203580 on CD28 mediated activation of PI 3-kinase.
The observed effects of SB203580 on CD28-driven [^Hj-thymidine incorporation may 
be explained by non-specific inhibition of PI 3-kinase, inhibition of which is known to 
abrogate CD28-stimulated proliferation. To examine this possibility radiolabelled Jurkat 
cells were incubated with the MAP kinase inhibitor SB203580 (0 to 30 pM) prior to co­
sedimentation with CHO-B7.1+ cells and extraction and quantitation of the radiolabelled 
phospholipids. Treatment of Jurkat cells with SB203580 (0 to 30 pM) was found to be 
without effect on the CD28-mediated accumulation of PtdIns(3,4,5)P3, (Figure 5.4.7).
These data indicate that the inhibitory effect of the p38 MAP kinase inhibitor SB203580 
on CD28-dependent T cell proliferation (Figure 5.2.3), is achieved independently of an 












Figure 5.4.7 p38 MAP kinase inhibitor SB203580 does not affect PI 3- 
kinase activation . Jurkat cells were radiolabelled with 32p? as described (see section 
2.2.11). Cells were then aliquoted (2xl07/point) and preincubated with SB203580 (lanes 
3 to 5) at 0.3 pM (3), 3 pM (4) and 30 pM (5) for one hour. Cells were then 
cosedimented with CHO-B7.1+ (lO^/point) for five minutes (lanes 2 to 5) before 
chloroform extraction of cellular lipids. Lipids were then solubilised in water by 
deacylation and subjected HPLC analysis, as described (see section 2.2.14). Data are 
from single representative experiment.
126
Section 5.5 Summary.
1) Protein kinase B has been confirmed as a downstream target for PI 3-kinase 
and demonstrated as a downstream target of CD28 in Jurkat cells and purified 
primary T cells by the use of in vitro kinase assays. Transiently expressed HA- 
PKB has also been demonstrated to co-immunoprecipitate from Jurkat cells with 
an unidentified phosphoprotein of approximately 180 kDa.
2) CD28 has been demonstrated to activate p70 S6 kinase in a PI 3-kinase dependent 
and rapamycin-sensitive manner. Since rapamycin had no effect on PI 3-kinase 
activation, rapamycin must exert its effect either downstream or on a parallel 
signalling pathway to PI 3-kinase.
3) CD28 ligation has been shown to induce tyrosine phosphorylation of SHIP and 
increase 5’-phosphatase activity associated with SHIP immunoprecipitates from 
murine DC27.1 cells. No direct association between SHIP and CD28 was 
detected however.
4) Whilst the specific p38 inhibitor SB203580, abrogates PMA/B7 and CD3/B7 
driven T cell proliferation, it also inhibits IL-2 driven proliferation of T 
lymphoblasts. Hence, the inhibitory actions of SB203580 on CD28-dependent T 
cell proliferation might be explained by inhibition of IL-2 rather than CD28- 
stimulated proliferation.
5) CD28 has been demonstrated to potentiate JNK activation induced by PMA in 
combination with ionomycin, in a wortmannin sensitive manner.
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SECTIO N  SIX
Activation of T cell costimulatory targets following CD95 ligation
6.1 CD95 m ediates killing of J u rk a t  cells.
CD95 is a member of the TNFR/GFR superfamily which signal for a broad spectrum of 
functional outcomes including thymocyte proliferation (TNFR2) [Tartagha et al. (1991)] 
and immunoglobulin class switching (CD40) [Kwabe et al. (1994)]. CD95 is widely 
accepted to trigger an apoptotic pathway when ligated [Itoh et al. (1991)], however there 
is evidence to support a positive, possibly costimulatory role for CD95-mediated signals. 
For example anti-CD95 Abs have been reported to cooperate with suboptimal TCR 
stimulation in the induction of T cell proliferation [Alderson et al. (1993)]. Additionally, 
T cells from CD95 defective Ipr mice are less responsive to antigenic stimuli than are 
normal T cells [Davignon et al. (1985)], which could be interpreted as implicating CD95 
in a stimulatory role. Moreover, recent reports studying murine T cells that fail to express 
FADD, have shown these cells to be defective in activation induced proliferation [Zhang 
et al. (1998)]. Given that under certain circumstances CD95 may be implicated in 
providing a stimlatory signal to a cell, the effect of CD95 ligation on downstream targets 
known to be activated in T cell costimulatory signalling was investigated. However, 
before attempting to examine the effect of CD95 ligation on costimulatory effectors, it 
was important to confirm that CD95 ligation resulted in cell death by apoptosis in our T 
cell models. The annexin-FTTC apoptosis assay kit allows detection of apoptosis at much 
earlier time points than previous protocols, such as those which assessed apoptosis by 
DNA fragmentation, since it is based on changes in the phospholipid bilayer which occur 
shortly after the triggering of an apoptotic stimulus [Martin et al. (1995)]. FITC- 
conjugated annexin-V was used to bind PS, a lipid normally restricted to the inner leaflet 
of the plasma membrane, but which is externalised as a rapid response to apoptotic 
signalling. Cells subjected to the annexin binding assay are analysed by FACS. Figure
6.1.1 illustrates apoptosis induction in Jurkat J6 cells in response to a four hour 
incubation with anti-CD95 antibody CH11. The abscissa represents early apoptosis as 
determined by annexin-FITC binding, whilst the ordinate represents plasma membrane 
integrity as assessed by propidium iodide exclusion. During the course of an apoptotic 
response, therefore, cells move from the lower left quadrant to the lower right (annexin 
bright), and finally undergo secondary necrosis and occupy the upper right (annexin 
bright, propidium iodide bright) portion of the dot-plot. Since four hours is a relatively 
short time point in apoptosis, the cells largely retain their membrane integrity and remain
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in the lower right (“early apoptosis”) region of the dot-plot. Treatment of Jurkat cells with 
CHI 1 mAb (0.1 pg/ml) induced apoptosis in 43% of the population whilst treatment of 
Jurkat cells with soluble Fas ligand induced a similar response with 38.9% being classed 
as apoptotic after four hours (Figure 6.1.1). Activation of the caspases is a general feature 
of apoptosis, thus the cell death observed in these experiments has been further 
characterised as apoptotic, by the inclusion of the pan-ICE protease inhibitor Z-VAD- 
FMK. Treatment of the cells with Z-VAD-FMK (30 pM) for one hour prior to incubation 
with CH11 was found to reduce even the basal levels of apoptosis and protect against 
CHll-induced apoptosis (Table 6.1). Contrastingly, treatment of cells with the PI 3- 
kinase inhibitors wortmannin (100 nM) and LY294002 (30 pM) was found not to inhibit, 
but rather potentiate apoptosis since 43.9% of Jurkat cells treated with CH11 were 
apoptotic after four hours, whilst populations of Jurkat cells pretreated with wortmannin 
and LY294002 showed 51.0% and 55.6% to be apoptotic respectively. These data 
suggest that apoptotic signal transduction pathways do not require activation of PI 3- 
kinase, but rather, PI 3-kinase may actually serve to inhibit CD95 mediated apoptosis. 
This observation would explain the increased susceptibility of JCaMl cells to cell death 
(Table 6.2) since in JCaM 1 cells CD95 ligation was found to elicit neglible activation of 
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1) Control 2) CH11 3) Fas-Ligand
Cells in LR quadrant 5.02% Cells in LR quadrant 43.12% Cells in LR quadrant 38.9%
Figure 6.1.1 CD95 ligation by CH11 and soluble Fas-ligand induces 
ap o p to sis . Jurkat cells (5xl0^/point) were incubated with anti-CD95 antibody CH11 
(0.1 pg/ml) (2) or soluble Fas-ligand supernatant (1:2 dilution) (3) for 4 hours. Samples 
were then analysed by FACS for annexin-FITC binding and propidium iodide exclusion. 
The control sample (1) was incubated in the absence of CH11. Data is from single 
representative experiment. (LR=lower right).
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CHI 1 + ZVAD-FMK (4 hr) 13.77
Table 6.1 C aspase inhib itors p ro tec t against CD95 m ediated apoptosis in  
Ju rk a t T cells. Control cells were incubated in medium for 4 hr. CHI 1 was used at 0.1 
pg/ml. Where indicated, cells were pre-incubated for with ZVAD-FMK (30 pM) for one 
hour. Data from single representative experiment.
Treatment % annexin v-FITC positive cells
Jurkat JCaMl
Control (4hr) 12.9 25.4
CH11 (4hr) 43.9 83.5
CHI 1+ wortmannin 51.0 ND
CHI 1+ LY294002 55.6 ND
Table 6.2 Effect of P I 3-kinase inh ib ito rs  on C D 95-m ediated a p o p to s is .
Control cells were incubated in medium for 4 hr. CH11 was used at 0.1 pg/ml. Where 
indicated cells were preincubated for with wortmannin (100 nM) or LY294002 (30 pM) 
for ten miutes. ND denotes not determined. Data from single representative experiment.
6.2 CD95 activates P I 3-kinase.
The enhancing effect of Fas-induced cell death by PI 3-kinase inhibition suggested that PI 
3-kinase may be activated by Fas. This is particularly interesting given that PI 3-kinase 
activation is a critical event in T cell costimulation by CD28, and that Fas can act as a 
costimulatory signal under certain circumstances. Therefore, it was important to 
investigate the effect of CD95 ligation on PI 3-kinase activity as assessed by accumulation 
ofPtdIns(3,4,5)P3. CH11 (0.1 pg/ml) treatment of Jurkat cells was found to result in an 
accumulation of PtdIns(3,4,5)P3 (Figure 6.2.1). However, whilst CD28 ligation was 
followed by a 6 to 8 fold increase over basal concentrations of PtdIns(3,4,5)P3 (Figure
6.2.1), ligation of CD95 either by CH11 or soluble Fas Ligand was followed by a two­
fold increase above basal concentrations of PtdIns(3,4,5)P3 (Figure 6.2.1) after 10
minutes. This data demonstrates that CD95 does activate PI 3-kinase, albeit at a lower 
stoichiometry than CD28. Since in JCaMl cells, CD28-mediated stimulation of PI 3-
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kinase is markedly impaired in comparison to that observed in Jurkat cells, the effect of 
CD95 ligation on PI 3-kinase was determined in JCaMl cells. Whilst in Jurkat cells Fas- 
ligand treatment was found to double cellular levels of PtdIns(3,4,5)P3, Fas-ligand











Control I '  5 ' 10’
Treatment
Figure 6.2.1 CD95 ligation induces PI 3-kinase activation in Ju rk a t c e lls .
[32p]_radiolabelled Jurkat cells (2x10^) were co-sedimented with CHO-B7.1+ cells
(107), exposed to CH11 (0.1 pg/ml), soluble Fas Ligand (1:2 dilution) or control
supernatant, and incubated at 37°C for the times indicated in the annotation. Cellular 
lipids were extracted by partitioning in chloroform, solubilised in water by deacylation 










Table 6.3 CD95 ligation stim ulates negligible P td In s(3 ,4 ,5 )P 3  
accum ulation in JC aM l cells. [32p]-radiolabelled Jurkat or JCaMl cells (2x 10^)
were treated with soluble Fas Ligand (1:2 dilution) and incubated at 37°C for the times 
indicated. Cellular lipids were extracted by partitioning in chloroform, solubilised in 
water by deacylation and analysed by HPLC as described (see section 2.2.14). Data from 
single representative experiment.
■  B7.1 
0  CH11 
11 Fas Ligand 
E3 Control supernatant
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6.3 CD95 regulates PKB activity.
From the initial observation that CD95 was capable of stimulating PI 3-kinase activity, as 
evidenced by increased cellular levels of PtdIns(3,4,5)P3 (Figure 6.2.1), experiments
were conducted to investigate whether CD95 activation of PI 3-kinase was sufficient to 
induce, activation of the downstream effectors of PI 3-kinase such as protein kinase B 
[Burgering and Coffer (1995); Franke et a l (1995)]. Given the contrasting functional 
roles of PKB (which promotes cell survival) and CD95 (which promotes cell death), 
these investigations yielded some intriguing results. Figure 6.3.1 demonstrates ligation of 
CD95 by CHI 1 Ab or soluble Fas Ligand, was followed by an increase in PKB activity 
within a minute, which is sustained for at least five minutes following stimulation. Given 
that CD95 activates PI 3-kinase (Figure 6.2.1), experiments were designed to examine 
the potential role of PI 3-kinase in the CD95 mediated activation of PKB by incubating 
cells with concentrations of wortmannin, previously demonstrated to inhibit PI 3-kinase 
activity (see section 3.1), prior to treatment of cells with CH11. These experiments 
however, yielded inconclusive data as demonstrated in Figure 6.3.2. In experiment one 
CD95 activation of PKB appears to be inhibited by preincubation of cells with 
wortmannin (100 nM). Whilst in experiment two, the activation of PKB actually appears 
to be potentiated by the presence of wortmannin.
Given the inconsistencies noted in the generated data, further experiments were 
performed in an attempt to elucidate the nature of signalling pathways utilised in the CD95 
mediated activation of PKB. Since MAPKAP kinase 2 is a direct substrate of p38, and 
has been described as potentially pbosphorylating PKB on serine residue 473 [Alessi et 
al (1996)], activation of the p38 pathway represents a potential mechanism for activation 
of PKB. Futher experiments were therefore performed using the inhibitor of p38 MAP 
kinase SB203580. Jurkat cells were treated with vehicle or with SB203580 (3-30 p,M) 
for one hour prior to the addition of CHI 1 or soluble Fas Ligand. SB203580 was found 
to partially inhibit both CH11 and Fas Ligand-stimulated activation of PKB in a dose- 
dependent manner (Figure 6.3.3). Contrastingly, the activation of PKB induced by 
treatment of cells with 9.3 mAb was found not to be sensitive to treatment with the p38 
MAP kinase inhibitor.
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Figure 6.3.1 CD95 ligation m ediates PKB activ a tio n . Jurkat cells (10^/point) 
were deprived serum for 16 hours, and stimulated as detailed in the annotation. The cells 
were lysed and PKB immunoprecipitated using anti-PKBa antibody. Immunoprecipitates 
were washed as described and in vitro protein kinase assays performed using histone 
H2B as a substrate (section 2.2.18). Reactions were quenched and proteins separated by 
SDS-PAGE using a 7-17% acrylamide gradient gel. The lower half of the gel was dried 
and autoradiography performed to assess protein phosphorylation (middle panel) 
Densitometric analysis was then performed on the autoradiograph (lower panel). Proteins 
on the upper half of the gel were Western blotted to PVDF membrane and immunoblotted 
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Wortmannin 100 nM
Figure 6.3.2 Effect of w ortm annin on CD95-m ediated activation of PKB.
Jurkat cells (10^/point) were deprived serum for 16 hours, and preincubated with 
wortmannin (lanes 8 to 13). Cells were then stimulated with CHI 1 (0.1 pg/ml) or soluble 
Fas Ligand (1 in 2 dilution of supernatant), as detailed in the annotation, followed by 
lysis in ice-cold NP40 lysis buffer. PKB was immunoprecipitated using anti-PKBa 
antibody. Immunoprecipitates were washed as described and in vitro protein kinase 
assays performed using histone H2B as a substrate (section 2.2.18). Reactions were 
quenched and proteins separated by SDS-PAGE using a 7-17% acrylamide gradient gel. 
The lower halves of the gels were dried and autoradiography performed to assess protein 
phosphorylation (lower panels). The proteins of the upper halves of the gels were 
transferred to PVDF membranes and immunoblot analysis carried out for the presence of 
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Figure 6.3.3 Effect of SB203580 on CD95-mediated activation of PKB. Jurkat cells 
(lOVpoint) were deprived of serum for 16 hours, and preincubated with SB203580 for 
one hour at the concentrations described in the annotation. Cells were stimulated as 
described, prior to lysis in ice-cold NP40 lysis buffer. PKB immunoprecipitates, derived 
from the cell lysates, were washed and in vitro protein kinase assays performed using 
histone H2B as a substrate (section 2.2.18). Proteins were separated by SDS-PAGE 
using a 7-17% acrylamide gradient gel. The lower half of the gel was dried and autora­
diographed to assess protein phosphorylation (middle panel). Densitometric analysis was 
then performed on the autoradiograph (lower panel). Proteins on the upper half of the gel 
were western blotted to PVDF membrane and immunoblotted with anti- PKBa antibody 
to demonstrate equal loading of protein (upper panel).
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6.4 CD95 activates p38 MAP kinase.
In light of the inhibitory effect of SB203580 on CD95 mediated PKB activation, further 
experiments were performed to investigate the role of the p38 MAP kinase cascade in 
mediating the effects of CD95 on PKB. Accordingly, experiments were performed to 
assess whether CD95 ligation could induce p38 activation. Figure 6.4.1 illustrates p38 to 
be tyrosine phosphorylated at its ISOpGY sequence in Jurkat cells, following treatment 
with anti-CD95 antibody CH11 (0.1 pg/ml). This activation of p38 MAP kinase was not 
due to environmental stress since incubation of the cells in the absence of CH11 did not 
result in the phosphoryation of p38 (Figure 6.4.1, lanes 6 and 7). Maximal p38 
phosphorylation however, was observed only after two hours treatment of Jurkat cells 
with CHI 1 Ab (Figure 6.4.1), thus the kinetics of p38 activation would not be suitable to 
support PKB activation, as described herein (Figure 6.3.1). Moreover, the activation of 
p38 MAP kinase, as assessed by tyrosine phosphorylation of TGY motif (Figure 6.4.1), 
was insensitive to the presence of the caspase inhibitor Z-VAD-FMK (30 pM), which
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Figure 6.4.1 CD95 activates p38 MAP kinase . Jurkat cells (10^/point) were 
treated as detailed in the annotation. Pretreatment with Z-VAD-FMK was for one hour at 
50 pM, CHI 1 mAb was included at O.lpg/ml, timed controls were incubated at 37°C 
for the times shown. Cells were lysed in ice-cold NP40 lysis buffer and proteins resolved 
by SDS-PAGE using a 10% homogeneous acrylamide gel. Proteins were transferred to 
nitrocellulose membranes and immunoblotted for phosphorylated p38 MAP kinase (upper 
panel). Blots were subsequently stripped of antibodies and reprobed for p38 MAP kinase 
to demonstrate equal loading of proteins.
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6.5 Summary.
1) CD95 ligation by CHI 1 mAb and soluble Fas ligand was demonstrated to induce 
apoptotic cell death in Jurkat cells. Apoptosis was inhibited by preincubation of 
the cells with Z-VAD-FMK.
2) Treatment of Jurkat cells with CHI 1 mAb and soluble Fas Ligand was found to 
mediate activation of PI 3-kinase. Cellular levels of PtdIns(3,4,5)P3 were found
to increase up to four-fold above basal levels after 10 minutes incubation with the 
antibody.
3) Ligation of CD95 by CHI 1 mAb or Fas ligand was found to rapidly activate 
PKB activity in Jurkat cells for at least five minutes, as demonstrated by in vitro
kinase assays.
4) Attempts to characterise the CD95 mediated activation of PKB yielded 
inconclusive results from the use of the PI 3-kinase inhibitor wortmannin. CD95 
mediated activation of PKB did however, appear at least partially sensitive to 
inhibition of p38 MAP kinase by SB203580, suggesting a potential role for p38 
MAP kinase in the CD95 mediated activation of PKB.
5) CD95 ligation was demonstrated to induce activation of p38 MAP kinase, 
however, maximal activation was only observed after a two hour treatment of the 
cells. The kinetics of CD95 mediated p38 MAP kinase activation are therefore 




7.1.1 CD28-mediated activation of PI 3-kinase.
Ligation of CD28 by B7.1 (this study) or anti-CD28 Abs [Pages et al. (1994); Prasad et 
al. (1994)] is sufficient to stimulate recruitment and activation of PI 3-kinase. In this 
study, ligation of CD28 has been demonstrated to stimulate in vitro lipid kinase activity 
associated with CD28 immunoprecipitates from Jurkat cells, which is presumably 
resultant from the activity of p i 10 catalytic subunits that co-associate with the CD28- 
bound p85 regulatory subunit, and is sensitive to inhibition by wortmannin i.e. class IA 
PI 3-kinases [Vanhaesebroeck et al. (1997)]. Analysis by in vitro lipid kinase assay is a 
useful technique since it is relatively efficient in terms of both time and use of 
radioisotopes, however, limitations occur in interpretation of the data generated since the 
assay itself imposes reaction conditions and a substrate specificity that may distort the 
enzyme properties. In contrast direct chloroform extraction of cellular lipids from 
metabolically radiolabelled cells allows for the study of changes in total phosphoinositide 
levels under more physiological conditions. This study has also used direct chloroform 
extraction of lipids therefore, to demonstrate CD28 mediated accumulation of D-3 
phosphoinositide lipids in Jurkat cells.
The accumulation of the lipid products of PI 3-kinase is inhibited by preincubation of 
cells with wortmannin and a large part of this thesis has used wortmannin in subsequent 
experiments to help identify downstream PI 3-kinase-dependent biochemical events. 
However, problems arise in the interpretation of experiments utilising pharmacological 
inhibitors, since targets other than PI 3-kinase may be subject to inhibition. Wortmannin 
for example inhibits at least three further enzymes in Ptdlns 4-kinase [Nakanishi et al. 
(1995)] and phospholipase A2 [Cross e ta l  (1995)] and mTOR [Brunn et a l (1995)], at 
concentrations coincindent with inhibition of PI 3-kinase and, at elevated concentrations, 
phospholipase D [Reinhold et al. (1990)] and phospholipase C [Bonser et al. (1991)]. 
Wortmannin inhibition of Ptdlns 4-kinase could lead to disruption of the cycle of lipid 
phosphorylation required to replenish the PtdIns(4,5)P2» which acts both as a substrate 
for phospholipase C and a precursor of PtdIns(3,4,5)P3- Accordingly, in this study, 
CD28 mediated activation of PI 3-kinase has been demonstrated as inhibited by the 
structurally unrelated molecule LY294002, which has been previously demonstrated to 
inhibit purified bovine brain PI 3-kinase with an IC5 0  of 1.4 pM [Vlahos et al. (1994)],
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whilst no significant effects of LY294002 were observed in further investigations on 
several enzymes including Ptdlns 4-kinase, src, MAP-kinase, S6 kinase, DAG kinase, 
PKA and PKC [Vlahos et al. (1994)]. There may however be further, as yet 
undetermined targets for LY294002.
There are further limitations to the use of pharacological inhibitors of PI 3-kinase , for 
instance p85 contains two SH2 domains which may interact with tyrosine phosphorylated 
proteins, and an SH3 domain, which may mediate interactions with proline rich regions 
of proteins, additional to the p i 10 binding site, thus the molecule is ideally placed to 
perform an adaptor protein role mediating interactions with other signalling proteins. The 
pharmacological agents wortmannin and LY294002 inhibit only the kinase function of 
p i 10, and thus will not affect the recruitment of p85 to phosphorylated receptors or any 
subsequent adaptor molecule function. This must be considered when interpreting results 
obtained from the use of pharamacological inhibitors of PI 3-kinase such as wortmannin.
A further problem exists in interpretation of data generated using pharmacological 
inhibitors since these compounds inhibit all classes of PI 3-kinases to variable extents. 
For example wortmannin inhibits class LA PI 3-kinases and class IE PI 3-kinases with an 
IC5 0  of <10nM [Arcaro and Wymann (1993); Volinia et a l (1995)], whilst the IC50 for
inhibition of class II PI 3-kinase is 40-50 nM, and mammalian class II PI 3-kinases such 
as PI 3-kinase C 2a are refractory to wortmanin [Domin et al. (1997)]. It is difficult 
therefore, to implicate class LA PI 3-kinases in a particular pathway using only such 
compounds. However, in the case of class LA PI 3-kinases molecular reagents have been 
developed which provide more definitive evidence that this class of PI 3-kinase is 
necessary for a particular process. Several cDNAs have been engineered to produce 
constitutively active or dominant negative inactive forms of PI 3-kinase, in order to 
demonstrate an effect of either increased PI 3-kinase activity or blocking PI 3-kinase (see 
section 1.5.4.3). It must be remembered however, that p85 may act as an adaptor protein 
with an extensive repertoire of protein-protein interactions, thus may interfere with 
signalling pathways by complexing with important proteins. Indeed, SHIP has been 
suggested to down-regulate Ras activity, following B cell antigen receptor ligation, by 
sequestration of the intervening adaptor protein She [Tridanipandi et al. (1997)]. Thus 
care must be taken in the interpretation of data derived from the use of either 
pharmacological or molecular reagents. Generally, the combined use of PI 3-kinase 
inhibitors and blocking or activation of PI 3-kinase using molecular reagents, allows for 
the construction of stronger arguments regarding the function of the enzyme. In this 
study, therefore, the CD28 mediated accumulation of the lipid products of PI 3-kinase, 
has been demonstrated to be resultant from the activation of class LA PI 3-kinase since it
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is sensitive to inhibition by wortmannin, LY294002 and expression of Ap85. Inhibition 
of CD28-mediated PtdIns(3,4,5)P3 accumulation in Jurkat cells by expression of Ap85
however, was not complete. The residual D-3 phospholipid production may be explained 
in a number of ways. Firstly, not all the transfected Jurkat cells might be expected to 
express Ap85. Hence, in cells that do not express Ap85, endogenous p85 will still be 
able to. interact with CD28. Secondly, the residual PtdIns(3,4,5)P3 production may be
due to the activation of different classes PI 3-kinase isoforms which may have different 
susceptibilities to wortmannin. For example, the high affinity IgG receptor (FcyRI) 
couples both class IA and class IB PI 3-kinases [Melendez et a l  (1998)].
Ligation of other cell surface antigen such as the TCR/CD3 complex, CD7 [Ward et a l 
(1995)], CD25, and signalling by growth factors, have all been reported to stimulate PI 
3-kinase activity within cells. The coupling of multiple receptors to the same signalling 
pathway, potentially presents a problem regarding specificity of the signal delivered by 
these receptors. This issue may be addressed in considering a number of features of the 
enzyme: For instance, several biochemically distinct PI 3-kinases exist which associate 
with different regulatory molecules, exhibit differing substrate specificities and display 
varying sensitivity to inhibition by wortmannin [Table 1.1]. Moreover, diversity of class 
IA PI 3-kinase signalling cascade is facilitated by (i) the ability of the class I p85/p ll0  
complex to phosphorylate three lipid substrates in Ptdlns, Ptdlns(4)P and PtdIns(4,5)P2-
In turn, these lipids may be compartmentalised within the cell to some degree; (ii) the 
p i 108 isoform differs from p i 10oc/p, in that it harbours an autophosphorylatory capacity 
whereas, pllOot/p phosphorylate p85 [Vanhaesebroeck et al. (1997)], thus p i 108 may 
potentially phosphorylate a pattern of protein substrates distinct from that stimulated by 
p i 10a/P; (iii) the SH2/SH3/proline rich regions of p85 can putatively mediate a plethora 
of protein-protein interactions. The diverse nature of this pathway is therefore well suited 
to be involved in mediating not only the diverse effects of CD28 on T cell biology, but 
also distinct effects of other T cell surface receptors.
7.1.2 Role of lck in CD28-mediated activation of PI 3-kinase.
The recruitment of PI 3-kinase to CD28 in the absence of lck confirms recent 
observations [Gibson et a l (1998)]. Despite the ability of lck-deficient JCaMl cells to 
display ligation-dependent recruitment of PI 3-kinase to CD28, HPLC analysis of the 
accumulation of PtdIns(3,4,5)P3 reveals an impaired activation of PI 3-kinase in these
cells in response to CD28 ligation by B7.1. Tyrosine phosphorylation of the YMNM 
binding motif, within the cytoplasmic tail of CD28, is well established to be a pre­
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requisite for PI 3-kinase recruitment [Pages et al. (1994); Prasad et al. (1994)]. Lck has 
previously been reported to be activated following CD28 ligation [August and Dupont
(1994)] and to phosphorylate the PI 3-kinase binding motif in a baculovirus expression 
system in insect cells [Raab et al. (1995)]. The demonstration that PI 3-kinase recruitment 
to CD28 occurs in the absence of lck however, suggests that, either lck is not responsible 
for phosphorylation of the binding motif in vivo or, the absence of lck can be 
accommodated for by compensatory phosphorylation of the binding motif by further 
tyrosine kinases such as p59fyn, ZAP 70 or ITK. The most likely of these kinases would 
be p59fyn since ITK and ZAP-70 fail to detectably phosphorylate CD28 in coexpression 
studies [Raab et al. (1995)] and optimal ITK activation is not obligatory for recruitment of 
PI 3-kinase to CD28 [Gibson et al. (1998)]. Contrastingly, GST-CD28 fusion proteins 
have been demonstrated to be an in vitro substrate for ITK immunoprecipitated from 
exponentially growing Jurkat cells [King et al. (1997)]. However, the authors also 
demonstrated that activation of ITK was partially dependent upon the integrity of 
173Tyr, implying ITK activation to be dependent upon the phosphorylation of l^ T y r .  
Furthermore, ITK has been proposed as a lying downstream of lck and fyn in CD28 
signalling [Raab etal. (1995)]. Thus, fyn is the strongest candidate for a CD28 
directed kinase, in the absence of lck. Co-expression studies in insect cells however 
[Raab et al. (1995)], reveal the magnitude of CD28 phosphorylation induced by fyn to be 
considerably less that induced by lck, whilst the recruitment of PI 3-kinase to CD28 is 
unaffected by the absence of lck, as detected by Western blotting. These observations 
imply that there may be a further, as yet unidentified, protein tyrosine kinase which is 
coupled to CD28 independently of l^ T y r , ancj required for PI 3-kinase recruitment.
The incomplete activation of PI 3-kinase in the absence of lck bears striking similarity to 
the previously reported mobilisation of intracellular calcium in JCaMl cells in response 
to anti-CD3 antibody [Straus and Weiss (1992)]. Intracellular calcium mobilisation, a 
consequence of PLCy 1 phosphorylation, occured only with slower kinetics and 
magnitude in cells which failed to express lck. A wild type response was restored to the 
JCaMl cells on transfection of the cells with lck cDNA [Straus and Weiss (1992)], 
demonstrating the requirement for lck. The observation that CD28 mediated PI 3-kinase 
activation is incomplete in the absence of lck, implies that this kinase plays an important 
role in the activation of PI 3-kinase, which may not be fully compensated for by other 
protein tyrosine kinases. The role of lck in efficient activation of PI 3-kinase could 
involve either, i) direct tyrosine phosphorylation of PI 3-kinase subunits. For example, 
L u etal. (1994) have previously correlated CD28 ligation with tyrosine phosphorylation 
of p i 10 in association with p85 which was impaired in the absence of lck. This would 
correlate well with the impaired activation of PI 3-kinase in JCaMl cells described in this
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study. Tyrosine phosphorylation of PI 3-kinase subunits remains a contentious issue 
however, since further groups have failed to detect tyrosine phosphorylation [Backer et 
al (1992); Hu et a l (1992)]. Alternatively, ii) tyrosine phosphorylation of further 
proteins may affect PI 3-kinase function. Lck has been demonstrated to be required for 
CD28-stimulated phosphorylation at least two protein substrates of 97 kDa and 68 kDa 
[Lu et a l  (1994)]. These proteins likely correspond to those later identified as p97vav and 
p62d°k [Klasen et a l (1998)], and the efficient phosphorylation of these may be 
necessary for full activation of PI 3-kinase by CD28. Vav and dok may affect PI 3-kinase 
function as a result of enhancement of Ras activity since dok associates with Ras-GAP 
[Yamanashi and Baltimore (1997)], this may allow for modulation of the cellular 
ditribution of Ras-GAPs sequestering these negative regulators away from Ras 
molecules. Also, the Dbl domain of Vav has been reported to display GNEF activity for 
ras, at least in vitro [Gulbins et a l (1993)], however, whilst in fibroblasts PI 3-kinase 
binds directly to Ras resulting in activation of the lipid kinase [Rodriguez-Viciana et al
(1994)], a recent report suggests this pathway may not be operative in T cells [Genot et 
a l  (1998)]. Lck induced phosphorylation of dok may mediate the recruitment of a further 
protein for example, Cbl, which associates with PI 3-kinase has been reported to 
associate directly with p6 2dok Recruited Cbl could enhance PI 3-kinase by allosterically 
modifying PI 3-kinase. The exact mechanism by which lck potentiates the CD28- 
mediated activation of PI 3-kinase however, remains an open question. These 
observations are summarised in Figure 7.1.
CD28 mediated PI 3-kinase activation in Jurkat cells appears to peak at five minutes and 
then diminish slightly, whilst in JCaMl cells, lipid production appears to plateau at 5 
minutes, albeit at much reduced levels compared to Jurkat. This difference may be 
accounted for in a number of ways. The elevated production of PtdIns(3,4,5)P3 in Jurkat
cells could lead to depletion of available lipid substrate, potentially limiting PI 3-kinase 
activity. Since PI 3-kinase is less active following CD28 ligation in JCaMl cells these 
constraints may not be encountered. Alternatively, CD28 mediated activation of PI 3- 
kinase could be subject to down-regulation following lck-dependent recruitment or 
activation of signalling molecules that may inhibit the PtdIns(3,4,5)P3 signal. In this
respect there are two possible molecules that might be involved in negative regulation of 
CD28-activated PI 3-kinase. Firstly, the results presented in this study demonstrate that 
tyrosine phosphorylation of SHIP, which has been reported as mediated by lck [Lamkin 
et a l (1997)], is induced by CD28 ligation and correlates with an increase in SHIP 
catalytic activity. Thus, given that PtdIns(3,4,5)P3 is a substrate for SHIP, lck mediated
activation of SHIP may serve to limit levels of the signalling lipid, this will be discussed 





Figure 7.1 Model of CD28-mediated sequential activation of PI 3 - 
kinase. 1) Following ligation, 173y of the CD28 cytoplasmic tail is 
phosphorylated. In vitro studies suggest lck as the strongest candidate for 
l ^ Y - k i n a s e  [Raab et al. (1995)] however, the absence of lck does not affect PI 
3-kinase recruitment to CD28, thus an unidentified kinase may mediate this 
phosphorylation. 2) Phosphorylation of CD28 I73y allows for PI 3-kinase 
recruitment via the association of CD28 with the SH2 domains of p85. 3) PI 3- 
kinase activtity is potentiated by lck, possibly via direct phosphorylation of the 
PI 3-kinase subunits or the regulation of such as Vav and p62dok [Klasen et al. 
(1998)]. 4) Vav displays GNEF activity for Ras at least in vitro, whilst dok 
may sequester the negative regulator Ras-GAP away from Ras or recruit further 
proteins such as Cbl which forms a complex with PI 3-kinase [Meisner et al. 
(1995)] and may allosterically modify PI 3-kinase.
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kinases which associates with CD28 and becomes tyrosine phosphorylated, following 
ligation of the cell surface antigen [August et al. (1994)]. The recruitment of ITK to CD28 
has been shown to be at least partially dependent on lck function [Raab et al. (1995); 
Gibson et a l (1996); Heyeck et a l (1997)]. Interestingly, proliferation studies using 
murine T cells defective in ITK have demonstrated that, whereas CD3 mediated 
proliferation was severely compromised in the absence of ITK, CD28 proliferative 
responses were significantly elevated, when compared with cells from control animals 
[Liao et a l (1997)]. This follows the pattern of PI 3-kinase function since the enzyme is 
activated by CD28, implying a costimulatory role, yet appears to play a negative role in T- 
cell antigen receptor function, at least in terms of NF-AT induction in Jurkat cells [Reif et 
a l  (1997)]. Hypothetically, if ITK function was to inhibit the activation of PI 3-kinase, 
the observations of Liao et a l may be explained by those of Reif et al. Possible 
mechanisms for ITK modulation of PI 3-kinase may stem from the tyrosine kinase 
activity of the molecule. However, whilst serine phosphorylation of p85 has been 
reported to reduce PI 3-kinase activity by 80% [Dhand et al. (1994)], tyrosine 
phosphorylation has been reported to largely correlate with lipid kinase activity as 
previously discussed. Alternatively ITK mediated tyrosine phosphorylation of either p85 
or any of the four tyrosine residues of the CD28 cytoplasmic tail [King et a l  (1997)] may 
cause an association with a PI 3-kinase inhibitory protein via SH2 or protein tyrosine 
binding domains.
7.1.3 PMA disrupts CD28 coupling and activation of PI 3-kinase.
Given the presence of several potential PKC phosphorylation sites within the cytoplasmic 
tail of CD28, one of which is juxtapositioned to the PI 3-kinase binding site, the 
possibility was considered that PKC may modulate PI 3-kinase binding to the 
cytoplasmic tail of CD28. Immunoblotting experiments revealed that phorbol esters 
partially inhibited CD28: PI 3-kinase associations, and the previously reported CD28- 
mediated increase in PtdIns(3,4,5)P3 [Ward et al. (1993)]. A number of lines of evidence
suggest that PMA exerts its effect via activation of PKC: Firstly, cells are protected 
against the effects of PMA by pretreatment with Ro31/8220, an inhibitor of PKC. 
Secondly, the effects of PMA are not mimicked by the non-PKC activating phorbol ester 
4 a  phorbol. However, PMA was found to have no reproducible effect on CD28 
phosphorylation and numerous PKC inhibitors failed to prevent the ligation stimulated 
phosphorylation of CD28. Furthermore, transfection of constitutively active PKCa and £ 
isoforms was without effect upon the basal CD28-induced lipid kinase activity of PI 3- 
kinase in Jurkat cells, although we cannot be sure that these proteins were expressed. 
Hence, the observed inhibitory effect of PMA on CD28: PI 3-kinase activation may be
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explained by effects of PMA-activated PKC on PI 3-kinase itself, rather than CD28. 
Certainly the 5 and 8 isoforms of PKC contain consensus sequence-recognition motifs 
for p85 SH2 domains and associate with PI 3-kinase [Ettinger et a l (1996)]. Moreover, 
PMA treatment stimulates phosphorylation of the p i 10 catalytic and p85 regulatory 
subunits on serine and threonine residues respectively [Reif et a l (1993)]. Since the p85 
subunit may act as a multi-functional adaptor molecule by virtue of its dual SH2, SH3 
and/or proline rich domains, PMA stimulated phosphorylation of the p85 subunit may 
disrupt protein-protein interactions involving the p85 subunit. Alternatively, the reported 
PMA-stimulated serine phosphorylation of the p i 10 subunit may modulate PI 3-kinase 
activity. Certainly, PMA can stimulate modest accumulation of PtdIns(3,4,5)P3 in
fibroblasts [Petrisch et a l (1995)] and platelets [Zhang et a l  (1996)]. However, neither 
PMA nor PKC inhibitors have any significant effect on the basal levels of 
PtdIns(3,4,5)P3 in Jurkat cells. This is an unexpected observation given that p21ras is a
potent downstream target of phorbol ester-activated PKC in T cells [Izquierdo et al 
(1992)], and in other systems p21ras can interact directly with the p i 10 catalytic subunit 
[Rodriguez-Viciana et al. (1996)] and has been reported to activate PI 3-kinase 
[Rodriguez-Viciana et a l (1994)]. Thus T cells may express distinct isoforms of PI 3- 
kinase whose activity is independent of a regulatory input from p21ras. Our data is 
consistent with the recent observations of Genot et a l (1998), who demonstrated that 
p21ras initiates Rac-1 but not PI 3-kinase/PKB mediated signalling pathways in T 
lymphocytes. Hence, the PI 3-kinase mediated signalling cascade is not a universal Ras 
effector molecule. The role of PKC in mediating inhibition of CD28-stimulated PI 3- 
kinase activation is represented in a speculative model in Figure 7.2.
Another unexpected observation was that although treatment with the PKC inhibitor 
Ro31/8220 almost fully prevented PMA stimulated down-regulation of p85 association 
with CD28, the levels of lipid kinase activity associated with CD28 immunoprecipitates 
were not similarly restored. The reason for this discrepancy is not clear, however this 
observation may reflect the differential involvement of various PKC isozymes in the 
regulation of PI 3-kinase/CD28 protein interactions and/or PI 3-kinase activity. Although 
these isozymes would be stimulated by PMA under the conditions employed in this 
study, they may exhibit different sensitivity to the PKC-inhibitor Ro31/8220 and this may 
be a possible explanation of these observations. Alternatively, this discrepancy may 
represent an in vitro artifact, since the PMA-stimulated down regulation of in vivo CD28- 
stimulated PtdIns(3,4,5)P3 accumulation that was observed in [32p]pi-iabelled cells was
almost totally prevented by pretreatment with Ro31/8220.
Phorbol ester disruption of CD28 mediated PI 3-kinase activation has been reported by
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other groups [Hutchcroft et al. (1995)] who ligated CD28 with mAbs. The work 
presented in this study has used the natural ligand B7.1 to stimulate CD28, an important 
consideration given the reported discrepancies between signals generated by mAb ligation 
and B7.1 in CD28 mediated activation of p21ras and PLC signalling pathways [Nunes et 
al. (1994)]. The inhibitory effects of PKC activation on CD28 coupling to PI 3-kinase 
may operate to limit CD28 signal transduction, and the physiological signal may be 
elicited by CD28 as part of a negative feedback mechanism. Indeed levels of 
diacylglycerol have been demonstrated to be elevated following CD28 ligation [Nunes et 
al. (1993)]. Alternatively, molecules such as the TCR/CD3 complex which activate PKC 
[Nishizuka (1988)] may mediate a possible cross talk mechanism that modulates CD28 
signalling.
Previous studies have reported that wortmannin does not inhibit IL-2 production from 
Jurkat after combined treatment with PMA and anti-CD28 mAb [Hutchcroft et al.
(1995)], implying that PI 3-kinase is not necessary for lymphokine production. 
However, leukaemic T cells may not be good functional models of T cell costimulation 
since these cells have been selected in culture to grow and proliferate in the absence of 
any costimulatory signal. Indeed, when peripheral blood-derived T cells are used as a 
model, nanomolar concentrations of wortmannin do inhibit both [^HJ-thymidine 
incorporation and IL-2 production induced by the combination of cross-linked anti-CD3 
mAb and B7.1 [Ward et al. (1995)]. Furthermore, the structurally unrelated and more 
specific PI 3-kinase inhibitor LY294002, has similar effects on CD28 driven IL-2 
production from normal T cells [Ueda et al. (1995)] indicating that the effects of 
wortmannin are unlikely to be due to the reported non-specific actions on other kinases. 
This study demonstrates that both PI 3-kinase inhibitors can also inhibit, albeit partially, 
normal T cell incorporation of [^H]-thymidine induced by CD28 ligation in the presence 
of 0.5 ng/ml PMA, a concentration that is not sufficient to disrupt PI 3-kinase coupling to 
CD28. In contrast, a previous study demonstrated that IL-2 production from normal T 
cells driven by sub-nanomolar concentrations of PMA and the CD28 mAb 248 was 
resistant to wortmannin [Ghioti-Ragueneau et al. (1996)]. This study has demonstrated 
that PI 3-kinase inhibitors can prevent the [^H]-thymidine incorporation (and presumably 
IL-2 production) induced by B7.1, in the presence of low concentrations of PMA. The 
reason for this discrepancy is not clear although previous studies have indicated that 
qualitatively different signals can be transmitted through CD28 by a panel of different 
CD28 mAbs and certainly, the CD28 mAb 248 is able to support IL-2 production in the 




















Figure 7.2 Model for PK C-m ediated down regulation of CD 28- 
activated PI 3-kinase signalling. 1) Since both PMA and PKC inhibitors 
were without effect on the phosphorylation profile of CD28, the observed 
inhibitory effect of PKC on PtdIns(3,4,5)P3 accumulation may be a consequence 
of a direct effect on PI 3-kinase. Indeed, PMA has been previously reported to 
induce threonine and serine phosphorylation of p85(3 and pi 10, respectively [Reif 
et al. (1993)]. 2) PKC may be activated by CD28 derived signals as a negative 
feedback mechanism or 3) TCR/CD3 signalling as a cross-talk mechanism.
Interestingly, [^H]-thymidine incorporation driven by CD28 ligation in the presence of 
higher concentrations of PMA (5-50 ng/ml) is markedly reduced in comparison to 
responses observed in the presence of lower concentrations of PMA. These functional 
observations in the presence of 5-50 ng/ml PMA correspond with the inhibitory actions of 
these concentrations of PMA on CD28 coupling to PI 3-kinase. Surprisingly the 
remaining responses to CD28 and higher concentrations of PMA appeared to be either 
less sensitive or completely resistant to PI 3-kinase inhibitors, despite the demonstration 
that a substantial component of the (approximately 20-30%) of the PI 3-kinase coupled to 
CD28 is unaffected by the phorbol ester treatment. A possible explanation for this
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observation is that higher concentrations (>5 ng/ml) of PMA are sufficient to provide 
post-receptor activation of the downstream targets of PI 3-kinase. Thus, T cell functions 
determined in the presence of higher concentrations of PMA would be expected to be 
resistant to PI 3-kinase inhibitors. Indeed several of the known and putative targets of PI 
3-kinase are activated by PMA such as the phorbol ester-sensitive PKC isoforms 5,e,r) 
[Toker et a l (1994)] as well as p70 S6 kinase [Chung et al. (1994)] and the ERK and 
JNK pathways [Nunes et a l (1996)], thus, the concentration of PMA appears to be 
critical in determining whether or not the resulting CD28-dependent T cell responses are 
sensitive to PI 3-kinase inhibitors.
7.2.1 Ligation-dependent phosphorylation of CD28 is insensitive to 
pharmacological inhibitors of serine/threonine kinases.
The data presented in this study shows that stimulation of CD28 by its natural ligand 
B7.1 results in heavy phosphorylation of CD28 on serine and threonine residues. The 
presence of several potential PKC phosphorylation sites [Nishikawa et a l (1997)] 
suggested that the observed serine/threonine phosphorylation of CD28 in response to 
B7.1 ligation might be mediated by PKC phosphorylation of the CD28 cytoplasmic 
tail. Indeed, PMA has been reported to induce the phosphorylation of CD28 exclusively 
on threonine residues using an in vitro immune complex assay, which detected activity 
of a threonine kinase co-associated with CD28 immunopiecipitates [Hutchcroft et a l
(1996)]. Since the conditions employed were not permissive to PKC activity, it was 
proposed that PKC induces in vivo phosphorylation of CD28 by one or more PKC 
isoforms, which in turn allows recruitment and activation of a kinase responsible for the 
in vitro phosphorylation of CD28 [Hutchcoft et a l (1996)]. It is possible however that 
the threonine kinase detected by immune complex assays may not be functional under in 
vivo settings and may be physiologically redundant. Indeed, in this study using a 
metabolic labelling approach with 32p, no direct effect was detected of PMA on CD28 
phosphorylation in Jurkat cells. Moreover, several known inhibitors of PKC had no 
effect upon ligation-dependent phosphorylation of CD28. The discrepancies between 
findings in this study and the observations of Hutchcroft et a l may be explained in a 
number of ways. The study that demonstrated PMA-induced threonine phosphorylation 
utilised the mild detergent Brij 96 in cell lysis buffers [Hutchcroft et a l (1996)]. Brij 96 
has previously been used to maintain CD3-PTK associations which are otherwise lost 
using more stringent detergents such as NP40 [Beyers et a l (1992)]. Secondly, the use 
of an in vitro immune complex assay system may preferentially support threonine 
kinase activity that is not active under normal in vivo conditions, leading to the detection
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of in vitro artifacts. Thirdly, the in vivo metabolic labelling approach adopted in this 
study may allow CD28 to be subjected to specific protein phosphatase(s) which target 
the PKC phosphorylation motif. These phosphatases may be lost during cell lysis and 
therefore would not be operative under in vitro immune complex assay conditions. 
Finally, it is possible that the differences between observations in this study and that of 
Hutchcroft et a l may be explained by the use of different Jurkat subclones, which may 
display biochemical differences.
In an attempt to characterise the nature of the CD28 targeted serine/threonine kinase, 
radiolabelled cells were preincubated with pharmacological agents reported to influence 
the activity of known serine/threonine kinases. Since both cAMP-dependent protein 
kinase (PKA) and cGMP-dependent protein kinase (PKG) are intracellular second 
messengers which display serine/threonine kinase activity, cells were incubated with 
cell permeable stable analogues of cAMP or cGMP namely, Rp-cAMPs, 8-bromo- 
cAMP or 8-bromo-cGMP, to assess their effect on basal and B7.1-stimulated CD28 
phosphorylation. Although CD28 has not been demonstrated to activate PKA, CD28 
costimulation has been reported to activate cyclic AMP-responsive element binding 
proteins in T lymphocytes [Hsueh et al. (1997)], implying some role for PKA in 
costimulatory signalling. Additionally, PKA has been implicated in the phosphorylation 
of another T cell surface antigen, namely CD27 [Sugita et al. (1997)] which, analagous 
to CD28, lacks any consensus motif for phosphorylation by PKA (RXXS). Thus 
neither CD27 nor CD28 could constitute a direct substrate for phosphorylation by PKA. 
In contrast to cAMP, CD28 has been reported to elevate levels of cGMP [Ledbetter et 
al. (1986)], suggesting that PKG may be activated subsequent to CD28 ligation. No 
effects however, were detected either on the basal phosphorylation state of CD28, or 
following B7.1 stimulation following treatment of cells with pharmacological agents 
known to affect the activity of PKA or PKG. These data therefore argue against the 
involvement of either PKA or PKG in the phosphorylation of CD28.
The 177Thr residue of the CD28 cytoplasmic domain, lies within a potential site for 
phosphorylation by the proline directed serine/threonine kinases such as ERK [Davis
(1994)]. ERK has been shown to phosphorylate Sos and down-regulate the Ras 
activation pathway in a proposed negative feedback mechanism [Buday and Downward
(1995)]. Additionally a striking analogy can be drawn between CD28-mediated signal 
transduction and feedback mechanisms proposed to operate in insulin signalling 
[Shepherd et al. (1998)]. Mutational analysis suggests that some or all of the serine 
residues (612ser, 632$erj 662ser an(j 731ser) within IRS-1 participate in the negative 
regulation of insulin stimulated PI 3-kinase activity induced by the phosphatase inhibitor
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okadaic acid [Mothe and Van Obberghen (1996)]. These residues all lie in consensus 
motifs for MAP kinase phosphorylation (PXSP), in close proximity to the YMXM 
tyrosine phosphorylation site of IRS-1. Since MAP kinase is activated by insulin in 
parallel with PI 3-kinase, this has been proposed as a basis for cross talk between the 
two pathways, leading to feedback regulation of PI 3-kinase activity [Shepherd et a l 
(1998)]. However, there are several reasons why it is unlikely that the known members 
of the MAP kinase family such as ERK, JNK and p38 MAP kinase are involved in 
mediating ligation-stimulated CD28 phosphorylation. Firstly, treatment of cells with the 
MEK inhibitor PD98059 had no effect upon the phosphorylation of CD28 induced by 
B7.1. Secondly, ligation of CD28 by B7.1 does not stimulate the ERK cascade [Nunes 
et a l (1994)] and hence would not be activated under the conditions employed in the 
assay. Similarly, it is unlikely that JNK subgroups of the MAP kinase family would 
mediate ligation stimulated CD28 phosphorylation since CD28 signals alone are 
insufficient to activate JNK, but instead require the additional presence of signals 
provided by either PMA/ionomycin or CD3 ligation [Su et a l (1994); Nunes et a l
(1996)]. Finally, although we have shown that CD28 can induce modest activation of 
p38 MAP kinase, it is unlikely that p38 is involved in the phosphorylation of CD28 
since the kinetics are much slower than B7.1-stimulated CD28 phosphorylation, and the 
p38 MAP kinase inhibitor SB203580 does not inhibit ligation-dependent CD28 
phosphorylation.
Ligation of CD28 is known to be followed by ceramide generation via the activation of 
acidic sphingomyelinase [Boucher et al. (1995)], downstream effector targets of which 
are known to include serine/threonine kinase activity in the form of ceramide activated 
protein kinase (CAPK). It was therefore important to investigate whether CD28 was a 
target for ceramide-activated kinases by treatment of cells with ceramide analogues C2 
ceramide, and the biologically inactive C2 dihydroceramide [Westwick et a l (1995)]. 
Both compounds were found to be without effect either on the basal, or the B7.1 
stimulated, phosphorylation of CD28. These data therefore strongly argue against the 
involvement of ceramide-activated kinases in the phosphorylation of CD28.
It is known that CD28 activates PTKs such as lck, fyn and ITK, and can act as a target 
for these PTKs. We postulated therefore, that the tyrosine phosphorylation may be 
required for the recruitment of CD28-directed serine/threonine kinase, either by direct 
interactions with phosphotyrosine residues, or indirectly via adaptor molecules. To 
determine if there was a requirement for activation of src family tyrosine kinases in the 
serine/threonine phosphorylation of CD28 therefore, Jurkat cells were incubated 
overnight with the inhibitor Herbimycin A, before co-sedimentation with CHO-B7.1+
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cells. Herbimycin A treatment of the cells resulted in a marked inhibition of B7.1 
stimulated CD28 phosphorylation. This experiment is open to a number of criticisms: i) 
the experiment was not repeated due to a lack of available inhibitor, ii) CD28 expression 
was not determined after incubation with Herbimycin, and iii) the observed effects may 
be due to an inhibition of cellular metabolism and hence ability to assimilate the 
radiolabel. However, taken with the results from CD28 mutation studies to be discussed 
later (section 7.2.3), this experiment provides evidence for src kinase function as a pre­
requisite to serine/threonine phosphorylation of CD28. A possible explanation for this 
observed dependance upon Tyr phosphorylation of CD28 could lie in the ability of 
173xyr to recruit adaptor molecules. Both p85 and Grb-2 associate with the 
phosphorylated YMNM motif within the CD28 cytoplasmic tail, and this may allow for 
recruitment of serine/threonine kinases. For example, Grb-2 has been reported to 
associate with the T cell antigen receptor on T cell activation and recruit a 
serine/threonine kinase via SLP-76, in Jurkat cells [Motto et a l (1996)]. Thus 
recruitment of a serine/threonine kinase appears to be dependent upon the prior activity 
of a tyrosine kinase. However, it should be noted that Herbimycin A is a fairly non- 
selective agent since it induces non-specific covalent modification of thiol groups, thus 
this data could reflect non-selective inhibition of the serine/threonine kinase activated by 
CD28 ligation [Mahon and O’Neill (1996)].
Since the serine/threonine phosphorylation of CD28 is a ligation-dependent event, it 
may be assumed to carry some physiological relevance. However, in the absence of any 
effective inhibitory strategy, it is difficult to determine whether serine/threonine 
phosphorylation of CD28 would positively or negatively regulate CD28-mediated 
activation of PI 3-kinase. Thus it is valid to postulate that serine/threonine 
phosphorylation may serve to enhance PI 3-kinase activity by stabilising protein-protein 
interactions. Striking analogy may be drawn however, with the IRS-1 mediated 
activation of PI 3-kinase. The IRS-1 protein recruits PI 3-kinase via a YMXM motif, 
whilst phosphorylation of some, or all, of the 612$er, 6 3 2 $ ^  662$er an(j 731<;er 
residues of IRS-1 negatively modulates insulin-stimulated PI 3-kinase activity. [Mothe 
and Van Obberghen (1996)]. Assuming similar mechanisms to be applicable to CD28- 
activated PI 3-kinase, serine/threonine phosphorylation of CD28 may serve as a 
receptor-operated negative feedback inhibition mechanism. This hypothesis is 
summarised in Figure 7.3.
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7.2.2 Which regions of the CD28 cytoplasmic tail are required for 
ligation-dependent phosphorylation.
The experiments performed with the CD28 deletion mutants demonstrate that the 
integrity of the PKC phosphorylation motif around l^ T h r  and/or the 173YXXM motif 
is required for optimal ligation-induced CD28 serine/threonine phosphorylation. It 
should be remembered that the non-specific nature of deletion mutation may mean 
several sites that may be of importance to CD28 phosphorylation may be disrupted. For 
example, the A21 mutant partially disrupts one proline rich motif (178pro-Arg-Arg-Pro) 
and completely deletes another (190pro-Tyr-Ala-Pro) (see Figure 2.1). Thus the 
reduced phosphorylation of CD28 in the A21 mutant may be as a result of impaired 
recruitment of serine/threonine kinase(s) via the proline rich regions. Three Tyr residues 
(188xyr, 19lTyr and 200xyr), as wep as the l ^ x h r  (which lies within a potential 
PKC phosphoylation site) and 202§er ^  aiso deleted in the A21 mutants and this may 
account for the small reduction in the overall phosphorylation profile of CD28 in A21 
compared to wild types controls. Certainly, site-specific mutagenesis studies have 
revealed that integrity of the l ^ T y r  ^ d  200xyr residues is necessary for costimulation 
of IL-2 production indicating their importance to CD28 signalling [Pages et al. (1996); 
Truitt et al. (1996)]. Although ligation-induced tyrosine phosphorylation of CD28 can 
be detected by immunoblotting with anti-phosphotyrosine mAb [Pages et al. (1994)], 
phosphoamino acid analysis of CD28 immunoprecipitated from [32p]-iabelled Jurkat 
cells has revealed tyrosine to form only a small percentage of the overall 
phosphorylation that can be detected. Thus, tyrosine phosphorylation may occur at very 
low stoichiometry relative to serine/threonine phosphorylation and it therefore seems 
unlikely that deletion of l^ T y r , 191xyr and 200xyr in A21 contributes significantly to 
reduction in total CD28 phosphorylation detected in CD28 immunoprecipitates derived 
from T cell hybridomas. Surprisingly, ligation-induced phosphorylation was not 
detected in the A30 mutant, in which the motif around l^ T h r ,  as wejj as the 
(p)^Tyr-M et-A sn-M et motif responsible for binding PI 3-kinase, are additionally 
deleted. The A30 mutant contains three serine residues (^ ^ S e r  which lies within a 
potential PKC phosphorylation site, as well as 166$er m d l^ S e r )  which might be 
expected to act as targets for serine kinases since phosphoamino acid analysis revealed 
approximately equal quantities of phosphoserine and phosphothreonine. One reason for 
the failure to detect phosphorylation of CD28 in A30 mutants, may be that the regions 
distal to 172Asp (e.g. the proline rich regions and the tyrosine residues at positions 
173, 188, 191 and 200) may be required for recruitment and/or activation of the 
serine/threonine kinase(s) responsible for the putative phosphorylation of these residues 
as already discussed.
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7.2.3 The involvement of PI 3-kinase in CD28 phosphorylation.
Interestingly, PI 3-kinase has previously been demonstrated to act as both a lipid kinase 
and a . protein serine/threonine kinase [Dhand et al. (1994)]. Indeed site-specific 
mutagenesis of the l^ T y r , which disrupts PI 3-kinase binding, results in complete loss 
of detectable serine/threonine phosphorylation and has been previously demonstrated to 
correlate with an 80% reduction of detectable CD28 tyrosine phosphorylation [Pages et 
al. (1994)] suggesting that the integrity of this PI 3-kinase binding motif is required for 
optimal phosphorylation. Therefore, PI 3-kinase may mediate B7.1 stimulated CD28 
phosphorylation, since it is rapidly and strongly recruited to CD28 following ligation. 
However, site-specific mutation of ^ OOjy^ which is sufficient to reduce the association 
of CD28 with PI 3-kinase by 80%, has no effect upon ligation induced tyrosine 
phosphorylation of CD28 [Pages et al. (1996)] and ligation-stimulated phosphorylation 
of CD28 is comparable in the DYF200 mutant to that observed in wild type CD28 
expressing cells. Nevertheless, whilst binding of PI 3-kinase to CD28 is reduced in the 
DYF200 CD28 mutant [Pages et al. (1996)] the amounts of PI 3-kinase bound to CD28 
may still be sufficient to mediate normal serine/threonine phosphorylation of CD28 
following ligation by B7.
Compelling evidence against a role for PI 3-kinase in CD28 phosphorylation was 
obtained from the experiments utilising wortmannin and LY294002, which failed to 
abrogate the ligation-stimulated phosphorylation of CD28. There are however, certain 
problems with the interpretation of the results obtained with PI 3-kinase inhibitors. For 
instance, it has previously been demonstrated that wortmannin does not prevent the 
ligation stimulated recruitment of PI 3-kinase to CD28 [Ward et al. (1995)]. Thus one 
possibility is that the inhibitors were not sufficiently effective to prevent CD28- 
associated PI 3-kinase activity. This remaining PI 3-kinase activity may be below the 
sensitivity of the assays employed to detect lipid kinase activity, but sufficient for 
maximal stimulation of CD28 phosphorylation. Furthermore, the proposed adaptor 
molecule function of the p85 subunit of PI 3-kinase may mediate the recruitment of a 
serine/threonine kinase responsible for phosphorylating CD28. This function of PI 3- 
kinase would be insensitive to PI 3-kinase inhibitors, but would be disrupted by 
mutagenesis of l^ T y r . Alternatively the ubiquitous adaptor molecule Grb-2, which 
contains SH2 and SH3 domains, has also been reported to bind to CD28 via the motif 
around l^ T y r ,  ^ 5^  at much lower stoichiometry than observed for PI 3-kinase 
[Schneider et al. (1995a)], and may be involved in the recruitment of a serine/threonine
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kinase responsible for phosphorylation of CD28. In contrast with the effects on PI 3- 
kinase, it is possible that mutation of 20Opyr has no effect on Grb-2 association with 
CD28, which would explain the lack of effect of this mutation on CD28 
phosphorylation. The involvement of CD28 173y binding adaptor proteins in CD28 








Figure 7.3 Proposed receptor-operated  negative feedback 
regulation of PI 3-kinase. Since serine/threonine phosphorylation of CD28 
is a ligation-dependent event it may be assumed to carry physiological relevance. 
By analogy with IRS-1 activation of PI 3-kinase, where serine phosphorylation 
of IRS-1 negatively regulates PI 3-kinase activity, this may represent a negative 
feedback mechanism, as follows: 1) Ligation of CD28 results in recruitment and 
activation of PI 3-kinase. 2) Adaptor molecules recruited to CD28 via SH2, SH3 
and/or proline rich interactions recruit unidentified serine/threonine kinase(s). 3)
CD28 is phosphorylated on serine/threonine residues. l^ T h r  may represent an 
important site since (i) it is proximal to the PI 3-kinase binding site of CD28, 
and (ii) deletion mutation of this residue abolishes detectable serine/threonine 
phosphorylation of CD28. PI 3-kinase does not mediate serine phosphorylation 
of CD28 since pharmacological inhibitors of PI 3-kinase do not affect CD28 
phosphorylation. The identity of the serine/threonine kinase responsible for 
phosphorylation of CD28 is not clear since this phosphorylation is resistant to a 
panel of inhibitors of known serine/threonine kinases. 4) serine/threonine 
phosphorylation of CD28 inhibits activation and/or fiither recruitment of PI 3- 
kinase.
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7.3.1 CD28-mediated activation of downstream effectors and regulators of 
PI 3-kinase-dependent signalling cascades: Protein kinase B.
The work detailed in section 5.3 constitutes the first demonstration that ligation of CD28 
by either anti-CD28 mAb or the natural ligand B7.1 results in the activation of the PI 3- 
kinase. downstream effector PKB in both the leukaemic cell line Jurkat and freshly 
isolated normal T lymphocytes. Additionally, this activation of PKB is seen to be 
inhibited by preincubation of the cells with wortmannin. The effects of ligation by B7.1 
are demonstrated as specific, since B7.1 induced PKB activation could also be prevented 
by prior incubation of the CHO-B7.1+ cells with CTLA4-Ig fusion protein. Since the 
CD28-mediated activation of PI 3-kinase is well established [Ward et a l (1993)], these 
data strongly suggest that PKB is likely to be a downstream component of the CD28 
activated PI 3-kinase dependent signalling cascade. This correlates well with the 
identification of PKB as a downstream effector of PI 3-kinase [Burgering and Coffer
(1995)] and the reported CD28-mediated activation of PI 3-kinase in response to Ab and 
B7 ligation [Ward etal. (1993); Pages e ta l  (1994)].
Immunoprecipitation of transiently expressed HA-tagged PKB from metabolically radio­
labelled Jurkat cells demonstrates that PKB is phosphorylated by a constitutively active PI 
3-kinase. An unidentified phosphorylated protein of approximately 180 kDa was 
observed to co-imunopreciptate with HA-PKB, and this may represent a PKB-associated 
protein tyrosine kinase or unidentified PKB substrate.
The demonstration that CD28 ligation results in the activation of PKB has several 
implications. The fact that CD28 can couple to PKB is highly relevant to the protective 
effects of PKB against cell death, given the recent insights into the function of PKB in 
promoting cell surival [Dudek et a l  (1997); Kulik et a l (1997)]. Previous studies have 
revealed that PI 3-kinase is involved in growth factor-dependent survival of PC 12 cells 
[Yao and Cooper (1995)] and also mediates insulin like growth factor-dependent survival 
of Rat-1 and COS-7 cells [Kulik et a l (1997)]. Recent evidence has demonstrated that 
PKB is both a downstream effector target of PI 3-kinase and a key mediator of growth 
factor induced cell survival and protection against c-Myc induced cell death in fibroblasts 
[Kauffmann-Zeh et a l (1997)]. The exact meachanism by which CD28 prevents 
apoptosis however are not yet determined. One possibility is that PKB may be involved 
in the upstream signalling events which determine the CD28 augmented expression of the 
cell survival factor BclXL- This may be analagous to the situation observed in IL-3
signalling whereby, in haematopoietic cells the cytokine IL-3, under conditions where it 
promotes cell survival, induces the phosphorylation of BAD at 1 ^ S e r  and l^ S e r  ^ ej
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Peso etal. (1997)]. In the absence of phosphorylation of these sites, BAD is thought to 
induce cell death by the formation of heterodimers with BclxL> and the concomitant
generation of BAX heterodimers. The IL-3 mediated phosphorylation of either the H 2 ser 
or the 136ser site may promote the survival of haematopoietic cells since phosphorylation 
of BAD has been correlated to its sequestration by the cytosolic protein 14-3-3 [Zha et al.
(1996)], liberating the cell survival factor BclxL-
PKB activation is known to have at least one further major outcome which may be 
relevant to the functional outcome of CD28 ligation in T cells, namely p70 S6 kinase 
activation [Burgering and Coffer (1995)], an event which has also been demonstrated to 
follow CD28 ligation. However the significance of CD28 induced activation of p70 S6 
kinase has not yet been fully investigated. Whilst not sufficient to drive proliferation, the 
induction of p70 S6 kinase activity may be necessary for the intitiation of cell cycle 
progression in resting T cells. Blocking of p70 S6 kinase either by injection of Ab or by 
the use of rapamycin has suggested a role for p70 S6 kinase in the G l-S phase transition 
[Laneetal. (1993); Reinhardetal. (1994)]. Considering the evidence that p70 S6 kinase 
is a downstream element of the PI 3-kinase signalling cascade [Burgering and Coffer
(1995)], a role for CD28 induced signals in the activation of p70 S6 kinase seems 
appropriate, particularly given the demonstration that CD28 driven T cell proliferation 
requires the activation of PI 3-kinase [Ward et al. (1995)]. Interestingly, rapamycin 
which potently inhibits p70 S6 kinase activation, also inhibits anti-CD28 mAb induced 
IkBoc down-regulation and c-rel translocation in Jurkat cells and primary T cells [Lai and 
Tan (1994)], indicating that regulation of transcription factors involved in CD28 
dependent regulation of cytokine/chemokine genes may involve the PI 3-kinase dependent 
signalling cascade. There is evidence however that this may not be the case in normal T- 
lymphoblasts since experiments using human T-lymphoblasts indicate that CD28-induced 
activation of NFkB is unaffected by pretreatment with PI 3-kinase inhibitors [Edmead et 
al. (1996)]. Further downstream targets for PKB exist in glycogen synthase kinase-3 
(GSK-3) [Cross et al. (1995)], which is serine phosphorylated and thus inactivated by 
PKB allowing the molecule to influence glycogen metabolism. Since PKB is activated by 
CD28, the idea that PKB regulates several downstream targets is consistent with the fact 
that many functional outcomes have been attributed to CD28, such as regulation of 
multiple cytokine/chemokine genes and protection against apoptosis.
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7.3.2 CD28 activates p70 S6 kinase.
Activation of p70 S6 kinase is known to involve the phosphorylation of at least nine 
phosphorylation sites and it appears that activation may be sequential in phosphorylation 
of proline-directed sites in the carboxy-terminal tail, followed by phosphorylation of 
389xhr and 229ser to yield a fully active kinase [Pullen and Thomas (1997)]. Despite the 
importance of these phosphorylation sites, until very recently, the identity of the kinases 
responsible for the phosphorylation of these residues remained unknown. In this study 
the PI 3-kinase inhibitor wortmannin has been used to assess the role of PI 3-kinase 
signalling to couple CD28 to p70 S6 kinase. Treatment of Jurkat cells with the PKC- 
activating phorbol ester, phorbol-12-myristate-13-acetate (PMA) resulted in the activation 
of p70 S6 kinase, which was inhibited by pretreatment with rapamycin, confirming 
previous observations [Chung et a l (1994)]. Rapamycin exerts its inhibitory effect when 
complexed with its cytosolic target protein FKBP. The inhibitory effect of rapamycin can 
be overcome by expression of a mutated version of mTOR that fails to bind the FKBP- 
rapamycin complex, indicating that mTOR is an upstream component of the pathways 
controlling p70 S6 kinase [Brown et a l (1995)]. Stimulation of Jurkat cells with anti- 
CD28 mAb also resulted in the activation of p70 S6 kinase. This CD28-dependent 
activation of p70 S6 kinase was inhibited by pretreatment with rapamycin, but resistant to 
pretreatment with the immunosuppressant cyclosporin A, suggesting p70 S6 kinase 
activation to be independent of the function of the phosphatase calcineurin, and 
correlating with the original demonstration that CD28 biochemical signals required for T 
cell proliferation are cyclosporin A-resistant [June et a l (1987)]. Pretreatment of Jurkat 
cells with nanomolar concentrations of wortmannin, previously shown to inhibit CD28- 
induced accumulation of the D-3 phosphoinositides (section 3.1), resulted in inhibition of 
CD28 induced activation of p70 S6 kinase. The observation that rapamycin, which 
potently inhibited CD28-mediated p70 S6 kinase activation, had no effect on the 
accumulation of PtdIns(3,4,5)P3, suggests that the effects of rapamycin were not due to
upstream inhibition of PI 3-kinase, and that rapamycin must function by inhibition of 
target(s) downstream of, or on separate pathways from PI 3-kinase. Thus, these data 
imply that either i) wortmannin and rapamycin inhibit CD28-mediated activation of p70 
S6 kinase at distinct points along the PI 3-kinase-dependent signalling pathway, or ii) 
rapamycin inhibits a further pathway required for p70 S6 kinase activity, and iii) 
activation of p70 S6 kinase is at least one downstream target for the PI 3-kinase signalling 
pathway following CD28 ligation on T cells.
Evidence for PI 3-kinase and mTOR forming components of separate cell signalling 
pathways is provided by the observation that removal of the NH2-terminal region of p70
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S6 kinase, results in a truncated kinase that is resistant to inhibition by rapamycin but still 
inhibited by wortmannin [Weng et a l (1995)]. However, this does not discount the 
possibility that wortmannin also targets the catalytic domain of mTOR itself, which 
displays homology to the catalytic domain of PI 3-kinase [Brown et al. (1994); Sabatini et 
a l (1994)]. Indeed, wortmannin and LY294002 have been demonstrated to inhibit the 
protein, serine kinase activity of mTOR [Brunn et a l (1996)] at concentrations 
corresponding to those required for inhibition of the lipid kinase function of PI 3-kinase, 
although this has not been consistently observed [Brown et a l (1995)]. Despite the 
reported homology with PI 3-kinase however, a lipid kinase function for mTOR has not 
been reported to date [Brown et a l (1995)].
The approach adopted in this study, to examine the regulation of p70 S6 kinase, by 
immunoblot analysis for electrophoretically retarded isoforms of p70 S6 kinase was 
intially attractive since it offered a simple protocol to graphically illustrate the activation of 
p70 S6 kinase. The nature of the protocol however entails a number of inherent draw 
backs. Firstly, since CHO-B7.1+ cells would have contributed proteins that would be 
recognised in Western blots, cell stimulations were performed using anti-CD28 mAb, 
which may lead to results discrepant from those obtained by ligation of CD28 by its 
natural ligand. Secondly, the protocol is not conducive to obtaining quantitative data. 
Expression of an HA-tagged p70 S6 kinase protein, followed by stimulation of cells with 
the natural CD28-ligand B7.1, and in vitro kinase assay, may have allowed for more 
quantitative data to be obtained.
Subsequent investigations have shown that the recently described kinase termed PDK1, 
which is capable of phosphorylating PKB on 308Thr [Alessi et a l (1997)], is also 
capable of phosphorylating p70 S6 kinase on 229xhr [Pullen et al (1998)], an event 
which appears essential in the activation of the enzyme [Pullen and Thomas (1997)]. 
PDK1 appears to be constitutively active and in vitro experiments have shown 
immunoprecipitated Myc-tagged PDK1 to phosphorylate p70 S6 kinase in a manner that 
is insensitive to wortmannin [Pullen et a l (1998)], correlating with the wortmannin 
insensitive phosphorylation of PKB by PDK1 in vitro [Alessi et a l (1997)]. Despite the 
constitutively active nature of PDK1, the molecule may be dependent upon 
PtdIns(3,4,5)P3 for its function, in phosphorylating PKB, since binding of the lipid to
the PH domains of both PDK1 and PKB results in their translocation to the membrane 
[Anderson et a l  (1998)]. Drawing an analogy with PKB, positional information may also 
be important in the activation of p70 S6 kinase, indeed, nuclear localisation of the related 
p85 S6 kinase appears to be a functional requirement for the molecule [Reinhard et al
(1994)]. If PDK1 function in phosphorylating p70 S6 kinase were to be similarly
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dependent upon the lipid products of PI 3-kinase, PDK1 would be placed as an 
intervening molecule between PI 3-kinase and p70 S6 kinase, and provide at least one 
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Figure 7.4 CD28-mediated activation of p70 S6 kinase in T cells. Ligation 
of CD28 by mAb was found to induce activation of p70 S6 kinase, which was sensitive 
to inhibition by wortmannin and rapamycin. Phorbol ester treatment of cells also 
stimulated activation of p70 S6 kinase. Activation of p70 S6 kinase in vivo is thought to 
involve sequential phosphorylation 1) initially by proline-directed kinases in an 
autoinhibitory region [Ferrari et al. (1992)], then 2) by a PtdIns(3,4,5)P3-dependent
kinase at ^ ^ T h r (sequence data suggests this to be same kinase as the putative PDK2) 
inducing a conformational change exposing 229^hr for 3) phosphorylation by PDK1 
[Pullen et al (1998)] to yield an active kinase. Thus the mechanism of activation of p70 
S6 kinase shares many common themes with the activation of PKB [Reviewed by 
Downward (1998)]. The nomenclature of residues is used as for the p70 S6 kinase a l l  
isoform, whilst identical phosphorylation sites exist in the p70 S6 kinase a l  isoform.
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Further analogy can be drawn between the activation of PKB and p70 S6 kinase since the 
389xhr phosphorylation site within p70 S6 kinase is analogous to the 473ser residue of 
PKB, which is phosphorylated by the putative kinase PDK2. As is the case for PKB 
phosphorylation of both these sites causes a synergistic activation of kinase activity. Thus 
PKB and p70 S6 kinase apparently share common mechanisms of activation and 
upstream kinases. Distinct from PKB however, p70 S6 kinase is initially required to be 
phosphorylated by proline directed kinases, such as MAP kinases, which phosphorylate a 
number of sites in the putative autoinhibitory carboxy terminus of p70 S6 kinase [Ferrari 
et al. (1992)]. The data presented in this thesis and subsequent data from the literature are 
summarised in Figure 7.4.
7.3.3 CD28 activates SHIP.
The lipid products of PI 3-kinase represent a minor, but very important signalling 
component of the cell membrane. Levels of these lipids therefore, need to be tightly 
regulated. The myo-inositol lipids are subject to degradation by lipid phosphatases 
which limit the availability of the putative signalling molecules. The D-5 phosphatases 
are the most well characterised PI lipid phosphatases and SHIP is one such inositol 
polyphosphate 5’-phosphatase, which exhibits a unique substrate specificity in that it 
hydrolyses only substrates phosphorylated at the D-3 position i.e. Ins(l,3,4,5)P4 and 
PtdIns(3,4,5)P3. This study has shown using in vitro protein kinase assay, that SHIP 
is phosphorylated following CD28 ligation and, immunoblotting with anti- 
phosphotyrosine Ab revealed that this phosphorylation resides within tyrosine residues 
of SHIP. Moreover, the functional activation of SHIP has been demonstrated following 
ligation of CD28 by in vitro SHIP assays using Ins(l,3,4,5)P4 as a substrate and 
monitoring the formation of Ins(l,3,4)P3. These results are in marked contrast to those 
of Osborne et al. who showed that tyrosine phosphorylation of SHIP by lck expressed 
in S. cerevisiae resulted in a inhibition of phosphatase activity [Osbourne et al. (1996)]. 
This discrepancy may reflect the heterogeneity within the cellular models utilised. 
Additionally, when the authors immunoprecipitated SHIP from RBL-2H3 cells they 
reported a high basal state of SHIP tyrosine phosphorylation which obscured any 
receptor mediated increase in phosphorylation [Osborne et al. (1996)]. In contrast this 
study and other reports [Giuriato et al. (1997); Kimura et a l (1997)], have clearly 
demonstrated receptor mediated tyrosine phosphorylation of SHIP. Differences in the 
biochemistry of the cellular models employed may therefore explain the functional 
discrepancies observed. The results presented in this study, and those of Giurato et a l 
(1997), who demonstrated thrombin activation of SHIP in platelets, argue against the
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notion that only negative signalling conditions, such as co-crosslinking of the B cell 
antigen receptor and FcyR, promote tyrosine phosphorylation of SHIP [Tridandapani et 
al. (1997)].
SHIP can bind directly to a phosphorylated immunoreceptor tyrosine-based inhibition 
motif (ITIM) present in the cytoplasmic domain of FcyRIIB [Ono et al. (1996)], and 
association has been reported between SHIP and immunoreceptor tyrosine-based 
activation motifs (ITAM) present in the CD3 complex and TCR £ chains. Despite the 
tentative description of CTLA-4 as an ITIM bearing molecule, on the basis of its 
association with the phosphatase SHP-2 however [Vivier and Daeron (1998)], neither 
CTLA-4 or CD28 encode any recognised ITAM or ITIM motifs. The mechanism by 
which SHIP actually couples to CD28 is obscure although there are several 
possibilities. These include interactions with intermediate adaptor proteins via its: i) 
SH2 domain, ii) proline rich regions or iii) the two NPXY motifs which bind 
phosphotyrosine motifs. An example of possible intermediate adaptor proteins is found 
in Grb-2 since this molecule has been previously demostrated to associate with CD28 
[Schneider et al. (1995a)] and SHIP is known to associate with Grb-2 via an interaction 
between its proline rich region and SH3 domain of Grb-2 [Kavanaugh et al. (1996)]. 
However, whilst this is an attractive hypothesis, under conditions where CD28 co­
association with p85 can be detected, no association of CD28 with SHIP was detected. 
Moreover, the association of Grb-2 with CD28 in DC27.1 cells has not been 
demonstrated to date (Daniel Olive, personal communication). In vitro kinase assays of 
SHIP immunoprecipitates demonstrate that CD28 ligation induces the phosphorylation 
of a 145 kDa subtsrate, presumably SHIP, in murine DC27.1 cells. This 
phosphorylation is accompanied by further molecules of approximately 40 kDa and 100 
kDa, the identity of which is unknown and these molecules may represent SHIP- 
associated protein tyrosine kinases and/or phosphorylated adaptor proteins that regulate 
activation and/or protein-protein associations of SHIP. Alternatively CD28 may affect 
SHIP activity via regulation of PLCyl. Stimulation of CD28 by mAb in DC27.1 cells 
induces tyrosine phosphoylation of PLCyl, which may receive further regulatory input 
from the lipid products of PI 3-kinase [Bae et al. (1998); Falasca et a l (1998)]. SHIP 
has been demonstrated to associate with the SH3 domain of PLCyl in RBL-2H3 cells 
[Osborne et a l (1996)] and this interaction may allow for CD28-mediated regulation of 
SHIP either by localisation of the phosphatase to regulatory proteins or substrate.
Activation of SHIP and subsequent hydrolysis of PtdIns(3,4,5)P3 has been proposed 
as inhibitory to the biological effects of PI 3-kinase [Deuter-Reinhard et al. (1997)]. The 
cellular function of SHIP is a moot point however, for instance, activation of SHIP may
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not represent a true “off signal” since SHIP activity results in an increase of level of 
PtdIns(3,4)P2> for which there may be downstream targets such as PKB [Franke et al.
(1997)] or PKC family members [Toker et al. (1994)], thus SHIP activity results in a 
“shunting” of the PI 3-kinase signal away from PtdIns(3,4,5)P3 targets towards 
Ptslns(3,4)7*2 targets. Thus, with respect to its activation by CD28, SHIP may be i) a
“house. keeping” receptor-operated negative feedback mechanism which keeps tight 
control of Ptdlns(3,4,5 )7*3-dependent signalling mechanisms and down-regulates
effects on mitogenesis, cellular transformation and immune function. In this respect 
SHIP would facilitate the controlled removal of Ptdlns(3,4,5)7*3 and thus remove a
membrane targetting signal for recruitment of PH domain containing signalling 
molecules, similar to that reported to occur during SHIP mediated inhibitory signals on 
Ptdlns(3,4,5)7*3/Tec kinase dependent signalling in B cells after BCR ligation
[Scharenberg et al. (1998)]. ii) Alternatively SHIP may divert signalling away from 
Ptdlns(3,4,5)7*3-dependent effectors towards effectors exclusively driven by 
Ptdlns(3,4)7*2 thus achieving functional diversity. It should be stressed that the notion 
that PtdIns(3,4,5)P3 and PtdIns(3,4)P2 may exert different functional outcomes is 
contentious since several studies have revealed these lipids to have either similar or 
different effects in a range of in vitro assays such as binding of PH domains or PKB 
activation [James etal. (1996); Freeh et al. (1997); Franke et al. (1997)]. This may be 
important in controlling the subtle mechanisms that regulate CD28 coupling to Vav, 
p6 2d°k and/or PKB and other signalling molecules not yet identified.
The increasing number of molecules reported to utilise the PI 3-kinase mediated 
pathway potentially poses a problem for the cell in preserving specificity in signal 
transduction and elicitation of appropriate responses. Differential recruitment and/or 
activation of SHIP by molecules engaging the PI 3-kinase pathway may enable tailoring 
of the resultant signal, since SHIP will influence both duration and intensity of 
PtdIns(3,4,5)P3 levels generated. Additionally SHIP will regulate the activity of its
own potential downstream targets, thus recruitment and/or activation of SHIP could 
constitute an important regulatory mechanism in activation of downstream target effector 
molecules. Whether SHIP is simply inhibitory to the costimulatory signal, generated via 
CD28 ligation, or results in enhanced activation of identified or novel targets of its lipid 
products requires further investigation. A model of SHIP regulation of CD28-mediated 
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Figure 7.5 Model for regulation of CD28-activated PI 3 -k in ase- 
dependent signalling cascade by SH IP. 1) CD28 ligation induces strong 
activation of PI 3-kinase resulting in the accumulation of PtdIns(3,4,5)P3 [Ward et 
al (1993)] and consequent activation of PI 3-kinase dependent cascades. 2) CD28 
ligation also induces tyrosine phosphorylation of SHIP and stimulation of its 
phosphatase activity. Although the mechanism of CD28 coupling to SHIP is not 
characterised a direct association is unlikely since no SHIP can be detected in CD28 
immunoprecipitates by immunoblot analysis. 3) SHIP catalytic activity will degrade 
PtdIns(3,4,5)P3 to PtdIns(3,4)P2 although this may not represent a true “o ff’ 
switch since there may be targets activated by this lipid, thus SHIP activity may 
“shunt” the CD28-mediated PI 3-kinase signal from Ptdlns (3,4,5)P3 targets 
towards PtdIns(3,4)P2 targets.
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7.4 Activation of the MAP kinases.
Of the three MAP kinase pathways described in mammalian cells, the ERK pathway is the 
best defined. This pathway is upregulated via Ras, which is transiently activated in 
response to TCR ligation. This study has used in vitro kinase techniques to demonstrate 
that JNK activation is induced by treatment of cells with CD3 mAb and CD28 mAb, or 
CD28 mAb in combination with PMA and ionomycin, confirming previous observations 
[Su et al. (1994)]. Furthermore, from immunoblot analysis using an antibody which 
recognises only the tyrosine phosphorylated form of p38, CD28 stimulation has been 
demonstrated to induce the activation of p38 MAP kinase. The relative contributions of 
ERK, JNK and p38 pathways in T cell activation cannot be determined unless specific 
pharmacological or molecular reagents that selectively block each of these pathways are 
available. In this study PD98059, a compound which specifically inhibits signalling 
through the ERK pathway by inhibition of MEK, and SB203580, which specifically 
inhibits the p38 MAP kinase, have been used to try to dissect out the effects of these 
pathways on T cell activation. The results are sumarised in Figure 7.6.
The MEK pathway can efficiently couple the TCR and phorbol ester-activated PKC to the 
ERK2 pathway [Genot et al. (1996)]. However the MEK inhibitor PD98059 induced 
only slight inhibition of CD3/CD28 driven proliferation, except at higher concentrations 
(e.g. <40% inhibition at 50 pM) which may compromise the specificity of the 
compound. The relative lack of effect of PD98059 on proliferation induced by the 
TCR/CD28 and CD28/PMA/ionomycin correlates well with previous observations 
derived from mice expressing dominant negative MEK-1 transgenes [Alberola-Ila et al.
(1995)]. These experiments revealed that MEK activation is not required for TCR- 
induced proliferative responses of mature thymocytes even though p21ras signals are 
indispensable [Alberola-Ila et al. (1995)]. Rather, it appears that MEK activation is critical 
to thymocyte maturation (positive selection) and differentiation from double negative 
CD4/CD8 to double positive thymocytes in Recombination-activating gene (Rag)-/ '  mice 
[Crompton et al. (1996)]. The lack of effect of MEK inhibitors on T cell proliferation may 
be explained by a growing body of evidence indicating that ras effector pathways other 
than the Raf-1/MEK/ERK2 pathway exist. For instance, activation of the MEK pathway 
is not sufficient for ras activation of the transcription factors API or NFAT in T cells 
[Genot etal. (1996)]. Similarly, in mast cells, ERK1/2 MAP kinases are not required for 
FcyRI regulation of NFAT at all, whilst activation of ras is essential [Turner and Cantrell
(1997)]. Indeed, it appears that ras stimulates a Rac-1 mediated pathway that regulates the 
transcriptional function of API complexes in T cells [Genot et al. (1998)] whilst Rac-1 is 
also an important ras effector involved in FceRI regulation of the transcriptional activity
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of Elk-1 and NFAT in mast cells [Turner and Cantrell (1997)].
Since phorbol ester-activated PKC can also activate p21ras [Downward et al. (1990)] 
similar arguments relating to the ras effectors being required for T cell proliferation can be 
used to explain the the lack of effect of PD98059 on PMA/CD28 and PMA ionomycin 
stimulated proliferation. The experiments presented in this study revealed only a slight 
inhibitory effect of PD98059 at higher concentrations which may indicate either i) non- 
selective effects of PD98059 at higher concentrations; or ii) a partial involvement of MEK 
in the proliferative responses of human T cells to CD28/CD3 Ab, since anti-CD28 Ab 
may provoke an accentuated increase in MAP kinase activation, the proliferative reponse 
of T cells in response to Ab stimulation may be unusually dependent upon MEK.
This study shows that the previously termed “stress activated kinase” p38 is also activated 
in T cells by CD28 and of integral importance to CD3/CD28 mitogenic signalling, since 
p38 inhibition with SB203580 correlated with inhbition of CD3/CD28 driven 
proliferation, although the effect of CD3 ligation on p38 activation however, was not 
determined. Additionally, evidence is presented that p38 is involved in transducing the 
mitogenic responses to IL-2. Care must be taken however, when interpreting the results 
from the IL-2 bioassay, which correlated inhibition of p38 to inhibition of IL-2 
production in response to CD3/CD28 stimulation, since the inhibitor may be carried over 
in the cell supernatant which was harvested for IL-2 assay. The possibility that 
SB203580 inhibits another protein kinase is unlikely, as it has no activity when tested on 
a large number of other kinases at high concentration [Cuenda et al. (1995)]. However, 
the possible existence of non-kinase targets cannot be absolutely discounted. These 
results imply that p38 MAP kinase has a novel role in mediating the proliferative response 
of T cells to cytokine stimulation.
To determine if the inhibitory effects of SB203580 on CD28 driven proliferation could be 
accounted for by non-specific inhibition of PI 3-kinase, the effect SB203580 was 
assessed on CD28 mediated accumulation of PtdIns(3,4,5)P3. Incubation of cells with
SB203580 however was found to have no effect on CD28-mediated PI 3-kinase 
activation indicating that PI 3-kinase activation lies either upstream of p38 activation or on 
a dichotymous pathway of CD28 signalling. The latter would correlate well with 
subsequent data, which suggests that one possible route by which CD28 may activate the 
p38 pathway is via the activation of p21-activated kinase (PAK) [Kaga et al. (1998)]. The 
activation of PAK has been proposed as a point of integration of the CD3 and CD28 
signals, whilst under these conditions the signal provided by CD28 can be mimicked by 
treatment of cells with ceramide analogues [Kaga et al. (1998)]. These data imply that
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CD28 may supply a PAK activating signal that is independent of PI 3-kinase. However, 
PI 3-kinase has previously been implicated in the insulin-mediated activation of PAK in 
muscle cells [Tsakiridis et al. (1996)], hence PAKs may be regulated by both ceramide 
and PI 3-kinase mediated signals. PI 3-kinase appears play some role in the activation of 
JNK, as evidenced by the wortmannin-mediated partial inhibition of anti-CD3 plus anti- 
CD28 Ab stimulated of JNK in Jurkat cells demonstrated in this thesis, which correlates 
with the reported requirement for PI 3-kinase activity in growth factor mediated JNK 
stimulation [Logan et al. (1997); Lopez-Ilasaca et al. (1997)], and JNK activation in COS 
cells [Klippel et al. (1996)]. This may be a cell-specific phenomenon however, since 
previous results have described that PI 3-kinase cannot stimulate JNK in NIH3T3 cells 
[Reif etal. (1996)].
CD28 may couple Rac/Rho effector PAK via regulation of p62^0^ and p97vav which are 
both tyrosine phosphorylated on CD28 ligation [Klasen et al. (1998)]. p62^0^ forms a 
complex with p i20 RasGAP and p i90 RhoGAP and it is postulated that tyrosine 
phosphorylation of p6 2 dok will modulate the cellular distribution of RasGAPs and 
RhoGAPs and sequester these molecules away from active ras and rac molecules, thereby 
prolonging the activation of Rac or Rho dependent pathways. Additionally, both dok and 
vav encode PH domains which may allow CD28 activated PI 3-kinase to induce either 
allosteric modification or membrane translocation of these molecules via binding of D-3 
lipids to their PH domains.
An emerging theme in the literature suggests that p38 and JNK/SAPK may play decisive 
roles in the control of cell death. This is supported by the observation that transfection of 
a constitutively active mutant of MKK3/6, the physiological activator of p38, along with 
p38 is sufficient to induce apoptosis in PC 12 cells [Xia et al. (1995)]. Additionally, 
transfection of dominant negative mutants of MKK3/6 in PC 12 cells or of p38 in NIH- 
3T3 fibroblasts dramatically inhibits apoptosis by nerve growth factor withdrawal [Xia et 
al. (1995)] and U.V. irradiation [Berra et al. (1997)]. Interestingly, deprivation of 
neutrophic factors in PC-12 or UV-irradiation of NIH-3T3 cells not only activates the 
stress kinase cascades, but also leads to a dramatic inhibition of the ERK pathway [Xia et 
al. (1995); Berra et al. (1997)]. This is particularly relevant since ERK has been shown to 
be required for survival signalling in response to fibroblasts growth factor [Gardner and 
Johnson (1996)] and insulin like growth factor 1 [Parrizas et al. (1997)]. Thus it seems 
that the ability of a cell to die or survive may be dictated by a critical balance between the 
ERK and the JNK/SAPK and p38 pathways [Canman and Castan (1996)]. Given the role 
of CD28 in determining cell survival, it seems entirely appropriate that it can regulate the 
pathways known to play important roles in cell survival and/or cell death.
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Figure 7.6 D iagram m atic sum m ary of results presented in sec tio n  
5 .4 . 1) Inhibition of p38 MAP kinase using SB203580 correlated with 
inhibition of [^HJ-thymidine incorporation in response to TCR/CD3 plus anti- 
CD28 mAb or anti-CD28 mAb plus PMA or IL-2. 2) The effect of TCR/CD3 
ligation on p38 stimulation however, was not determined. These data indicate a 
novel role for the previously termed “stress activated” kinase in T cell activation 
and proliferation. 3) In contrast the MEK inhibitor PD98059 was found to inhibit 
T cell [^H]-thymidine incorporation driven by TCR/CD3 plus CD28 only 
partially at higher concentrations of the drug, which may be explained by 
inhibition of non-specific targets. [3H]-thymidine incorporation driven by IL-2 
or anti-CD28 mAb plus PMA was not inhibited by PD98059. 4) The apparent 
redundancy of ERK in proliferative responses may suggest further cellular 
functions for the pathway, for example studies suggest an important role in 
thymocyte maturation [Alberola-Ila et al. (1995)]. Size of arrow indicates 
inferred importance of pathway to functional outcome.
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7.5 CD95 activation of costimulatory targets.
Given the crucial role of CD95 function in the immune system, the events linking CD95 
ligation to apoptosis have been the subject of intense investigation. Reports have 
demonstrated that CD95 employs a number of signal transduction pathways such as 
activation of the caspases [Enari et al. (1995)], which may be peculiar to apoptotic 
pathways. Other CD95 targets however are also activated by mitogenic signals. For 
example, it has also been reported that ceramide levels increase after CD95 ligation 
[Cifone et al. (1994)], and CD28 ligation [Boucher et al. (1995)], and Fas has been 
demonstrated to couple to fyn, a PTK pivotal to T cell activation. Given the contrasting 
agendas of the apoptotic and stimulatory pathways, it might be assumed that the effect of 
CD95 ligation on costimulatory targets would either be negligible or inhibitory. However, 
considering that under certain circumstances Fas may be implicated as providing a 
costimulatory signal (as detailed in section 1.8) the effect of Fas ligation was investigated 
on signalling targets known to be stimulated by mitogenic stimuli.
7.5.1 CD95 activates PI 3-kinase and downstream effectors.
PI 3-kinase has been implicated in a wide range of cellular functional responses, see 
Table 1.3. The data presented in this study imply that PI 3-kinase is also activated by cell 
death-inducing receptors since ligation of CD95 is shown to induce the accumulation of 
the lipid products of PI 3-kinase (section 6.2). The activation of PI 3-kinase is not 
necessary for efficient death signalling however, since treatment of Jurkat cells with the 
PI 3-kinase inhibitors wortmannin and LY294002 potentiated, rather than inhibited, 
CD95-mediated cell death. This also correlated with increased CD95-mediated cell death 
seen in JCaMl cells which display severely impaired activation of PI 3-kinase. These 
observations are summarised in Figure 7.7.
The magnitude of CD95-induced PI 3-kinase activation is markedly lower than that 
observed on CD28 ligation. However, the D-3 phosphoinositides, particularly 
PtdIns(3,4,5)P3, are generally restricted to the membrane compartments in which they
are made, leading to a high degree of compartmentalisation, allowing for high 
concentrations of the lipids to be encountered locally which may enable activation of 
downstream effectors of PI 3-kinase. Given this, investigations were carried out to see if 











Figure 7.7 PI 3-kinase activation antagonises cell death . PI 3-kinase 
inhibitors LY294002 and wortmannin potentiated, rather than inhibited, CD95- 
mediated cell death, thus PI 3-kinase may antagonise cell death. This correlates 
with increased CD95-mediated cell death seen in JCaMl cells, which fail to express
p56^c^ or induce substantial CD95-activated PI 3-kinase. Size of arow indicates 
inferred importance of pathways to CD95 signal tmsduction
The elevation of PtdIns(3,4,5)P3 in response to either anti-Fas Ab or Fas Ligand was 
found to correlate with an increased activation of the PI 3-kinase effector PKB as 
assessed by in vitro kinase assays. CD95 activation of PI 3-kinase offers the best 
established route for CD95 regulation of PKB activity that is, via direct binding of the 
lipid products of PI 3-kinase to PKB inducing a conformational change and co­
localisation of PKB with PKB activating upstream kinases, such as PDK1 [Anderson et 
al (1998)]. Attempts to demonstrate this routing by the use of wortmannin however, 
yielded inconclusive data since both stimulation and inhibition of CD95-mediated PKB 
activation was observed. These results lead to the consideration that CD95 may mediate 
PKB activity by signalling pathways independent of PI 3-kinase. PKB regulatory 
pathways independent of PI 3-kinase clearly exist, since activation of PKB is reported to 
be achieved by cellular stresses such as heat shock and hyperosmolarity, and this
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activation appears insensitive to inhibition by wortmannin [Konishi et al. (1996)]. 
Additionally, cAMP has been shown to stimulate PKB in a wortmannin-independent 
manner [Sable et al. (1997)]. The p38 MAP kinase pathway which can be activated in 
response to cellular stresses is activated by CD95 [this study; Juo et al. (1997)], and the 
downstrean target of p38 namely, mitogen-activated protein kinase 2 (MAPKAP 2) can 
phosphorylate PKB on 473<Ser, at least in vitro [Alessi et al. (1996)], and might 
therefore contribute to the activation of PKB by cellular stress. It should be noted 
however, that anisomycin, a good activator of MAPKAP kinase 2, does not activate 
PKB [Alessi et al. (1996)], thus CD95-mediated activation of PKB may require input 
further to p38 activation. Considering the potential role of p38 in CD95 mediated 
activation of PKB, cells were preincubated with a specific inhibitor of p38, namely 
SB203580. These experiments demonstrated at least a partial inhibition of CD95 mediated 
PKB activation, in a dose dependent manner, implying that p38 activation by CD95 may 
be a contributory factor in regulation of PKB. The incomplete nature of inhibition of 
CD95-mediated p38 activation may be explained by the existence of SB203580 resistant 
isoforms. Indeed, to date, four members of the p38 group of enzymes have been 
described in p38, p38|3, p38y and p385. The most recently described group member 
p385, has been demonstrated to be expressed in Jurkat cells, and characterised as 
completely resistant to inhibition by pyridinyl imidazole inhibitors [Jiang et al. (1997)].
However, there is a strong line of evidence to suggest that CD95 does not activate PKB 
via p38. For instance, maximal activation of p38 was achieved at two hours following 
ligation of CD95, whilst the time course of CD95 mediated p38 activation was much 
quicker with maximal activation after five minutes. However, activation of PKB may be 
achieved by p38 activity occuring below the sensitivity of the assay used in this study. 
The CD95 activation of p38 was found to be insensitive to the presence of Z-VAD-FMK, 
whereas others have reported this activation to be completely inhibited by caspase 
inhibitors [Juo et al. (1997)]. This inconsistency may be explained in a number of ways: 
Firstly, the inhibitor may have been degraded during storage. This seems unlikely since 
the compound is essentially a tripeptide which has previously been stable whilst stored at 
-20°C and retains its ability to inhibit CD95-induced cell death. Secondly, the 
discrepancy may be explained by subtle differences in the biochemistry of the cell models 
used since Juo et al. used a Jurkat subclone A3, which has been selected for its 
susceptibility to CD95-mediated apoptosis [Juo et a l (1997)]. Certainly caspase 
independent mechanisms exists for activation of p38 since activation by sorbitol and 
etoposide is resistant to YVAD-FMK and Z-VAD-FMK [Juo et al. (1997)], and these 
mechanisms may be differentially regulated in Jurkat A3 cells. Thirdly, further CD95- 
activated control mechanisms may exist which also regulate PKB. The integrity of the PH
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domain has been found to be essential for the activation of PKB in intact cells in response 
to activated PI 3-kinase [Franke et al. (1997)], and heat shock [Konishi et a l (1996)]. 
This points to an essential role for the PH domain in the activation of PKB by PI 3-kinase 
dependent and independent mechanisms. Structural studies have shown that the PH 
domain is distantly related to the immunosuppressant FK506 binding protein (FKBP), 
and it is possible that FKBP associates with a heat shock protein, hsp90 [Callebaut et a l
(1992)]. It is therefore a possibility, that some heat shock proteins may bind to the PH 
domain of PKB, allowing stress activated pathways to regulate PKB activity. Many 
further proteins may associate with the PH domain of PKB, in particular, two isoforms 
of PKC have been demonstrated to associate with the PKB PH domain in PKC8 
[Konishi etal. (1996)], and PKC£ [Konishi et a l  (1994)]. Both of these PKC isoforms 
are activated by the lipid products of PI 3-kinase [Nakanishi et al. (1993); Toker et a l  
(1994)]. Intriguingly however, in the context of CD95 signalling, PKC£ has been 
demonstrated as activated by ceramide signals [Lozano et a l (1994)], and PKC8 has 
been reported as activated by proteolytic cleavage resultant from caspase activity [Emoto 
et a l  (1995)]. These relationships are summarised in the Figure 7.8. Attractively, each 
branch of this signalling scheme offers a point for pharmacalogical intervention: (i) since 
PI 3-kinase dependent signals can be inhibited by the use of wortmannin [Thelen et a l
(1994)] or LY294002; (ii) caspase dependent signals are subject to inhibition by cell 
soluble fluoromethylketone peptides Z-VAD and YVAD [Sarin et a l  (1996)], or 
expression of the viral protein CrmA; (iii) p38 dependent signals would be subject to 
inhibition by SB203580, and (iv) ceramide dependent signals can be inhibited by the use 
of chloroquine (although this is a relatively non-specific inhibitor). It may be possible that 
CD95 mediated activation of PKB requires the presence of one or more of these signals, 
explaining the inconclusive results obtained in section 6.3.2. Clearly, the signalling 
mechanisms by which CD95 activates PKB require further examination. The rationale for 
CD95 activation of PKB seems hard to justify given the two such incongruous functions 
ascribed to the respective molecules [Itoh et al. (1991); Haussler et al. (1998)]. Transient 
activation of PKB could serve to “prime” downstream targets of CD95, certainly PKB 
can interact with members of the Bel family o f proteins, and further undefined PKB 
targets may exist. Alternatively, it may be that CD95 mediated PKB activation is a 
transient phenomenon, redundant in death signalling pathways. Certainly, PI 3-kinase 
function appears unnecessary, or inhibitory, to efficient death signalling in Jurkat cells. A 
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Figure 7.8 Potential routes for CD95 regulation of PKB activ ity . CD95 
activation of PI 3-kinase provides the most obvious route for activation of PKB, 
however, experiments using wortmannin proved inconclusive since both potentiation and 
inhibition of PKB activity was observed. Thus further pathways, represented above, may 
couple CD95 to PKB. PKC5 and £ isoforms have been demonstrated to interact with the 
PKB PH domain and may regulate PKB activity. Compounds marked in red represent 
potential points for pharmacological dissection of these pathways. Activation of ceramide 
[Cifone et al. (1994)] and caspases [Enari et al. (1995)] are recognised features of CD95 
signalling. Activation of PI 3-Kinase (section 6.2) and p38 (section 6.4) following CD95 





7 .6  SUM M ARY
From the work presented in this study a number of conclusions can be drawn.
1) Lck function is not necessary for PI 3-kinase recruitment to CD28, however, it is 
required for efficient CD28-mediated activation of PI 3-kinase, as evidenced by 
the severely impaired accumulation of PtdIns(3,4,5)P3 in JCaMl cells.
2) PMA-activated PKC inhibits PI 3-kinase association with, and activation by 
CD28 following ligation by the natural ligand B7.1. Despite the presence of 
several phosphorylation sites within the cytoplasmic tail of CD28, the inhibitory 
effect of PMA on CD28/PI 3-kinase association is not mediated via modulation of 
the CD28 phosphorylation profile since treatment of cells with PMA, PKC 
inhibitors or transient expression of constitutively active PKC isoforrms does not 
affect CD28 phosphorylation.
3) Ligation of CD28, by the natural ligand B7.1, is followed by heavy 
phosphorylation within serine/threonine residues of the CD28 cytoplasmic tail, 
which occurs independently of PI 3-kinase and PKC and is not detectably 
affected by a panel of inhibitors of known serine/threonine kinases.
4) Truncation and point mutation of the CD28 cytoplasmic tail reveals ligation- 
stimulated phosphorylation of CD28 to be dependent upon the integrity of 173y.
5) CD28-mediated activation of PI 3-kinase results in the activation of the 
downstream effectors PI 3-kinase and p70 S6 kinase.
6) CD28 ligation induces tyrosine phosphorylation, and stimulates the catalytic 
activity of SHIP. Since no direct association could be detected with SHIP, CD28 
affect SHIP activity via an undefined regulatory mechanism.
7) CD28 induces activation of p38 MAP kinase, whilst pharmacological inhibition of 
p38 correlates with inhibition of IL-2 driven or CD28-dependent T cell 
proliferation.
8) CD95 ligation induces apototic death in Jurkat cells which is potentiated by 
inhibition of PI 3-kinase.
9) CD95 induces activation of p38 MAP kinase after one hour, and transient 
activation of PKB by an uncharacterised regulatory mechanism.
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7.7 FUTURE DIRECTIONS
Recruitment o f PI 3-kinase to CD28.
The signal transduction pathway mediated by PI 3-kinase is suggested as pivotal to T cell 
activation since nanomloar concentrations of wortmannin inhibit CD28 mediated 
costimulation of IL-2 production in resting and activated human T cells [for review see 
Ward et al. (1996)]. The present study demonstrates that CD28 recruits p85a and 
activates Class IA PI 3-kinases in a manner at least partially dependent on the src family 
tyrosine kinase lck. To date however, three distinct isoforms of p i 10 have been identified 
in p i 10a, p llO p and p i 108, and these may not be functionally equivalent for example 
p i 108, unlike p i 10a or (3, does not phosphorylate the tightly associated p85 subunit, but 
instead harbours an autophosphorylatory capacity [Vanhaesebroeck et al. (1997)]. The 
use of antibodies raised against specific isoforms of the catalytic subunit of PI 3-kinase 
would enable the analysis of the contribution of these distinct isoforms in CD28 
signalling, for example the use of Western blotting and in vitro lipid kinase techniques 
could determine if these molecules all associate with CD28 and are activated by CD28, in 
a ligation dependent manner.
CD28 phosphorylation studies.
Despite the attention of several laboratories, the identity of the tyrosine kinase which 
phosphorylates CD28 at the ^^YM NM  motif remains to be resolved. Whilst in vitro 
studies suggest Lck as strongest candidate [Raab et al. (1995)], the absence of Lck does 
not affect PI 3-kinase recruitment to CD28, thus an unidentified kinase may mediate this 
phosphorylation. A recent report has demonstrated that a member of the Btk/Tec family of 
protein tyrosine kinases namely, rlk (resting lymphocyte kinase ) also termed Txk, is 
capable of specifically phosphorylating CTLA-4 at its (p)YVKM motif [Schneider et al.
(1998)] which can bind the SH2 domains of PI 3-kinase [Schneider et al. (1995)]. Rlk 
may also be capable of phosphorylating CD28 in an over-expression system [Schneider et 
al. (1998)]. It would be interesting to use Western blotting and in vitro kinase techniques 
to further define the relationship between CD28 and rlk by answering such questions as 
do the molecules associate in intact cells, and does rlk phosphorylate CD28 in vitro?
The ligation dependent serine/threonine phosphorylation of CD28 has received less 
attention than the tyrosine phosphorylation. In the absence of any effective, specific 
inhibitory strategy its effect on CD28 signal transduction cannot be determined however, 
both enhancement by stabilising protein-protein interactions, or inhibition by disruption 
of CD28 coupled signalling pathways in a manner similar to that proposed to operate in 
insulin signalling [Shepherd et al. (1998)] may be envisaged. Given the pivotal role of
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CD28 signal transduction to T cell activation and thus immune function, and considering 
that this phosphorylation may be resultant from the activity of a specific kinase since it 
was resistant to a panel of inhibitors of known serine/threonine kinases, the nature and 
identity of the CD28 directed serine/threonine kinase becomes an important issue. The 
177 j residue is suggested as an important substrate by the present study since truncation 
mutation of this residue abrogates CD28 serine/threonine phosphoryation. Given the non­
specific nature of deletion mutation, the significance of should be further
investigated by point mutation of CD28 and expression in DC27.1 cells to determine 
more specifically if 177t [s required for the serine/threonine phosphorylation of CD28.
CD28 activates SHIP.
The present study demonstrates the inositol phosphatase SHIP to become tyrosine 
phosphorylated and activated in response to CD28 ligation in murine DC27.1 cells. 
Whilst in B cells SHIP is known to associate directly with CD32 via an ITIM within its 
cytoplasmic domain [D’ambrosia et al. (1995)], the cytoplasmic domain of CD28 encodes 
no recognised ITIM, and no direct association between CD28 and PI 3-kinase could be 
detected. Thus the question arises as to how CD28 couples to SHIP. In vitro kinase 
assays of SHIP immunoprecipitates reported in this study, reveal SHIP to co- 
immunoprecipitate with four unidentified phosphoproteins which could represent 
intervening kinases between CD28 and SHIP. In particular, two phosphoprotein co- 
immunoprecipitating with SHIP, of approximately 60 kDa, could represent the protein 
tyrosine kinases p59fyn and p 5 6 ^ .  Western blotting of SHIP immunoprecipitates may 
reveal if these molecules associate with SHIP.
Since SHIP substrates include PtdIns(3,4,5)P3 [Damen etal. (1996)], SHIP activity may 
be presumed to inhibit cellular levels of PtdIns(3,4,5)P3, whilst increasing levels of 
PtdIns(3,4)P2- Whilst no SHIP was found to be expressed in Jurkat cells, these cells 
have provided a useful model for the examination of ligation induced fluctuations in levels 
of phosphoinositol lipids within the cell, by direct chloroform extraction of these lipids 
followed by deacylation and anion exchange HPLC analysis. Jurkat cells could therefore 
provide an interesting background to study the effects upon phosphatidylinositol lipid 
levels of transfection of active and inactive forms of SHIP into these cells.
The SHIP substrate PtdIns(3,4,5)P3 is essentially membrane bound by virtue of the fatty 
acyl side chains of phosphoinositides. This implies that in order to hydrolyse its 
substrate, SHIP must translocate to the membrane on activation. This ligand induced 
redistribution of SHIP could be determined by intracellular staining for SHIP and 
subsequent analysis by microsopy. Since SHIP is known to encode a PH domain
175
[Damen et a l (1996)] it would be valid to postulate that a potential mechanism for cellular 
redistribution of SHIP would be provided by the binding of phosphoinositide products of 
PI 3-kinase enabling interaction with the plasma membrane, similar to the suggested 
mechanism of regulation of PDK1 activity [Anderson et a l  (1998)]. This hypothesis 
could be examined either by the use of mutant CD28 expressing DC27.1 cells which do 
not activate PI 3-kinase (i.e.DYF173 cells), or the use of pharmacological inhibitors of PI 
3-kinase.
CD95 mediated activation o f PKB.
The CD95 mediated activation of PKB is an interesting observation considering the 
incompatibility of the reported functions of the respective molecules [Itoh et a l  (1991); 
Hausler et a l (1998)]. It may be that CD95 mediated activation of PKB is a transient 
phenomenon, thus a more comprehensive characterisation would be appropriate 
encompassing a wider timescale than that of the present study. The inconclusive data 
generated from the use of pharmacogical inhibitors of PI 3-kinase suggest that further 
pathways may be involved in the CD95 mediated activation of PKB, as discussed in 
section 7.5.1. The postulated involvement of caspases, p38 MAP kinase or ceramide 
could be examined by the use of readily available pharmacological inhibitors of these 
molecules in the in vitro kinase assays previously utilised in this study.
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